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Abstract 
 
Current research into the mechanisms of muscle atrophy associated with cancer cachexia have 
centred on the catabolism of skeletal muscle, as it is one of the most profound physical changes of 
the disease. Currently research is lacking regarding the mechanisms causing cardiac tissue wastage. 
However, muscle breakdown is believed to involve a number of molecular interactions between the 
tumour and host. Increased levels of oxidative stress have been found in cancer cachectic skeletal 
muscle and has been linked to the activation of the protein breakdown pathway known as the 
ubiquitin proteosome system (UPS). The aim of the first study detailed in chapter 4 of this thesis was 
to examine the role of oxidative stress and the UPS in the hearts of mice with cancer cachexia.  
The results of the first study showed that a marker of DNA oxidation, 8-OH-2dG levels were 1.5-fold 
higher in the heart of mice with cancer cachexia, and this was associated with a 1.7- fold lower level 
of NOX2 mRNA and twofold higher xanthine dehydrogenase (XDH) mRNA in the same hearts. Cancer 
cachexia was also associated with a 1.5-fold lower level of superoxide dismutase (SOD) activity in the 
heart. Accompanying these pro- and antioxidant differences was a significantly higher level of mRNA 
for the key ubiquitin proteasome system (UPS) elements MURF-1 (4.3=fold) and MAFbx (3.8-fold) in 
the hearts of mice with cancer cachexia.  
The first study of this thesis demonstrated that cardiac atrophy of cachectic mice is associated with 
oxidative damage to DNA in the myocardium. The higher levels of XDH mRNA in cachectic hearts 
suggest that xanthine oxidase may have an important role to play in producing oxidative stress. It 
appears that the combination of higher XDH expression and lower SOD enzyme activity are key 
contributors to oxidative stress and cardiac tissue damage in cancer-induced cardiac atrophy. 
Oxidative stress in the myocardium as with skeletal muscle may also induce increased expression of 
the E3 ligases MURF-1 and MAFbx as seen in this study. 
The second study of this thesis detailed in chapter 5 aimed to further investigate the molecular and 
histological characteristics of cardiac atrophy in cancer cachexia using a temporal model. The second 
study used the same nude mouse model of cancer cachexia (CC) as in the first study. Nude mice 
were inoculated with MAC13 (cancer control) or MAC16 tumours producing cancer cachexia. These 
animals randomised for tissue harvesting at time 0, 12, 21 and 29 days post inoculation with cancer 
cells. The second study found that whilst tumour size did not significantly vary between groups the 
MAC16 mice lost weight over time reaching a maximum of 10% total body weight loss by day 26. 
There was a significant negative correlation between tumour size and animal weight as expected. 
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However, tumour size did not correlate with the rate at which animals lost gross body weight. 
Cardiac mass was significantly reduced in the MAC16 group compared to cancer control from day 12. 
Whilst significant reduction in peri-renal fat was evident from day 21 and quadriceps from day 29 
compared to cancer control. This study also investigated the histological changes of the atrophying 
cancer cachectic heart. Histological analysis revealed a significant reduction in total heart area from 
day 21 versus compared to day 0. Whilst myocardial wall thickness was significantly reduced form 
the posterior and lateral left ventricular walls on day 21 before all other heart muscle walls reduced 
in size by day 29. Cardiac collagen content was reduced significantly in the day 29 cancer cachexia 
group by 50% compared to cancer controls. The molecular portion of this study aimed to cover 
important oxidative measures and signalling molecules which may be important aetiological markers  
of cardiac atrophy in cancer cachexia. The molecular analysis revealed that serum IL-6 levels were 
significantly increased on day 12 whilst mRNA levels were elevated on day 21 and 29 compared to 
controls. Serum MCP-1 (monocyte chemoattractant protein-1) was not found be increased at any 
time point, while mRNA transcripts of the chemoattractant molecule revealed significant increases 
from day 12 to 29 compared to controls. Another chemoattractant molecule regulated upon 
activation, normal T-cell expressed and secreted (RANTES) was also significantly elevated at the gene 
level compared to controls on day 21 and 29. In terms of oxidative balance in the cachectic 
myocardium SOD enzyme activity was decreased compared to cancer control on day 12 while 
xanthine dehydrogenase activity (XDH) was increased. A measure of DNA oxidation (8-OH-2dG) was 
significantly increased from day 12 to day 29 in cancer cachectic hearts compared to controls. Both 
MAPK (mitogen activated protein kinase) and NFκβ (nuclear factor kappa beta) have been shown to 
activate muscle atrophy via redox signalling. However, only NFκβ at day 12 in cancer cachectic hearts 
was significantly elevated compared to controls. Finally the gene transcripts of the important 
ubiquitin ligases MURF-1 (muscle RING-finger protein 1) and MAFbx  showed increases from day 12 
to day 29 in the cancer cachectic myocardium compared to cancer control. 
The second study gave a more detailed molecular aetiology of cardiac atrophy secondary to cancer 
cachexia. The results suggested that cardiac atrophy in a cancer cachectic nude mouse is an early 
and important feature of the disease process. Whilst serum IL-6 accompanies early cardiac atrophy 
significant increases in the cytokine at the local level may sustain muscle mass reduction in the long 
term. Oxidative stress is also an early feature in the pre-cachectic disease stage whereby there is 
increases in the activity of XDH and an inability for the SOD enzyme to compensate for increases in 
radical oxygen species. NFκβ phosphorylation is evident in the pre-cachectic heart while mRNA 
markers of the UPS are increased at all time points. The results from the first two studies gave 
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valuable information for the third treatment study by providing potentially important therapeutic 
molecular targets.        
The final study of this thesis detailed in chapter 6 analysed the potential for oxypurinol (oxy) and 
eicosapentaenoic acid (EPA) to treat cardiac atrophy secondary to cancer cachexia. Both oxy and EPA 
were chosen as potential treatments for cardiac atrophy secondary to cancer cachexia as they have 
been shown to have anti-oxidant and anti-inflammatory properties. Whilst oxy was not able to 
preserve total body weight or cardiac mass in CC mice EPA did show potential in ameliorating 
disease. EPA was able to significantly delay time to significant weight loss, preserve cardiac mass and 
inhibit tumour growth. Whilst all treatment groups were able to significantly reduce DNA oxidation 
by-product 8-OH-2dG and mRNA expression of XDH, only the EPA and EPA/oxy in combination 
groups were able to reduce IL-6 mRNA expression. Furthermore, the EPA group brought about a 
larger reduction of 8-OH-2dG levels compared to the oxy and EPA/oxy in combination. The EPA and 
EPA/oxy combination group were also able to decrease gene expression of the ubiquitin ligases 
MAFbx and MURF-1 to a much further extent compared to oxy alone.  
The results of study 3 suggest that EPA and not oxypurinol is an effective treatment for cancer 
cachexia and the preservation of cardiac mass in this mouse model of the disease. The results also 
further provide evidence that IL-6 in this model is an important aetiologic factor in cancer cachexia. 
Furthermore, oxypurinol appears to blunt the anti-cachectic effects of EPA when used in cancer 
cachectic nude mice.  
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1.0 Literature review 
Cachexia is a serious secondary condition that is associated with a number of life threatening 
diseases including cancer, congestive heart failure, AIDS and sepsis (Rubin, 2003). The principle 
outcome of cachexia is weight loss which increases the morbidity and mortality of a patient.  
Metabolic alterations associated with cancer cachexia (CC) causes a disruption in the balance of 
anabolism and catabolism in tissues such as skeletal muscle and the heart (Costelli et al, 2001). CC as 
a condition is defined to be evident in a patient who is undergoing involuntary weight loss of more 
than 5% compared to their initial body weight. The disease has recently been classified as a 
spectrum of stages depending on the degree of weight loss and its response to treatment (Fearon et 
al, 2011).   
 
Figure 1.1 Spectrum of cancer cachexia and its definitions (Fearon et al, 2011)  
CC is found more commonly with certain types of tumours and is also correlated with the location of 
malignancy. Patients with solid lung and upper gastrointestinal tract malignancies have a greater 
incidence of the disease compared with those with breast or lower GI tract cancer. Specifically 
patients with pancreatic and gastric cancers are known to have the highest frequency of cachexia. 
(Rubin, 2003., Fearon & Moses, 2002). It is currently unknown why varying rates of cancer cachexia 
develop in relation to the site of malignancy. Interestingly cancerous tumours do not need to directly 
invade tissues which exhibit atrophy. CC is a condition where global immune responses and 
signalling molecules are needed to produce the disease in a range of tissues. Essentially the disease 
is a consequence of severe metabolic dysfunction in which patients exhibit a significant loss of 
adipose tissue and lean body mass (Skipworth et al, 2007).  
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Sufferers of CC exhibit symptoms of severe weight loss, anorexia, early satiety, weakness, anaemia 
and oedema. The severe physical manifestations of the disease also present a significant 
psychological burden (Skipworth et al, 2007). Williams et al, 1999 found that cancer patients may 
lose up to 14.2% of their stable body weight at the time of diagnosis and up to 24.5% at their final 
clinical assessment. The weight loss associated with cancer sufferers is known to occur due to the 
wastage and atrophy of a number of organ systems such as skeletal muscle, adipose tissue and the 
heart muscle. Currently research into the mechanisms of CC have centred on skeletal muscle loss as 
it is one of the most profound physical and visual changes of the disease. However, more recently 
animal studies have also found that CC causes significant cardiac atrophy (Acharyya et al, 2004., 
Costelli et al, 2001., Tian et al, 2010., Tian et al 2011). To date many of the physiological mechanisms 
which cause tissue wastage in CC are largely unknown, particularly with respect to the atrophy of the 
heart muscle.  
Although very limited, clinical research does exist examining the contribution of cardiac atrophy with 
regard to CC, suggesting that heart tissue wastage is a frequent and important clinical event in a 
cancer patient population. Investigating the basic physiological and clinical manifestations of cardiac 
atrophy Hellerstein & Santiago-Stevenson, 1950 reviewed 2000 autopsy cases and found 85 proven 
cases of cardiac atrophy of which 62 or 73% were seen in cancer patients. Of the cancer patients 
with cardiac atrophy none involved tumour invasion of the myocardium. Further cases of cardiac 
atrophy in CC patients were detailed by Inagaki et al, 1973 examining the causes of death in 816 
cancer patients. This study found that after systemic infection, organ failure including that of heart 
failure was the second most common cause of death. Furthermore, heart failure in this patient 
population was largely manifested through cardiac insufficiency, most cases of which were not due 
to tumour invasion as was the case with all other organs in this category. 
The consequences of heart tissue wastage directly relates to adverse patient outcomes. Upon clinical 
examination of patients with cardiac atrophy as a consequence of cancer, studies have revealed 
small and inactive hearts with faint heart sounds and declining blood pressure with the progression 
of illness (Hellerstein & Santiago-Stevenson, 1950). Although further investigation on the clinical  
consequences of such atrophy has not been adequately investigated it is known that patients with 
CC report lowered quality of life scores, decreased physical performance, increased risks of 
treatment failure, higher risks of treatment side effects and an increased rate of mortality (Dewys et 
al, 1980). Furthermore, the characteristic feature of CC, being tissue atrophy is positively correlated 
with survival rates in patients (Laviano et al, 2007). CC is largely responsible not only for reducing a 
good prognosis for cancer sufferers but for imparting considerable disability both physically and 
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mentally. In 2003, 2% of all people with a form of impairment reported cancer as the main condition 
causing the disability (ABS, 2006). Furthermore, in Australia cancer contributes a considerable 
overall disease burden and is the leading cause of death. In 2006 there were 106,000 new cases of 
cancer reported whilst the disease contributed to 28% of all deaths in Australia (AIHW, 2006., ABS, 
2006). In late stage disease up to 80% of these cancer patients will develop CC which includes 
atrophy of the heart muscle and consequently dysfunction.  
1.1 Gross body mass alterations 
In general the gross alterations seen in CC patients relate to changes in body mass. As a 
consequence of CC, patients lose a combination of fat, lean tissue and heart weight (Argiles et al, 
2007). Archaryya et al, 2004 found heart sizes in an animal model of CC to be significantly reduced 
and describes the reduction as a classic feature of cancer cachexia. Furthermore, a study by Costelli 
et al, 2001 showed that heart sizes were significantly reduced in an animal model of cancer cachexia 
and that this was due to an increase in protein catabolism. However, current research has focused 
more specifically on gross body alterations which are readily evident upon visual examination of the 
cachectic patient. Studies have thus predominantly examined and measured the atrophy associated 
with skeletal muscle and adipose tissue.  
Measurements of body mass distribution in cachectic patients have provided a basis for changes in 
tissue distribution in this chronic disease. However, measures such as weight, skin fold tests and 
other anthropometric methods; although simple do not provide adequate and complete assessment 
of patients as they do not take into account water retention (Fouladiun et al, 2005).  This is an 
important fact when considering that cachectic patients commonly exhibit increasing water 
retention which is correlated to disease progression (Langstein et al, 1991). Thus body composition 
measurements should involve measurements of fat mass, lean tissue and body water content, 
including extracellular fluid. Fouladiun et al, 2005 used clinical and metabolic data to assess time 
course changes of body composition in cancer patients. The measures used in this study were from 
the more complete DEXA method. The DEXA method is able to assess body mineral content, lean 
tissue and body fat mass. From the data obtained it was evident that both body fat and lean tissue 
mass were significantly reduced in cancer patients over time. The body compartmental analyses 
revealed that fat was preferentially lost from the trunk, followed by the leg and arm tissue 
compartments. Furthermore, serum albumin, whole body fat and caloric intake were significant 
predictors of survival. Importantly factors known to be involved in the pathogenesis of cancer 
cachexia, insulin, IGF-1, C-reactive protein, leptin and ghrelin were found to be predictors of both 
adipose and lean tissue content. The loss of body tissues is thought to largely result from the 
dysregulation of important body systems such as regulators of the immunity, protein synthesis and 
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degradation. As a consequence CC patients are known to experience a number of debilitating 
symptoms. Fearon et al, 2006 found that patients with CC have a significantly reduced quality of life 
which is directly related to the degree of body mass alterations and weight loss. Generally, clinical 
information is still lacking with regard to cardiac tissue mass in relation to disease progression and 
it’s correlation with important markers of the disease. Future clinical studies should examine post-
mortem heart weight/morphology of patients who have had CC as well as an evaluation of those 
suffering from the disease by the use of non-invasive echocardiographic measures of heart wall 
mass, left ventricular ejection fraction, stroke volume and cardiac output. 
1.2 Symptomology of cancer-cachexia 
General symptomology of cancer cachexia patients include pain associated with the neoplasm itself, 
dehydration, mood disorders, asthenia and fatigue. Management of these symptoms is usually via 
the use of pharmacological interventions including analgesics, antidepressants and psychostimulants 
(Del Fabro et al, 2006). Fatigue is one of the most common symptoms encountered by CC patients 
with or without end-stage palliative care. It has been recognised as one of the longest lasting and 
possibly the most disruptive of symptoms associated with CC (Curt et al, 2000). Fatigue in the cancer 
cachexia patient imparts its symptoms in the form of impaired physical and cognitive functioning. 
With impaired cognitive function, patients experience difficulty in concentrating, lack of motivation 
and a subsequent lack of interest in partaking in activities. Physically, patients usually perceive 
muscle weakness and decreased energy levels (Servaes et al, 2002). Other symptoms experienced by 
CC patients include co-morbidities such as infection, depression and various secondary effects of 
cancer therapy. Specifically, cancer therapy is also known to cause anaemia and malnutrition further 
exacerbating fatigue and weight loss. The mechanisms involved in producing fatigue are 
multifactorial, complex and as yet incompletely understood. One area of possible contribution is the 
effect of cardiac insufficiency and its contribution to fatigue. A reduction of heart muscle mass 
through atrophy is known to cause a drop in cardiac output and may contribute to the feeling of 
fatigue (Webb et al, 1986). Further theories include the dysregulation of serotonin (5-HT) whereby 5-
HT levels and their respective receptors are thought to be upregulated. This has been shown to lead 
to reduced somatomotor drive and modified hypothalamic-pituitary-adrenal axis function promoting 
a reduced capacity for physical activity (Ryan et al, 2007).   
1.3 Host-Tumour interaction 
The mechanisms by which CC causes wastage of the heart, adipose and skeletal muscle tissue is 
highly complex and involves a number of chemical interactions between the tumour and the host. 
These mediators can be categorised into two important groups being either tumour derived and 
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humoural factors. In searching for potential contributing factors, two important chemicals have been 
found both in animals and in the urine of cachectic patients. These chemicals are known to be 
produced and released by tumour cells and have been designated lipid mobilising factor or LMF and 
proteolysis inducing factor (PIF). These factors have been isolated from MAC16 tumour bearing mice 
and are known to produce protein and fat breakdown (Gordon et al, 2005). LMF has been shown to 
induce triglyceride hydrolysis (Hirai et al, 1998). Whilst PIF has shown powerful cachectic effects as 
evidenced when purified and administered to mice producing a 10% decrease in body weight within 
a 24-hour time period (Cariuk et al, 1997., Todorov et al, 1996).  
In many CC patients resting energy expenditure (REE) is increased despite total energy expenditure 
and physical activity being reduced (Moses et al, 2004). It is thought that this increase in REE is due 
to an increase in futile metabolic cycles. The cori cycle appears to be largely activated in cachectic 
patients as tumours do not use the Krebs cycle or mitochondrial oxidative phosphorylation to a large 
extent as oxygen levels are too low. The tumour uses large amounts of glucose and lactate forms as 
a bi-product (Tisdale, 2005). The liver via the Cori cycle converts circulating lactate back into glucose. 
The inefficiency of gluconeogenesis by converting lactate to glucose is thought to contribute 
significantly to overall increases in cachectic patient REE. 
Elevated humoural factors are predominantly in the form of cytokines released in response to 
tumour presence. The release of cytokines results in a persistent inflammatory response to the 
tumour and is largely due to resulting T-helper cell mediated release.  Important cytokines that are 
thought to be involved in the wastage of cachectic patients and animal models include TNF-α, IL-6, 
IL-1 and INF-γ (Martignoni et al, 2005., Noguchi et al, 1996). These cytokines also elicit an acute 
phase protein response in the liver which requires valuable host proteins for construction. 
Furthermore, cytokines such as TNF-α have been found to independently increase levels of ROS in 
tissues as well as activate protein degradation pathways.  
Current research suggests that host-tumour interaction is needed in order to produce cachexia as a 
disease in its most destructive and complete form. Hence combinations of immune related cytokines 
released together with tumour derived factors are needed to produce the gross metabolic 
dysfunction that leads to the tissue wastage seen in CC patients. It is these chemical interactions 
which are at the centre of the disease.  
1.4 Elevated resting energy expenditure 
Unlike starvation where basal metabolic rate is decreased in order to conserve energy many cancer 
cachexia patients exhibit increases in resting energy expenditure (Bosaeus et al, 2001). This is 
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important when considering that cachectic patients have decreased caloric intake which would 
suggest that even normal metabolic rates would contribute to a negative energy balance. However, 
studies have shown varied results regarding metabolic rates in cancer cachectic patients. These 
differences are largely due to varying tumour types and locations between studies. Studies 
investigating the metabolism of patients with lung and pancreatic cancers show significantly 
elevated resting energy expenditure (Falconer et al, 1994., Jatoi et al, 2001). Bosaeus et al, 2001 
examining 297 unselected cancer patients by indirect calorimetry found hypermetabolism was 
frequent, but was not found in all patients in the cohort. This may be explained by the fact that the 
cohort had a mixture of cancer patients with varied types of tumours. This fact is exemplified by 
patients with gastric or colorectal cancer, showing no elevation in resting energy expenditure (Fredix 
et al, 1991). In contrast Fouladiun et al, 2005 examined 311 unselected patients with a variety of 
tumours and found no significant changes in REE. However, this study had a majority of patients 
with tumours known not to be associated with hypermetabolism and were largely not of the lung or 
pancreatic type which are associated with elevated metabolic rates. Furthermore, this study did not 
examine differences within the cohort for changes in REE between types and location of tumours. 
The reason for such a variation based on tumour types is currently unknown and it is still under 
investigation. However, common mediators such as the cytokines TNF-α and IL-1 have been linked to 
hypermetabolism in cachectic patients across the board including patients with inflammatory 
conditions such as rheumatoid arthritis (Roubenoff et al, 1994). Roubenoff et al, 1994 showed that 
in patients with cachexia, cytokine production via endotoxin stimulation was directly associated with 
REE when comparing patients to controls. Contrasting these findings, serum levels of TNF-α were 
undetectable in pancreatic cancer patients. However, serum Il-6 was elevated in these patients but 
was not significantly different between cachectic patients with and without acute phase response. 
Further investigations found that isolation of peripheral mononuclear cells and not from that of 
blood have significantly higher cytokine responses with both TNF-α and IL-6 elevated in cachectic 
patients with acute phase protein response (Falconer et al, 1994). These results suggest that the 
acute phase response commonly seen in CC patients is important in producing hypermetabolism and 
that local rather than systemic cytokine release plays an important role in mediating cachexia.  
Another suggested mechanism of hypermetabolism seen in a cancer cachexia patient population 
relates to brown adipose tissue. Brooks et al, 1981 found that weight loss in a rat model of cancer 
cachexia was associated with a high metabolic rate in brown adipose tissue. Although little 
information exists with regard to human investigation, examination of peri-adrenal tissue autopsy 
samples found brown adipose tissue in 80% of cachectic patients compared to aged matched 
controls (Shellock et al, 1986). Furthermore, uncoupling proteins (UCP-2 and UCP-3) which has been 
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found to increase skeletal muscle thermogenesis and energy expenditure may play role in the 
hypermetabolic response of some cachectic patients (Gordon et al, 2005). Those patients showing 
elevated metabolism however once treated successfully either surgically or by chemotherapy 
whereby the primary tumour is removed have a normalisation of REE (Arbeit et al, 1984). 
1.5 Acute phase protein response 
Another factor which contributes to the state of hypermetabolism in cachectic patients is the acute 
phase response (APR). APR is a characteristic feature of a number of systemic disorders centred on 
global inflammatory events as evidenced in diseases such as trauma, sepsis and cancer cachexia. 
Importantly APR is needed in restoring homeostasis in response to infection and inflammation. 
Characteristically there is a reaction to elevated circulating cytokines whereby the liver produces 
acute phase proteins. These acute phase proteins such as fibrinogen and c-reactive protein have 
important functions in response to infections and contribute to haemostasis and microbicidal 
activity in the body. Thus, APR is needed to fight infection and for the repair of damaged tissues 
(Moshage, 1997). With regard to cancer cachexia APR is a common feature seen in up to 45% of 
pancreatic cancer patients (Falconer et al, 1994). Although the role for APR in cancer patients is 
unknown the stimulus for the response appears to be due to the release of cytokines in response to 
tumour presence. The common cytokines which are known to stimulate APR include IL-1, IL-6 and 
TNF-α. All of which have been shown to be elevated in animal models of cancer cachexia (Tisdale, 
1997). Fearon et al, 1990 when assessing circulating cytokines in patients with hepatic metastasis 
secondary to colorectal cancer found that IL-6 levels were significantly higher compared to controls. 
Furthermore, the APR in pancreatic cancer patients is associated with a significantly higher REE 
compared to cancer patients with no APR. APR is also associated with elevated spontaneous 
peripheral blood mononuclear production of TNF-α and IL-6 (Falconer et al, 1994). Suggesting that 
the local production of cytokines including that produced in the liver have an important role in 
regulating APR. The resulting metabolic change in patients with cancer cachexia with APR is 
exacerbated weight loss. This occurs as a result of characteristic protein breakdown from tissues 
such as the heart and skeletal muscle and usage from the free amino acids released by these tissues 
by the liver to produce acute phase proteins. The net effect is an elevation in protein synthesis in the 
liver to produce acute phase proteins. Importantly the amino acids needed for the acute phase 
proteins are derived from those once contributing to the structure of cardiac and skeletal muscle. 
Furthermore, rates of negative phase reactants being proteins such as albumin have been found to 
be the same as controls in pancreatic cancer patients (Fearon et al, 1999). Thus the 
hypoalbuminaemaemia seen in cancer cachexia patients may be due to increased transcapillary 
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escape secondary to increased micro-vascular permeability and may explain why the condition is 
associated with fluid accumulation.   
Figure 1.2 Depiction of the interplay between host and tumour derived factors acting on organs to 
bring about net tissue atrophy (Tisdale, 2005). 
1.6 Cancer-anorexia cachexia syndrome 
Anorexia or involuntary weight loss is another common feature of cancer cachexia which contributes 
to and exacerbates tissue wasting. Again, similar to that of fatigue in the cachectic patient, anorexia 
is multifactorial and is described as the consequence of cachexia and not the cause. The first issue 
leading to nutritional dysfunction is the involvement of the neoplasm in the alimentary canal in 
some patients with gastrointestinal cancers. This can cause mechanical obstruction, pain and early 
satiety. Furthermore, the cachectic state is known to alter the perception of food taste whilst 
symptoms of depression are linked to reduced food intake (Argiles et al, 2007). Usually a negative 
energy balance coupled with weight loss is a very strong stimulus for food intake. However unlike 
the urges to consume food in starvation, patients suffering from cachexia experience a degree of 
reduced stimulus. This is despite the rapid and significant weight loss that characterises the disease. 
Essentially anorexia seen in cancer cachexia patients is the failure of physiological mechanisms that 
would normally result in the stimulus for food intake (Inui, 2002).   
Gelin et al, 1991 showed that tumour bearing mice with cachexia had decreased food intake 
compared to controls. Furthermore, treatment with anti-TNF and anti-IL-1 or in combination 
attenuated anorexia. Whilst the administration of important cachectic cytokines in animals without 
tumours can reproduce the distinct features of the anorexia syndrome found in cancer cachexia 
12 
 
(Inui, 2002). Thus sufficient evidence exists as to suggest that cytokines play an important role in the 
cachexia-anorexia syndrome. These cytokines may produce long term inhibition of feeding by 
stimulating the increased expression and release of leptin. Leptin levels are usually decreased in the 
presence of starvation and weight loss which is in turn detected by the hypothalamus. However, in 
CC the increased expression and release of leptin from adipose tissue may render this corrective 
mechanism ineffective and inoperable (Wigmore, 1997). Other mechanisms of appetite 
dysregulation in CC relate to neuropeptide Y or NPY. NPY is found in the brain and hypothalamus 
and is downstream from the leptin pathway (Inui, 2002). NPY is known to be the most potent 
feeding stimulatory peptide and has been shown to be effective in driving appetite in tumour 
bearing rats injected with the chemical (Chance et al, 1996). The typical cytokines seen to produce 
cachexia again have been shown to disrupt this pathway. IL-1 administered into the cerebral 
ventricles of rats has been shown to antagonise NPY (Sonti et al, 1996).  
Another pathway of importance is the melanocortin signalling pathway. It comprises of a family of 
proteins regulating appetite, temperature, memory, behaviour and immunity (Inui, 2002). The 
dysregulation of the melanocortin system relates to the unresponsiveness of the body to losses in 
weight with CC. Usually the system will respond to decreases in body weight in periods of starvation 
for example by decreasing its activity including that of adrenocorticotropin hormone and hence 
conserving energy. However, in cachexia this mechanism similar to that of the leptin and NPY 
pathways is dysregulated and stays active, thus not contributing to the conservation of energy 
(Marks et al, 2001). Evidence exists suggesting that melanocortin receptor blockade is able to 
reverse anorexia and to some extent cachexia. This was achieved in animal models of CC and 
suggests a pivotal role for melanocortin signalling in cancer-anorexia syndrome (Wisse et al, 2001., 
Lechan & Tatro, 2001). Furthermore, the dysregulation of the melanocortin system during cachexia 
may contribute to the state of hypermetabolism seen in animal models and patients with cancer 
cachexia. This is important when considering that lowered food intake cannot completely explain the 
wasting seen in cancer-cachexia. Bosaeus et al, 2001 when assessing the dietary intake and resting 
energy expenditure of unselected cancer patients found that energy intake per kilogram body 
weight did not differ to weight stable patients and that hypermetabolism was frequently seen in this 
population. Thus, although anorexia contributes to the state of cachexia decreased food intake is 
only one of a multitude of mechanisms contributing to the disease. 
1.7 Cancer cachexia and mechanisms of muscle tissue loss 
The understanding of mechanisms of overall protein loss is essential in providing possible 
therapeutic targets for cachectic patients. In the heart like all systems the overall rates of protein 
synthesis and degradation is precisely balanced. Even minute decreases in protein synthesis or an 
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acceleration of protein degradation can result in a marked loss of tissue mass and body weight as a 
whole. The understanding of the molecular mechanisms related to CC is thus an important part of 
elucidating the pathophysiology of the disease. However, contributing pathways leading to cardiac 
atrophy in CC are still largely unknown and many studies draw from investigations of mechanisms 
related to skeletal muscle loss. Skeletal muscle tissues have three major proteolytic systems which 
have also been found to be active in the heart; being the calcium dependent calpain system, 
lysosomal protease pathway and the ubiquitin proteosome system (UPS). The calcium dependent 
calpain and the lysosomal systems appear not to be involved in bulk protein breakdown but are 
important in the initial steps of protein degradation.  
1.7.1 Atrophy of the heart muscle in cancer cachexia 
Hellerstein & Santiago-Stevenson, 1950 investigated atrophy of the heart by examining 2000 
autopsy cases. 85 proven cases of cardiac atrophy were found and studied with regard to the 
relevant aetiologic factors, histological features and clinical status of patients. The study maintained 
a ridged criterion for inclusion and based the post mortem diagnosis of cardiac atrophy on significant 
loss of myocardial mass, wrinkling of the epicardium, increased nuclei to muscle fibre ratio and 
decreased muscle fibre size. The cases of which were included suffered from a number of 
debilitating diseases the most important of which were malignant neoplasm’s. Neoplasm’s 
constituted 73% of patient cases in which cardiac atrophy was found. Within this group malignant 
carcinoma affecting a number of different organ systems constituted the main pathologic diagnosis 
before death. Upon histological examination the atrophied hearts exhibited compactly arranged, 
narrow, short and twisted muscle fibres. Variations of nuclei were evident and were smaller than 
normal in some cases. The epicardium was grossly examined and was found to be wrinkled in most 
patient cases. Interestingly during clinical examination of patients before death most hearts were 
considered to be normal in size with radiologic examination. However at autopsy the weight of these 
hearts were lower than normal and the organ was considered to be atrophied. This discrepancy or 
apparent increase in heart size prior to death was most likely due to dilatation. Other clinical 
features of patients with cardiac atrophy were faint and distant heart sounds. A definite trend for a 
fall in blood pressure accompanying disease progression was also evident. Importantly, some 
patients also exhibited passive hyperaemia presumably as a consequence of cardiac insufficiency. Of 
the patients classified as having cardiac atrophy 16 of these patients had ECG measures before 
death. 13 of these patients showed abnormal results with low voltage QRS complexes, low or absent 
T waves and prolongation of P-R and Q-T intervals. The clinical findings in this patient population 
suggest that cardiac atrophy secondary to diseases such as cancer cause significant changes in the 
ability of the heart to pump adequate blood around the body. This was evidenced by cases of low 
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blood pressure, faint heart sounds and was probably manifested as passive hyperaemia. These 
results complement more recent studies of cardiac atrophy associated with malnutrition. Webb et 
al, 1986 describes the condition as having a number of important negative effects. Such as low 
cardiac output with decreased QRS voltage and ventricular arrhythmias associated with a prolonged 
Q-T interval. Furthermore, it is known that loss of myocardial proteins and subsequent cardiac 
atrophy is an important factor in sudden death as seen with rapid weight loss (Van Itallie & Yang, 
1984).  
In a separate study by Inagaki et al, 1973 reviewing the specific causes of death in 816 cancer 
patients, organ failure after systemic infection was the most important factor in mortality. Within 
the category of organ failure, cardiac insufficiency was the most likely cause of death, most cases of 
which were not associated with tumour invasion of the heart (Inagaki et al, 1973). Thus, cardiac 
atrophy is not only a characteristic feature of CC but also contributes to considerable disease 
burden. The implications of heart tissue wastage have not been adequately studied. However, the 
limited studies examining cardiac atrophy suggest that the event is secondary to and tightly 
associated with neoplastic conditions; and has the potential to be life threatening in many patient 
cases.  
Only scant research exists as to the molecular mechanisms and changes in the atrophying heart 
secondary to cancer cachexia. Tian et al, 2010 using a mouse model of CC found that fractional 
shortening of cardiac muscle is reduced when examined with echocardiographic imaging. The study 
also found that cardiac muscle exhibited fibrosis when examined histologically and that gene 
expression of troponin I was also reduced. Atrophy of the heart is defined as an acquired reduction 
in the size and mass of the organ and is described as a classic feature of CC (Acharyya et al, 2004). 
Significant decreases in heart weight by 60% have been shown in a rat model of CC compared to 
control (Costelli et al, 2001). Tian et al, 2010 was one of the first studies to identify cardiac 
dysfunction in vivo in cancer cachectic mice. Tian and colleagues used a murine colon-26 
adenocarcinoma model of cancer cachexia. It was surmised that cardiac dysfunction measured as 
decreased fractional shortening in these mice was possibly due to cardiac fibrosis. Moreover, mice 
were found to express the foetal gene program which is a change from MHC-α to MHC-β mRNA. This 
change in MHC isoforms has been associated in the past with heart failure (Tian et al, 2010). 
Currently little research exists examining the physiological processes which accompany cardiac 
atrophy and the contribution to disease particularly with CC. Interestingly, a study by Cosper and 
Leinwand, 2011 found that in the same mouse adenocarcinoma model of cachexia the reduction of 
cardiac mass seen as a reduction in all sarcomeric proteins is via autophagy and not the Ubiquitin 
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proteasome system (UPS). However, in contradiction to this is a more recent study by Tian et al, 
2011 demonstrated that apart from cardiac dysfunction and again a change to the foetal MHC 
isoform, the mRNA of UPS E3 ligases were increased. Furthermore, Tain et al, 2011 found that there 
was increased protein ubiquitinylation in the hearts of cancer cachexia mice compared to controls 
suggesting that indeed the UPS has a role to play in the disease. A recent review of the importance 
of the UPS in cardiac disease was undertaken by Willis et al, 2013. Willis and colleagues in 
summarising the current literature stated the importance of the UPS in cardiac cell signalling and 
protein degradation. Furthermore, it appears the UPS and autophagy pathways do crosstalk and 
interact at some levels. Despite recent advances in the understanding of cardiac atrophy secondary 
to cancer cachexia it is still unknown how molecular events proceed throughout the disease in a 
temporal basis. Furthermore, less is known about heart atrophy in cancer in a patient population.  
With regard to the importance of cardiac atrophy in terms of an organism function Xu et  al, 2011 
has used both measures of cardiomyocyte function and in vivo m mode echocardiography of cancer 
cachectic mice to assess function. Xu et al, found that the atrophy of the heart caused by cancer 
cachexia in mice is associated with severe impairment of myocardial contractility via significantly 
reduced fractional shortening of the myocyte. Little data exists in terms of human studies examining 
the functional consequence of cardiac atrophy. However, NASA has studies the effect of cardiac 
atrophy after space flight and bed rest. Perhonen et al, 2001 found that unloading of the human 
heart was associated with reduced LV wall size and diastolic dysfunction. The importance of these 
studies suggest that not only is atrophy of the heart related to reduced cardiac functioning but it 
may impede the ability for patients to physiologically withstand arduous cancer treatments.  
 
1.7.2 The calpain system 
The calpain system is part of an intracellular family of non-lysosomal cysteine proteases and 
constitutes the early process of proteolysis (Razeghi & Taegtmeyer, 2006). The calpain system is 
ubiquitously present in a number of tissues including the myocardium (Ohsumi et al, 1984). The 
regulation of this system is under the influence of small changes in calcium concentrations and the 
associated endogenous inhibitor calpastatin (Skipworth et al, 2006). Calpains exist in a number of 
forms; the major components are calpains 1, 2 and 3. Calpain 1 and 2 are also known as μ and m 
(milli) respectively corresponding to the micro and milli-molar calcium requirements for activation. 
Essentially calpain has a calcium binding domain similar to that of calmodulin and its activity is 
regulated by intracellular calcium concentrations and the withdrawal of the endogenous inhibitor 
calpastatin (Singh et al, 2004).  
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The calcium activated calpain system has been shown to be involved in the degradation of the 
contractile protein troponin I and certain cytokeletal protein elements such as fodrin, desmin, alpha-
actin and spectrin. The role and contribution of muscle specific calpain 3 however is less understood 
and its inhibition rather than activation is thought to be required for atrophy to occur (Skipworth et 
al, 2006).  Once activated the calpain system is predominantly involved in the disintegration of 
myofibrillar proteins thus making them available to the UPS (Goll et al, 2003).  
Calcium activated proteases have been shown to be involved in a number of disease states 
associated with atrophy of the heart including ischemia reperfusion injury, the unloaded rat heart 
and cancer cachexia (Costelli et al, 2001; Razeghi & Taegtmeyer, 2006). Razeghi et al, 2006 states 
that the calpain system is a regulator of cardiomyocyte atrophy which is evidenced by an increase in 
the gene expression of key markers of calpain activity being calpain 1 and 2 and a decrease in the 
inhibitory regulator calpastatin.  Thus, the calpain system constitutes an important mechanism in the 
heart muscle which can influence contractile proteins and function. Costelli et al, 2001 used a 
method to isolate calpastatin and calpain and measured their activities using a direct assay protocol. 
The study investigated the influence of calcium dependent proteolysis in a model of CC examining 
both the gastrocnemius and heart muscle. The cachectic rats injected with Yoshida ascites hepatoma 
cells exhibited a significant reduction in the wet weight of both tissues over a 6 day period to the 
same degree. This was accompanied by a significant decrease in calpastatin activity in the heart 
suggesting that the calpain system was activated in the heart of tumour bearing rats. The calpain 
system was found to be activated early in the rat model of CC and decreasing levels of calpastatin 
persisted for the experimental period of 6 days.  
Interestingly suppression of the calpain system by inhibitors of intracellular calcium has not been 
successful in attenuating disease in various animal studies of CC (Temparis et al, 1994, Baracos et al, 
1995). However, the general consensus is that the calpain system is not involved in bulk protein 
degradation and is instead more important in activating a number of signal transduction pathways 
(Costelli et al, 2001). Calpains are known to be capable of degrading ion channels, enzymes, cellular 
adhesion molecules and cell surface receptors. Calpains have also been shown to cleave xanthine 
dehydrogenase to xanthine oxidase and thus indirectly contributing to the formation of superoxide 
radicals (Skipworth et al, 2006). Thus, both the calpain and lysosomal system may precede bulk 
muscle breakdown which has been largely shown to be due to the activation of the UPS in skeletal 
muscle. However, information is lacking as to the role of the UPS in the heart of cachectic animals 
and patients.  
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1.7.2 The ubiquitin proteasome system 
Proteins first targeted by the calpain and lysosomal system may then be passed to the UPS. The UPS 
is the principle mechanism by which muscle proteins are degraded. The steady and progressive 
depletion of muscle mass in CC is the predominant phenotypic feature of the disease and would 
suggest a pivotal role in systems of protein degradation. The UPS has been found to be upregulated 
both in experimental models and patients with CC (Khal et al, 2005., Bossola et al, 2003). Thus, 
constituting a significant contribution to muscle loss and associated negative outcomes.  
Before proteins can be degraded by the UPS they must first be conjugated to multiple molecules of 
ubiquitin. Ubiquitin is a 76-amino acid that is readily available in the cytoplasm of all cells including 
cardiomyocytes. In order for this conjugation or targeting system to occur ubiquitin must first be 
activated in the presence of ATP by the action of an enzyme called ubiquitin activating enzyme (E1). 
Activated ubiquitin is then transferred from the enzyme E1 to the active site of another enzyme 
designated ubiquitin carrier protein or E2. Various isoforms of E2 have been found in skeletal 
muscle, but only the expression of 14-kD E2 appears to be regulated in muscle wasting (Tisdale, 
2005). Bound E2 with ubiquitin is important as it recognizes the E3 conjugating enzymes. There are 
several hundred different intracytoplasmic E3 protein ligases, however only three have been shown 
to be critical for activation of proteolysis during muscle atrophy (Muscaritoli et al, 2007). These 
ligases are termed, E3 alpha and more recently, two specific muscle ligases have been found which 
are shown to be important in a number of conditions causing atrophy including CC. These are 
termed muscle-specific F-box (MAFbx)/atrogin-1 and muscle specific ring finger 1 or MURF-1 (Bodine 
et al, 2001). The importance of MAFbx/atrogin-1 and MURF-1 were evidenced in a study by Bodine 
et al, 2001 which showed that mice deficient in these E3 ligases were resistant to muscle wasting. 
Essentially the E3 ligases allow conjugation reactions to take place which form a chain of ubiquitins 
linked to each other and the protein substrate. Only when ubiquitin is targeted to a selected protein 
can it then be recognised by the proteasome. The ubiquitin/protein complex is then unfolded after 
being transferred to the 19 s subunit of the proteasome. The unfolded proteins can then be 
transported into the central chamber of the 20s core proteasome where the proteins are cleaved 
progressively by proteolytic sites of the inner rings. Together, the two regulatory 19s subunits 
flanking the 20s core proteasome form the 26s proteasome. The proteins are cut into small peptides 
of 6 to 12 amino acids and then released and hydrolysed into amino acids by cytosolic 
exopeptidases. Upon release of the amino acids ubiquitin is returned to the cytoplasm where it is 
recycled for use by the proteolytic pathway (Ciechanover, 1994) (refer figure 1.0).  
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Figure 1.3 Above depicts the molecular events of the ubiquitin proteasome pathway in muscle. 
Importantly the E3 ligases MURF-1 and MAFbx have been found to be expressed in cardiomyocytes 
and associated with a number of disease states which lead to the the degradation of contractile 
proteins. Adams et al, 2007 investigated the mRNA expression of MAFbx, MURF-1, TNF-alpha and 
troponin I in a model of congestive heart failure (CHF). Interestingly this study found a positive 
correlation between the mRNA levels of TNF-alpha that of the E3 ligases MAFbx/Murf-1. 
Furthermore the exposure of cardiomyocytes to TNF-alpha resulted in troponin I unbiquitinylation 
which led to the impairment of contractility (Adams et al, 2007). Specifically Murf-1 is able to bind to 
the sarcomeric protein titin and degrade cardiac troponin I. Whilst MAFbx interacts with calcineurin 
A, alpha-actin-2 and degrades MyoD (Kedar et al, 2004). Further evidence of the importance of the 
UPS in atrophy was found via the investigation of cardiac atrophy using a model of heterotopic 
transplantation. The mRNA transcript levels of six known regulators of the UPS was examined, most 
importantly was the increased expression of ubiquitin B (UbB) whilst the ubiquitin ligases Mafbx and 
MuRF-1 were found to be decreased. The unexpected decrease in ubiquitin ligases was explained by 
an increase in insulin like growth factor 1 (IGF-1) expression in the same atrophied hearts. IGF-1 is 
known to inhibit FoxO3 otherwise known as the subfamily of forkhead transcription factors which is 
known to regulate the expression of ubiquitin ligases Mafbx and MuRF-1. Thus increased IGF-1 may 
contribute to prevention of excessive atrophy of the heart by activation of FoxO3 and suppression of 
Mafbx and MuRF-1 at least in this model of atrophy (Razeghi et al, 2006). A murine model of CC was 
investigated to assess the contribution of the UPS. Lazarus et al, 1990 found that the rates of 
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unbiquitin conjugating enzymes were significantly increased in this model. In cancer patients with CC 
the gene and protein expression of the proteosome subunits C2 and C5 was increased 3 fold in 
skeletal muscle samples compared to patients without weight loss with or without cancer. Increased 
levels of E214K expression was also found to be increased in CC patients with weight loss. The level of 
proteosome subunit expression was found to be dependent on the degree of weight loss and peaked 
when weight loss was around 12-19%. Further increases in weight loss meant a subsequent decrease 
in proteosome subunit expression (Khal et al, 2004). These results are consistent with those by Khal 
et al, 2005 investigating the gastrocnemius and pectoral muscles of cachectic mice. The results 
showed that the expression of subunits C2 and C5 as well as the ubiquitin conjugating enzyme E212k 
was significantly higher than control. Specifically there was a 6-8 fold increase in the C2 proteosome 
subunit and a 2 fold increase in C5 and E212k. Interestingly these increases peaked at the same point 
as with cachectic patients around 12 to 20%. Weight loss above 25-27% revealed a relative decrease 
in the expression of regulatory proteins of the UPS. This may indicate that other factors such as the 
suppression of protein synthesis may be important when weight loss is above 20% in patients and 
animal models with CC. Currently little data exists as to the contribution of protein synthesis 
pathways associated with the loss of myocardial proteins with CC. Razeghi et al, 2003 found that in 
an atrophying rat heart there was a concurrent increase in the expression of ubiquitin conjugating 
enzyme (UbcH2) and components of the mTOR (mammalian target of rapamicin) pathway which is 
thought to be the most important signal for the activation of protein translation. The simultaneous 
activation of the mTOR pathway may suggest a compensatory mechanism for heart muscle loss with 
unloading and or needed for active remodelling. Similarly one of the only studies examining the 
atrophying heart of a cachectic mouse investigated gene expression of important markers of cardiac 
remodelling. Specifically, remodelling genes where found to switch to foetal isoforms. 
Echocardiography revealed decreased cardiac wall thickness and an increase in the expression of 
important UPS ligases MURF-1 and Atrogin-1 were increased (Tian et al, 2011). Another study by 
Cosper & Leinwand, 2010 using a similar adenocarcinoma CC mouse model found that autophagy 
rather than the UPS may be central to cardiac atrophy. This was evidenced by an increase in UPS 
ligases MURF-1 and ATROGIN-1 gene expression in skeletal muscle samples but not cardiac.  Whilst 
markers of autophagy with regard to both gene transcripts and protein analysis were shown to be 
increased. The degree of atrophied hearts in the CC mice was also shown to be worse in the male 
mouse group. This may be due to oestrogen protection but this theory is currently unsubstantiated 
(Cosper & Leinwand, 2011).  
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1.8 Oxidative stress in cancer cachectic patients 
Current research regarding the affects of ROS on the heart has centred on the progression of 
myocardial fibrosis, hypertrophy and heart failure rather than atrophy as seen with CC. It is well 
known that CC is associated with increases of key inflammatory cytokines and oxidative stress as 
part of a systemic response to tumour presence (Gomes-Marcondes & Tisdale, 2002, Barreiro et al, 
2005). TNF-α for example has been shown to induce the production of oxidants via increases in 
mitochondrial derived superoxide anions (O2-) (Hennet et al, 1993).   
A common finding with regard to muscle wasting evident in murine models of cancer cachexia is the 
associated increase in levels of important markers associated with oxidative stress, namely MDA 
(malondialdehyde). Barreiro et al, 2005 studying the role of ROS in a model of cancer-induced 
cachexia found that protein levels of MDA are increased in tumour bearing rats whilst levels of 
important antioxidant enzymes such as superoxide dismutase remain unchanged in cachectic 
muscles. These results suggest an inability of key antioxidant enzymes in handling increased ROS, 
thus contributing to the development of oxidative damage and instigating protein loss.  Another 
important aspect of muscle wasting in cachexia is the contribution of nitrosative stress. In a rat 
model of the disease gastrocnemius muscles were assessed via western blot analysis and protein 
tyrosine nitration was found to be significantly increased in rats with advanced cachexia (Barreiro et 
al, 2005).  Murr et al, 1999 assessing the contribution of oxidative stress in a cancer patient 
population found that an indicator of oxidative stress (neopterin) was elevated and that this increase 
correlated with stage of disease, worsening prognosis and survival time. A consistent finding by 
Kaynar et al, 2005 pointed out that patients with either non-small-cell or small cell lung cancer have 
elevated levels of MDA and xanthine oxidase activity compared with controls. Furthermore, patients 
treated with a combination of antioxidant therapies have shown positive results in that lean body 
mass after supplementation has increased significantly after a period of 2 and 4 months. Antioxidant 
therapy in a CC patient population has been shown to decrease levels of both ROS and 
proinflammatory cytokines (IL-6 & TNF-α). These effects translated into an increased quality of life 
for patients after antioxidant therapy (Mantovani et al, 2004). 
1.8.1 Oxidative systems in the heart 
There are a number of different sources of ROS in the heart including that derived from the 
mitochondria (tetravalent reduction of O2), xanthine oxidase, NADPH oxidase and lipoxygenase. 
Oxidative stress has been found to be a fundamental part of the pathogenesis of many conditions 
affecting the cardiovascular system. Free radicals are known to cause damage to macromolecules 
such as membranes, DNA and proteins; contributing to cell death and necrosis in the heart. Of the 
various sources of ROS, NADPH oxidase appears to be a major contributor to the generation of 
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superoxide and appears to be important with regard to redox signalling (Cave et al, 2005). GP91phox 
is the important catalytic unit of the NADPH oxidase complex. It was first found in phagocytes and is 
important in host defences as it produces O2- capable of damaging and destroying bacteria. Several 
isoforms of gp91phox have now been discovered in non-phagocytic tissues around the body and 
termed NOX1-5. gp91phox has since been renamed NOX2 and is abundantly expressed in endothelial 
cells, fibroblasts and cardiomyocytes. NOX1 does not appear to be significantly expressed in 
cardiomyocytes though has been found in cultured vascular smooth muscle cells. NOX4 on the other 
hand is widely expressed and is coexpressed by both endothelial cells and cardiomyocytes. The 
NOX2 to NOX4 ratio expression ratio by real-time PCR is 1:2 (Byrne et al, 2003). The NADPH oxidase 
complex consists of a membrane bound and cytosolic portion. The cytosolic or regulatory 
components include p47phox, P67phox, P40phox and RAC. The membrane bound portion of the complex 
named cytochrome b558 consists of a NOX and p22phox subunit. The p22phox subunit acts to stabilise 
and provide a binding site for the regulatory protein p47phox during translocation and activation of 
the cytosolic complex whilst NOX forms the catalytic core for superoxide production. NADPH 
oxidases can be activated by a number of pathological stimuli including g-coupled receptor agonists 
(AII), cytokines (TNF-α), growth factors, ischaemia-reperfusion and mechanical stress. The activation 
of tissue associated NOX is similar to that seen in phagocytic cells, whereby translocation of the 
regulatory cytosolic components to the membrane is essential for NADPH activation. Once the 
cytosolic components are activated the cytosolic units including p47phox, P67phox, p40phox and RAC are 
phosphorylated. At present the actions of these phosphorylations is unknown except for that of 
p40phox. It is known that the p47phox subunit is heavily phosphorylated and changes its 
conformational shape allowing translocation and binding to the membrane bound component 
p22phox (El-Benna et al, 2005). The P47phox component plays a pivotal role in oxidase activation as it is 
also responsible for the recruitment and facilitation of P67phox binding to the b558 cytochrome. The 
RAC cytosolic component is also necessary for the activation/regulation of oxidase activity and is 
dormant until activated. When stimulated it together with P47phox, P67phox and P40phox migrates to 
the membrane. At which point RAC binds to guanosine triphosphate (GTP) and in this GTP bound 
state interacts with P67phox. The RAC/P67phox complex is then targeted to NOX thus activating the 
catalytic production of superoxide (2O2 + NADPH → 2O2- + NADPH+ + H+) (Cave et al, 2005; Opitz et al, 
2006; Kawahara et al, 2007).  
.. 
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Figure 1.4 NADPH oxidase. Membrane bound NOX2 requires the translocation of cytosolic subunits 
to the cytochrome B558 for activation (Assari, 2006).  
Like that of superoxide production via NADPH oxidase many of the important free radicals affecting 
the heart are derived from oxygen. NADPH oxidase essentially produces O2-, from O2 which can then 
be converted to hydrogen peroxide (H2O2) via superoxide dismutase or SOD. Superoxide disumutase 
is an important antioxidant in the heart and its dysregulation has been implicated in a number of 
diseases including that of CC (Russell et al, 2007). The endogenous antioxidant enzyme system is 
capable of dismutating O2- from a variety of sources including that of NADPH oxidase. Three different 
types of SOD’s exist in the heart all of which catalyse reactions that dismutate superoxide. The 
production of superoxide molecules from the tetravalent reduction of O2 in the mitochondria is one 
source of O2-. This usually occurs as the reduction of O2 is not completely efficient and hence 
incompletely reduced O2- can leak from the electron transport chain. This particular source of O2- has 
been found in disease states such as ischemia reperfusion injury. However, has not been 
investigated as a potential source of ROS in the heart afflicted with cachexia. Normally in the heart 
O2- leakage from the electron transport chain is dismutated by manganese superoxide dismutase or 
MnSOD to H2O2 in the mitochondrial matrix. Any O2- that escapes the mitochondria can then be 
converted to H2O2 spontaneously or via the action of copper-zinc superoxidedismutase (CuSOD) 
located in the cytosol. H2O2 is reduced to H2O and O2 by another two important antioxidant enzymes 
catalase and glutathione peroxidase. Outside of the cell itself exist extracellular SOD or ecSOD which 
accounts for only a small amount of total SOD activity. H2O2 can also react with metals including iron. 
This is termed the Fenton reaction and produces the hydroxyl radical (OH). Another alternative is the 
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Haber-Weiss reaction which involves O2- reacting with H2O2 producing hydroxyl radicals. The OH 
radical is very reactive, although it is not as stable as O2- or H2O2 and will react predominantly at its 
site of formation (Kevin et al, 2005). 
In the heart xanthine oxidase is another important enzyme capable of catalyzing the oxidation of 
hypoxanthine and xanthine to uric acid whilst reducing O2 to O2- and H2O2. Importantly, hydrogen 
peroxide is a non-radical but is freely permeable and is a highly reactive oxygen species. As 
mentioned hydrogen peroxide can then be converted to H2O and O2 by important antioxidant 
enzymes such as catalase and glutathione peroxidase. Nitrosative stress includes the involvement of 
nitric oxide synthase which can also generate the free radical nitric oxide (NO). NO can interact with 
O2- to form ONOO- or peroxynitrite. However, peroxynitrite may be part of the antioxidant system as 
it is far less reactive then the alternative OH. radical (Kevin et al, 2005). Excessive nitric oxide (NO) 
production can also produce ONOO- through a reaction with O2-. ONOO- appears to be the most 
important product of NO production which can elicit deleterious effects through the nitration of 
amino aromatic amino acids, lipids and DNA bases (Barreiro et al, 2005). Both ROS nitrosative stress 
are known to be involved in the pathogenesis of many cardiovascular related diseases including that 
of congestive heart failure (CHF), myocardial stunning and the initiation of atrophic signalling.  
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Figure 1.5 Details of the various sources of ROS in the heart and the pathways or balance between 
antioxidant enzymes and free radicals (Trachootham et al, 2009). 
 
1.8.2 Oxidative stress as a potential contributor to cardiac 
atrophy in cancer cachexia 
It is known that oxidative stress in the cardiovascular system plays a crucial role in remodelling and 
can lead to the loss of functional tissue through a number of mechanisms including apoptosis. 
However the role of oxidative stress in the atrophying myocardium of a cancer cachectic patient is 
currently unknown. As discussed earlier there are a number of sources within the myocardium 
capable of producing excess or pathologic levels ROS. These include the mitochondria, nitric oxide 
synthase, xanthine oxidase and NADPH oxidase. In terms of atrophy of the myocardium like that of 
skeletal muscle, cardiomyocyte size is dependent on the relative rates of protein synthesis and 
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degradation (Razeghi & Taegtmeyer, 2006).  However, no such studies have examined the role of 
ROS in the atrophy of hearts afflicted with CC. In many other cardiomyopathies ROS may be 
produced in excess which leads to injury and disease progression exemplified by myocardial 
dysfunction. Furthermore, increased ROS can lead to inflammation and fibrosis via oxidative stress 
induced activation of pro-inflammatory pathways via the redox sensitive transcription factor NFκβ 
(Valen et al, 2001). ROS is also thought to lead to increased inflammatory cell aggregation by 
increasing endothelial cell adhesion molecules such as VCAM-1, Pselectin and macrophage migration 
inhibitory factor. (Lee et al, 2001., Patel et al, 1991., Takahashi et al, 2001). It is currently unknown 
whether there is an increase in ROS production in the atrophying cachectic heart. However, as with 
skeletal muscle, oxidative stress may be a player and have various other implications other than 
atrophy. A study by Williams & Allen, 2007 found that in a mouse model of Duchennes muscular 
dystrophy (DMD) there was an increased level of superoxide production. This was paralleled with an 
increase in NADPH oxidase levels in heart tissue. The cardiomyocytes in this model also exhibited 
decreased fractional shortening and compromised calcium handling. Importantly a clinically relevant 
end point associated with both animal models and patients with DMD is heart failure. Furthermore, 
the treatment of mdx (muscular dystrophin deficient) mice with the antioxidant (N-acetylcysteine) 
improved calcium handling and returned fractional shortening to control values.  
Possible instigators of ROS production with regard to the heart afflicted with CC are 
proinflammatory cytokines. They have been found to be essential in causing disease related atrophy 
in skeletal muscle but are yet to be investigated with regard to cardiac atrophy. However, cytokines 
are a known activator of ROS in a state of global inflammation whereby TNF and IL-1 are known to 
stimulate neutrophils, monocytes, T cells and endothelial cells to generate free radicals and damage 
the myocardium (Das et al, 1990). Furthermore, TNF can also affect the cardiovascular system 
directly by decreasing myocardial contractility, enhancing apoptosis, and incite endothelial 
dysfunction (Das, 2000). Furthermore, it is unknown whether levels of circulating angiotensin II are 
elevated with cancer cachexia. Although, Sukhanov et al, 2011 was able to mimic human cachexia by 
infusing angiotensin II into animals brining about skeletal muscle proteolysis and increased levels of 
ROS. Further research is needed to investigate the potential of the renin angiotensin system and its 
contribution to ROS and cachexia. 
Interestingly both cardiac atrophy and hypertrophy appear to be linked to a pro-inflammatory state. 
The variation or contribution between ROS in atrophy versus hypertrophy could possibly be 
explained by the difference in the myriad of other signalling mechanisms or input involved in heart 
failure versus CC. In the first instance congestive heart failure is a consequence of sustained 
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increases in cardiac workload that is most commonly secondary to hypertension or following 
myocardial infarction. This is accompanied by a change in myocardial wall thickness as a result of 
increased muscle stress and myocardial demand that initially compensates to normalise cardiac 
workload.  However, pathologic cardiac hypertrophy eventually leads to CHF as the ventricle dilates 
and becomes impaired. With CC however the disease is characterised by systemic inflammation as 
well as tumour derived mediators such as PIF and with advanced disease prolonged periods of bed 
rest. Essentially creating a state of low cardiac workload coupled with factors known to induce 
significant degrees of atrophy in related tissues such as skeletal muscle. In elucidating the similarities 
in pathways in atrophy between skeletal muscle and the heart Razeghi et al, 2003 used an unloaded 
rat model of cardiac atrophy. The study identified that TNF-α, a known regulator of the UPS was 
increased as well as ubiquitin conjugating activity. However, the study did not assess whether an 
increase in TNF-α was also linked to excessive amounts of ROS. It may be possible that the presence 
of known regulators of ROS production like that of inflammatory cytokines is causing increases in 
oxidative stress. Furthermore, it is unknown whether an increase in oxidative stress in the heart 
causes an increase in the UPS through direct protein degradation or and\or via redox signalling 
mechanisms. However, it is known that as with skeletal muscle in cancer-cachexia, the UPS is 
activated early in the atrophying heart. Interestingly this study also identified that the mTOR 
pathway responsible for protein translation was also activated in the unloaded rat heart and may 
indicate a compensatory mechanism for myocardial protein loss. Furthermore, important cytokines 
that are central to the development of CC are shown to increase ROS in the heart as well as skeletal 
muscle. This increase in ROS is capable of directly inducing oxidation and damage of various 
molecules including membranes and genetic material thus causing cellular damage and accelerated 
cell death via apoptosis and necrosis (Cave et al, 2005).  
1.9 Redox signalling and the activation of proteolytic pathways 
together bring about muscle atrophy 
The limited research undertaken to elucidate the pathways responsible for the breakdown of the 
heart with CC have shown an increase in the calpain pathway (Costelli et al, 2001). Although it is 
proposed that this activation does not fully account for the total breakdown of cardiac tissue with 
cachexia. Previous studies have shown that the increased proteolytic rates in muscle preparations 
have not been suppressed by inhibitors of the calpain pathway (Baracos et al, 1995., Temparis et al, 
1994). It has been suggested however that calpains do not contribute to bulk proteolysis and are 
instead important for the activation of signal transduction pathways (Costelli et al, 2001). Thus, a 
situation of increased calpain activity as seen in hearts afflicted with CC may constitute a causative 
or a regulatory mechanism of atrophy and may precede bulk protein breakdown. This is further 
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substantiated by a study undertaken by Razeghi et al, 2006 using a unloaded rat heart model. The 
study found that in some unloaded rat hearts calpain 1 and 2 as well as calpain activity was 
increased. However, in the hearts of animals overexpressing the endogenous inhibitor calpain 
cardiomyocytes size still significantly decreased suggesting an important role for other proteolytic 
systems such as the UPS.  
Razeghi et al, 2003 used a rat model of cardiac atrophy to examine the contributions of pathways of 
protein synthesis and degradation. The study found that transcripts of TNF-α are elevated early in an 
unloaded rat heart model of cardiac atrophy. The increased expression of TNF-α was paralleled by 
an increase in the expression of the important ubiquitin-conjugating enzyme UbcH2. This may be 
one reason explaining why previous studies have shown that increased levels of TNF-α lead to 
contractile dysfunction of the myocardium. Interestingly, p70S6K and 4EBP1 being downstream 
components of the mTOR pathway were also activated in the atrophying heart. The simultaneous 
activation of protein synthesis pathways may involve a protective or at least a compensatory 
mechanism in the unloaded rat heart. It is currently unknown whether this possible adjustive 
mechanism is present in the heart of a patient afflicted with cancer cachexia.  Patten et al, 2001 
mentions that there is a clear link between myocardial dysfunction and the release of circulating 
cytokines such as IL-1β and TNF-α in response to sepsis. It would appear that inflammatory cytokines 
have a role to play in driving muscle atrophy and in cardiac remodelling. Both TNF-α and IL-6 
administered to rats have been shown to reduce the mRNA expression of β-myosin heavy chain and 
α-actin compared with saline controls (Patten et al, 2001). A study by Adams et al, 2007 used a rat 
model of congestive heart failure to assess the involvement of cytokines in the remodelling of the 
heart. The study found that levels of TNF-α were increased 3.1 fold and that this was positively 
correlated with increases in important UPS ligases namely MAFbx and MURF-1. Furthermore, these 
rats showed a decrease in contractility via the proteolysis of troponin I. The pathway linking the 
global inflammatory response in diseases such as sepsis, CCF and CC are largely unknown. However, 
NFκβ has been shown to respond to both cytokines and ROS. Zhou using a mouse model of cancer 
cachexia found that tumour bearing mice show an increase in TNF-α, IL-6 and NFκβ. 
In elucidating the mechanisms by which ROS contributes to the loss of lean body mass Gomes-
Marcondes & Tisdale, 2002 attempted to replicate the oxidative stress seen in cancer cachexia by 
using murine myotubes in cell culture. The myotube cells were exposed to H2O2, which induced 
oxidative stress. The results found that this oxidative stress caused an increase expression of 
important UPS elements including the 20s proteasome and the E214k conjugating enzyme. In further 
elucidating the role of ROS in cachexia important factors such as PIF have again been introduced to 
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myogenic cell culture. PIF administration to myotube cells caused significant proteolysis. Importantly 
antioxidant therapy with butylated hydroxytoluene and D-α-tocopherol led to the attenuation of 
total protein breakdown in these cells. This may explain the success of antioxidant therapy in certain 
patient populations. Furthermore, in this same experimental model specific inhibitors of NADPH 
oxidase such as diphenylene iodonium were shown to attenuate ROS production in cells exposed to 
either PIF or angiotensin II. Thus, the ROS and subsequent oxidative stress seen in cachexia may be 
in large part derived from NADPH oxidases (Russell & Tisdale, 2007).  In assessing pathway which 
links ROS production of cachectic factors and proteolysis Wyke & Tisdale, 2005 administered PIF to 
murine myoblasts in culture. PIF was able to induce total protein breakdown including the loss of 
myosin. PIF also increased the expression of the UPS that was attenuated via the use of a Iκβα 
mutant. Usually NFκβ needs the phosphorylation of its inhibitory molecule Iκβα to translocate to the 
nucleus to promote transcription of an array of genes. The Iκβα mutant however had mutations of 
the phosphorylation sites required for degradation. Hence PIF’s inability to induce expression of the 
UPS in the mutant Iκβα myotubes suggests a key role for NFκβ in linking PIF to the activation of 
proteolysis. Thus PIF appears to be capable of inducing proteolysis in cachectic muscles by both 
inducing oxidative degradation of Iκβα likely through the activation of pro-oxidants molecules. The 
exact mechanisms that link ROS to cancer cachexia and its contribution to the pathogenesis of the 
disease are still incompletely understood. Furthermore, little is known with regards to the role of 
ROS as a contributing mechanism of cardiac muscle atrophy as a consequence of cancer cachexia. 
There are a number of intracellular signalling pathways implicated in the regulation of cardiac 
muscle wasting with cancer cachexia. Both anabolic and catabolic pathways like that seen in skeletal 
muscle such as the UPS and the mTOR pathway are likely to be involved. At least in skeletal muscle it 
has been shown that cachectic factors are able to increase proteolytic activity whilst suppressing 
protein synthesis. Furthermore, the induction of protein degradation via PIF, TNF-α and ROS all 
appear to activate NFκβ (Elley & Tisdale, 2007). Thus, the nuclear transcription factor NFκβ appears 
to be a common pathway mediating proteolysis. NFκβ is a transcription factor that regulates a 
myriad of processes in cardiomyocytes including inflammation, apoptosis, proteolysis and protein 
synthesis (Skipworth et al, 2006). Although pathways involving the production of ROS and the 
activation of NFκβ appear to bring about increases in the expression of key UPS units in skeletal 
muscle, it is unclear if this occurs in the heart. Another important pathway being p38MAPkinase is 
also important in muscle atrophy, as it is sensitive to redox signalling. Derbre et al , 2012 found that 
in unloaded rat hind limbs there is increased XO activity and ROS in the soleus muscle along with an 
increase in p38MAPkinase. Furthermore, previous research by Reid, 2005 found that p38 signalling 
promotes skeletal muscle atrophy via MAFbx ubiquitin ligase. Thus, providing a link between pro-
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oxidant enzymes such as XO and the predominant protein breakdown pathway in muscle. 
Importantly there is no current research adequately assessing the role of redox signalling and its 
implications in cardiac atrophy secondary to CC. Research is needed to assess whether a state of 
oxidative stress is present in the cachectic heart and determine the possible link between ROS and 
proteolysis. This would be best achieved by examining important pro and antioxidant systems in the 
cachectic heart in a time course manner to assess whether oxidative stress is predominant and the 
possibility of it being an initiating factor in early cachexia. Furthermore, treatment trials inhibiting 
possible targets of oxidative stress would be important in establishing the importance of the event in 
cardiac muscle and provide insight into possible therapeutics for patients.   
1.10 Summary 
In summation CC is associated with a myriad of metabolic changes which bring about weight loss. 
Beyond the loss of total body weight patients with CC experience a poorer prognosis and increased 
rates of mortality. There are two levels by which metabolic changes in CC bring about weight loss. 
Both systemic and local metabolic alterations in CC are brought about by a host-tumour interaction. 
On a systemic level patients with CC have an elevated REE which contributes to the loss of lean 
tissue. This elevated REE appears to be the product of inefficient energy usage by the tumour, an 
acute phase response and general inflammation. Some patients also experience anorexia which 
further dampens the ability to maintain and regain weight. On a local level much of the current 
research surrounding CC is focused on the atrophy of skeletal muscle as it is one of the most 
profound physical changes associated with the disease. Both inflammatory mediators and tumour 
derived cachectic factors have been shown to independently bring about tissue atrophy in 
experimental animal models. Thus, in a patient these factors work together to bring about significant 
weight loss over time. Importantly, recent studies have shown that cardiac muscle atrophy is also 
present in animal models and patients with CC. However, the molecular mechanisms by which 
cardiac atrophy occurs secondary to CC are largely unknown. It is possible however, to draw upon 
research of skeletal muscle atrophy to select pathways for investigation. Studies have shown that 
skeletal muscle proteolytic pathways are switched on in response to CC. Specifically; the UPS is 
upregulated at a gene and activity level in animals with CC. Furthermore, cachectic skeletal muscle 
has also been shown to be in a state oxidative stress which is linked to the activation of the UPS. It is 
currently unknown whether oxidative stress is an initiating factor in CC or whether it plays a role in 
the myocardium. An important step in linking oxidative stress to muscle atrophy is redox signalling. 
Redox signalling as well as pro-cachectic factors have been shown to activate NFκβ and 
p38MAPkinase in skeletal muscle which in turn is associated with increases in the UPS.  
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In the heart like all cells there exists a balance of pro and anti-oxidant systems. These systems have 
been shown to be disrupted in cardiac disease bringing about structural cardiac changes. Generally 
these changes are varied and depending on the stage of the disease can involve hypertrophy, 
fibrosis and atrophy. Currently no data exists examining the potential for oxidative stress to 
contribute to the atrophying cachectic heart. Furthermore, the molecular and histological 
characterisation of muscle atrophy and indeed of the myocardium over time has yet to be 
investigated. Likewise as no recommended treatment for cancer cachexia exists thus there is little 
data examining potential therapeutics for cardiac atrophy in CC.  
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2.0 Hypothesis and Aims 
2.1 Hypothesis: 
This thesis was undertaken as three separate studies to test the hypothesis set below. In general the 
hypothesis set by this study is based on evidence of the molecular mechanisms associated with 
skeletal muscle atrophy in CC animal models. It is hypothesised that cardiac muscle will have the 
same molecular aetiology of atrophy secondary to CC as seen in skeletal muscle and that targeting 
these changes will be of therapeutic benefit. The following are the specific hypotheses of this thesis. 
x Study 1: Oxidative balance and the ubiquitin proteasome system in the atrophic cachectic 
heart. 
o The total body weight and heart mass of animals bearing MAC16 tumours will be 
significantly reduced  
o A state of oxidative stress exists in the heart of CC mice 
o mRNA levels and enzyme activity of important pro-oxidant enzyme will be elevated 
in the cachectic heart and contribute to the disease 
o Protein levels of the NADPH oxidase subunits will be elevated and be a significant 
contributor to cardiac atrophy 
o As a response to elevated oxidative stress levels endogenous antioxidant enzymes 
will be elevated to compensate for this 
o Oxidative stress in the cachectic heart will be associated with increases in the UPS as 
seen in skeletal muscle 
 
x Study 2:  Temporal study of the molecular and structural alterations in the cachectic heart. 
o Animals with MAC16 tumours will have a steady decline in weight loss over time as 
seen in previous studies 
o Tumour size will increase with time and be negatively associated with animal weight 
o Heart mass will significantly decrease over time like that of skeletal muscle 
o Histological parameters will show a universally decreased heart size with a relative 
change in cardiac chambers which is progressive over time 
o Heart collagen content will be increased in cancer cachectic hearts over time 
o Decrease in heart mass will be associated with increases in local and systemic 
inflammatory markers, oxidative stress and increased expression of the ubiquitin 
proteasome system 
o Oxidative stress will be associated with the activation of redox signalling molecules 
providing a link between radical oxygen species and proteolysis 
 
x Study 3: Therapeutic intervention of cancer induced cardiac atrophy with 
eicosapentaenoic acid and oxypurinol. 
o In general the therapeutic benefit of EPA and oxypurinol on ameliorating total body 
weight and cardiac tissue loss will be similar however, will be more profound when 
administered in combination.  
o Intervention of MAC16 bearing mice with EPA and oxypurinol will partially 
ameliorate total body weight loss and tumour growth. 
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o Both treatments will prevent loss of cardiac tissue by the end of the experimental 
period 
o Intervention will decrease markers of oxidative stress   
o Amelioration of oxidative stress will be accomplished by the interventions in varying 
ways whereby: EPA will increase levels of endogenous SOD and oxypurinol will 
inhibit the endogenous pro-oxidant enzyme XO. 
o Expression of UPS elements will be decreased in treatment animals 
2.2 Aims 
The following are the aims of this thesis based on the hypothesis put forth in section 2.1. Again the 
aims will be detailed based on three separate study sections detailed below. 
x Study 1: Oxidative balance and the ubiquitin proteasome system in the atrophic cachectic 
heart. 
o To investigate the degree of cardiac atrophy in a mouse model of cancer induced 
cachexia 
o Assess the following molecular alterations of the atrophic myocardium 
 Oxidative stress 
 Pro/anti-oxidant system balance 
 Expression of the prominent proteolytic system 
x Study 2:  Temporal study of the molecular and structural alterations in the cachectic heart. 
o To investigate the gross body mass alterations and tumour burden of cancer 
cachectic mice over time 
o Assess the change in organ mass and structure of cancer cachexia animals over time 
o Investigate the structural changes associated with cardiac atrophy secondary to 
cancer cachexia 
o Investigate the following molecular alterations involved in cardiac atrophy of cancer 
cachectic mice just prior, early and late in the evolution of cancer cachexia weight 
loss 
 Oxidative stress 
 Endogenous pro/anti-oxidant balance 
 Systemic and local inflammatory mediator levels 
 Levels of key cellular redox signalling pathways 
 Expression of the prominent proteolytic pathway 
 
x Study 3: Therapeutic intervention of cancer induced cardiac atrophy with 
eicosapentaenoic acid and oxypurinol. 
o To investigate the therapeutic potential of EPA and oxypurinol in ameliorating total 
body weight loss of cancer cachectic mice 
o Assess the anti-cancer therapy of EPA and oxypurinol 
o Examine the effect of the therapies on preserving organ weight in particular the 
heart muscle 
o Investigate the following molecular mechanisms which EPA and oxypurinol may 
bring about therapeutic treatment of cardiac atrophy in cancer cachectic mice 
 Cellular oxidative balance 
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 Expression of the key proteolytic pathway 
This thesis will undertake three separate studies to test our hypotheses and answer the aims we 
have set forth. The following are the titles and chapters of each of those studies: 
x Chapter 4: Oxidative balance and the ubiquitin proteasome system in the atrophic cachectic 
heart 
 
x Chapter 5: Temporal study of the molecular and structural alterations in the cachectic heart 
 
x Chapter 6: Therapeutic intervention of cancer induced cardiac atrophy with 
eicosapentaenoic acid and oxypurinol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
3.0 Chapter 3 Methods 
 
3.1 Cell culture of MAC13 and MAC16 cells 
The murine adenocarcinoma cell line 13 (MAC13) and 16 (MAC16) were donated by Professor 
Michael Tisdale (pharmaceutical Science Research Institute, Aston University, Birmingham, UK) and 
kept at -80°C until further use. Cells were cultured to 80% confluence and passaged into multiple 
culture flaks to provide enough for injection into the nude mice. 
3.1.1 Preparation of cells and culture medium 
Cell culture medium was prepared by adding 52.5 ml of RPMI1640 media with L-glutamine (Roswell 
Park Memorial Institute, GIBCO, USA) and 50 ml of foetal bovine serum (FBS, Invitrogen, USA) to a 50 
sterile falcon tube. 2.5 ml of penicillin and streptomyacin was added to the cell culture media falcon 
tube which was subsequently heated to 37°C.  
Cells were stored in eppendorf tubes and removed from the -80°C freezer and thawed at room 
temperature. The thawed cell suspension was centrifuged at 200xg for 5 minutes at 25°C. Following 
this the media was removed and the pallet was resuspended in 10 ml of fresh cell culture media pre 
heated to 37°C. The pallet was resuspended in the fresh media by pasteur pipette mixing.  
3.1.2 Culturing murine adenocarcinoma cells 
10 ml of the heated cell culture medium was then added to a 250 ml T-75 ventilated cell culture flask 
(Sarstedt, Australia). The cells resuspended in fresh culture medium were then added to the flask. 
The cell culture flask was kept in a humidifier at 37°C where the cells were allowed to grow. 
Meanwhile, cells were given fresh media every 48 hours. This was achieved by removing pre-
prepared growth media from a 4°C fridge and heating to 37°C in a water bath. Meanwhile half of the 
culture medium from flasks containing either MAC13 or MAC16 cells was removed and then 
replaced with heated growth media. Cell flasks were placed back into the humidifier and allowed to 
growth to 80% confluence at which time they were split.  
Splitting of the MAC13/16 cells firstly involved the removal of culture medium via pastuer pipette to 
leave the MAC cells which are attached to the bottom of the culture flask. 0.05% trypsin EDTA 
(Sigma, USA) was preheated to 37°C and added to the cell culture flasks to detach cells from the 
flask and placed into the incubator for 3 minutes. The cell culture flask was then tapped gently on 
the side to detach cells. The detachment of cells was visualised with microscopy before adding 7 ml 
of growth media to inactivate trypsin. Following this, the cells were transferred into 2 or 4 new cell 
culture flasks by adding either 5 or 2.5 ml of the original flask cell culture suspension to new flasks. 
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Thus, either 5 or 7.5 ml of fresh pre heated growth medium was then added to the new flasks to 
make a new 10 ml culture. Flasks were then placed into the incubator for further growth to 80% 
confluence or preparation for injection into nude mice to start the cancer cachexia physiological 
model.      
  3.1.3 Passaging of MAC13/MAC16 cells into balb/c nude mice 
Each of the three separate animal studies undertaken in this thesis is detailed below. All of these 
studies used the same cell culture, cell passage and balb/c nude mouse animal model of CC. The 
passaging of cell lines to mice was accomplished by firstly removing all of the growth media from the 
cell culture flasks via pastuer pipette. 3 mls of trypsin is then added to the flask which is placed into 
the 37°C incubator for 5 minutes. Once the flask is removed from the incubator it is gently tapped to 
dislodge the cells. After this 7 ml of fresh growth media is added to the flask and the total 10 ml is 
transferred to a sterile falcon tube. The falcon tube with MAC cell suspension is centrifuged at 500 
xg after which the supernatant is removed and replaced with 1.5 ml sterile PBS. The cell/PBS mixture 
is then transferred to a sterile 2 ml eppendorf tube. This is enough volume of MAC cells to passage 
into 5 nude mice given the extra volume wasted in the needle hub. 200 μL is then drawn up via a 25 
g needle into a 0.5 ml synringe. The syringe with cell suspension was kept warm in an polystyrene 
esky with a 37°C heat pad until injected into the flank of a balb/c nude mouse.   
3.2 Animal model of cancer induced cachexia 
There were three separate studies undertaken in this thesis. The animal model for each study was 
similar in that 8 week old female nude mice were all randomised to receive an injection of MAC13 or 
MAC16 cancer cells in their flank. The differences in each study were related to the aims put forth at 
the beginning of the experimentation. Study 1 was focused on the aetiologic molecular events of 
cardiac atrophy secondary to advanced cancer cachexia. To achieve this study 1 used a murine 
model of cancer cachexia and harvested tissues for analysis when these animals reached there 
ethical limit for weight loss being 25% of the initial reading.  Study 2 aimed to further understand the 
aetiologic events of cardiac atrophy in cancer cachectic mice by collecting tissues in a time 
dependent manner. Study 2 used the same mouse model as study 1 however; animals were 
randomised to be euthanised for tissue harvest 0, 12, 21 and 29 days after inoculation with MAC 
cells. Study 3 then used the data collected from studies 1 and 2 to target molecular events in the 
cachectic heart and assess the therapeutic benefit. To achieve this study 3 again used the same 
mouse model of cancer cachexia as the previous two studies and randomised these animals to 
receive one of two potential therapeutics or the drugs in combination. Study 3 animals were 
euthanised 29 days after the inoculation of MAC cells as this was the time taken until most animals 
reached there ethical limits of tumour size and weight loss.   
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3.2.1 Study 1 – Oxidative balance and the ubiquitin proteasome 
system in atrophic cancer cachectic hearts 
Study 1 experimental procedures were carried out with approval from the Victoria University animal 
ethics committee (AEETH 07/05). Six week old BALB/c nu/nu nude mice purchased form the Animal 
Resource Centre, Western Australia and were acclimatised for two weeks prior to injection of the 
cancer cell lines. Animals were maintained under controlled conditions of a 12 hour light/dark cycle 
at 21qC. Food and water was provided ad libitum. Food and water was weighed before and after the 
experimental period to ensure weight loss in the CC group was not due to a decrease in caloric 
intake. Animals were randomised into three weight matched groups consisting of a no cancer, 
cancer control and cancer cachexia. To establish these groups the control animals received no 
injection of MAC cells, cancer control received an injection of MAC13 cells and cancer cachexia 
received an injection of MAC16 cells. 
3.2.2 Study 2 – Temporal study of the molecular and structural 
alterations in the cachectic heart 
Study 2 experimental procedures were approved from the Deakin University animal welfare 
committee under ethics number AWC 2/08. Female Balb/c nu nu mice aged 8 weeks (Animal 
Resource Centre, Cannning Vale, Australia) were randomised to one of four time points being 
days 0, 12, 21, 29. At each time point animals were then further randomised to either cancer 
control or cancer cachexia. A total of eight groups existed with n= 20 animals per group.  Animals 
were housed in groups of 5, with free access to food and water throughout the study. Animals 
groups were housed in cages complete with HEPA filter system. Ambient temperature was set to 
22°C±2°C with humidity at 40-60% and a 12-hour light/dark cycle. The standard chow and water 
supplied ad libitum was weighed and documented at the end of each week of experimentation to 
determine caloric and water intake between groups. This project does recognise the limitations 
of not having individual animal calorie and water intake data. It has been previously shown that 
water and calorie intake does not significantly differ between nude mice bearing during the 
development of MAC13 or 16 tumours (Monitto et al, 2001). Therefore this project is not 
replicating individual animal calorie or water intake as has been done previously. Individual 
animal weight was measured and recorded daily to determine differences between groups. 
Whilst tumour size was measured and recorded using digital callipers. Mice were euthanised via 
injection of sodium pentobarbital injection via a 27 gauge needle (30 mg/Kg) (Virbac Animal 
Health, Regents Park, Australia). All tissues were harvested directly after euthanasia. The heart 
was harvested weighed and a base to apex measure was completed using digital callipers. The 
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brain, kidney, peri-renal fat, liver, quadriceps, soleus tissues were also weighed. All tissues were 
prepared for gene, enzyme or protein analysis by placing harvested tissue in eppendorfs which 
was immediately immersed in liquid nitrogen. Tissue samples were then stored in a -80°C freezer 
until further laboratory analysis was undertaken. Heart tissue from n= 10 animals per group was 
also prepared for histological analysis by immersion and storage in 4% paraformaldehyde. 
 
3.2.3 Study 3 – Therapeutic intervention of cancer induced 
cardiac atrophy with eicosapentaenoic acid oxypurinol.  
Study 3 experimental procedures were approved from the Deakin University animal welfare 
committee under ethics number AWC 13/2010. Female Balb/c nu nu mice aged 8 weeks (Animal 
Resource Centre, Cannning Vale, Australia) were sourced for the study. The same animal model of 
cancer cachexia as used in study 1 and 2 were used for this therapeutic study so that comparisons 
could be made.  The animals were acclimatised for a period of one week prior to the injection of 
cancer cell lines. The nude mice were housed in groups of 5, with free access to food and water 
throughout the study. Animals groups were housed in cages complete with HEPA filter system. 
Ambient temperature was set to 22°C±2°C with humidity at 40-60% and a 12-hour light/dark cycle. 
The standard chow and water supplied ad libitum was weighed and documented at the end of each 
week of experimentation to determine caloric and water intake between groups. Individual animal 
weight was measured and recorded daily to determine differences between groups. Whilst tumour 
size was measured and recorded using digital callipers. All animals were injected with MAC16 cells in 
the flank via a 27 gauge needle on day 1 of therapeutic intervention. Animals at this time were 
randomised to a one of four groups of n= 10 being no treatment, EPA (EPAX, Aalesund, Norway, 0.4 
g/kg/day), Oxy (Sigma-Aldritch, Castle-Hill, Australia; 1 mmol/L in drinking water) and EPA and oxy in 
combination. At the end of 29 days post intervention mice were euthanised via injection of sodium 
pentobarbital injection via a 27 gauge needle (30 mg/Kg) (Virbac Animal Health, Regents Park, 
Australia). All tissues were harvested directly after euthanasia. The heart, brain, kidney, peri-renal 
fat, liver, quadriceps, soleus tissues were weighed. All tissues were prepared for gene, enzyme or 
protein analysis by placing them in eppendorfs and immediately immersed in liquid nitrogen. Tissue 
samples were then stored in a -80°C freezer until further laboratory analysis was undertaken.  
Across all studies animals were monitored daily before being euthanised for tissue harvest at the 
appropriate time point. For ethical reasons if an animal was significantly ill, reached a weight loss of 
greater than 25% of their initial reading or tumour growth exceeded 1000 mm3 the animal would be 
euthanised and tissues used for analysis if this occurred at an experimental time point.  
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3.3 Gene expression analysis 
Gene expression was completed on samples from all three studies. The genes selected for study 
were based on the results of previous experimentation on skeletal muscle samples of CC animal 
models. The studies undertaken in this thesis hypothesized that gene transcripts found to be 
changed in cachectic skeletal muscle samples would also be important in the aetiology of cardiac 
atrophy secondary to CC. 
3.3.1 RNA extraction 
Total RNA was extracted from frozen heart tissue samples using tri reagent (Astral scientific, Sydney, 
Australia) using the manufactures methods. 10 mg of heart tissue was placed into 2 ml screw top 
cryovials wth 500 mg homogenization beads and 1 ml of tri reagent. The cryovials were then placed 
into the fast-prep homogenizer (MP Biomedicals, Australia) for 30 seconds at speed 6 followed by 
cooling on ice for 5 minutes. The homoginisation and cooling steps were repeated 3 more times 
before centrifuging samples at 12,000 g for 10 minutes at 4°C. The supernatant was removed and 
transferred to an eppendorf tube. 100 μL of bromochloropropane was then added to the samples 
before shaking them for 15 seconds. The samples were stored for 5 minutes at room temperature 
before centrifuged at 12,000 g for a further 15 minutes at 4°C. The supernatant was then transferred 
to a new eppendorf tube. 500 μL of isopropanol and 20 μL of 75% ethanol were then added and 
samples shaken again for 10 seconds. Following this the samples were stored for 5 minutes at room 
temperature and centrifuged once again at 12,000 g for 8 minutes at 4°C. The supernatant was then 
removed and discarded whilst 1 ml of 75% ethanol was added to the samples. The samples were 
then subjected to a vortex and further centrifuged at 7,500 g for 5 minutes at 4°C. The supernatant 
was removed and the RNA pallet was air dried before being dissolved in 30 μL of nuclease free 
water. The RNA samples were quantified using the NanoVue apparatus (GE Healthcare Biosciences, 
Australia).  
3.3.2 Reverse transcription 
cDNA was generated from 0.5 μg RNA using the Marligen cDNA synthesis kit (Marligen Biosciences, 
Sydney). Following RNA extraction the samples were placed on ice and 10 μL of reaction was set up 
in a microeppendorf tube. Each sample tube contained 2 μL of cDNA synthesis, 0.5 μL of reverse 
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transcriptase, 1 μg of RNA sample and nuclease free water to make up to a volume of 10 μL. The 
samples were then placed in a MYCycler Thermal Cycler (Bio-Rad, USA) and set to 1 cycle at 22°C for 
5 minutes, 1 cycle at 42°C for 30 minutes, 1 cycle at 85°C for 5 minutes and held at 4°C. The cDNA 
samples were then stored in a -80°C freezer until further analysis. 
3.3.3 Real time polymerase chain reaction (RT-PCR) and gene 
analysis 
RT-PCR was undertaken using the iQ5 multicolour RT-PCR detection system (Bio-Rad, USA). The PCR 
reactions were undertaken using the iQ SYBR Green Supermix (Bio-Rad, USA). The genes analysed 
and the respective primer sequences used to target these genes are detailed in table 3.1 below. All 
primers were designed using Primer 3 and obtained from GeneWorks (Hindmarsh, Australia). 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
18s 
MURF-1 
MAFbx 
GTAACCCGTTGAACCCCATT 
AGGAGCAAGTAGGCACCTCA 
 
AAGATCAAACGCTTGCGAAT 
ATCCAATCGGTAGTAGCG 
GTCCATGTCTGGAGGTCGTT 
 
GAACATCATGCAGAGGCTGA 
NOX1 TGGTCATGCAGCATTAAACTTTG CATTGTCCCACATTGGTCTCC 
NOX2 TTGGGTCAGCACTGGCTCTG TGGCGGTGTGCAGTGCTATC 
NOX4 TGTTGGGCCTAGGATTGTGTT AAAAGGATGAGGCTGCAGTTG 
p67phox CTGGCTGAGGCCATCAGACT AGGCCACTGCAAGAGTGCTTG 
p40 phox GCCGCTATCGCCAGTTCTAC GCAGGCTCAGGAGGTTCTTC 
CuZn SOD TGAACCAGTTGTGTTGTCAG TCCATCACTGGTCACTAGCC 
Mn SOD TGGCTTGGCTTCAATAAGGA AAGGTAGTAAGCGTGCTCCCACAC 
XDH ATCTGGAGACCCACTGCACC TGTGCTCACGAAGAGCTCCAT 
Table 3.1 Primer sequences for target genes 
Each primer was rehydrated to a final concentration of 100 μM using nuclease free water. All 
primers were stored at 100 μM concentration until use. Primers were further diluted to a final 
concentration of 2.4 μM. Prior to use the cDNA samples were also diluted 1:10 with nuclease free 
water. The RT-PCR was set up in a total reaction of 25 μL which contained 12.5 μL of SYBR green 
supermix, 3.12 μL forward primer, 3.12 μL reverse primer, 3.12 μL nuclease free water and 3.12 μL 
cDNA sample. The conditions for PCR were 95°C for 4 minutes, 40 cycles of 95°C for 10 seconds, 50°C 
for 30 seconds, 72°C for 20 seconds followed by 95°C for 1 minute and 50-95°C read every 1°C, held 
for every 3 seconds. Flourescent emission data was collected and mRNA levels were analysed using 
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the critical threshold (CT) value. The expression of the gene of interest was calculated using the 2-
deltaCT and normalized to the cDNA concentration per sample.  
The cDNA concentration was quantified by the Quant-iT OliGreen ssDNA quantification kit 
(Invitrogen, Australia) according to the manufacturer’s instructions. This entailed the preparation of 
oligo standards which was prepared as per table 3.2 below. Next, a black 96 well flouro plate with 5 
μL of standard or sample was prepared. 95 μL of 1x TE buffer and 100 μL of 1x ssDNA reagent was 
added to the wells. The plate was the incubated at room temperature for 5 minutes whilst been 
protected from light. The fluorescence was read using a microplate analyser (Fusion-Alpha HT, 
PerkinElmer) with excitation set at 485 nm and emission at 538 nm.   
Table 3.2 Oligo standards 
 
3.4 Protein quantification and western blot analysis 
 
3.4.1 Protein extraction method 
The BioRad DC protein extraction and quantification kit (BioRad, Australia) was used to prepare 
homogenates for western blot analysis. Firstly 10 mg of heart tissue was dissected from harvested 
hearts and placed in 2 ml screw cap tubes with 500 mg of ceramic beads. 200 μL of lysis buffer 
(BioRad, Australia) was then added to the tube. The tube with tissue and beads was placed into the 
fast prep tissue homogeniser (MP Biomedicals, Australia) for 20 seconds at speed 6. The tissue 
homogenate was then placed on ice after each homoginisation step for 5 minutes before repeating 
the fast prep procedure a further 2 times.  
The protein quantification assay was achieved using the materials and methods supplied with the 
BioRad DC Protein Assay kit (BioRad, Australia). As a lysis buffer was used in the homgenisation of 
cadiac muscle a working reagent A was created. This was achieved by adding 20 μL of reagent S to 
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each ml of reagent A. Next 4 dilutions of a protein standard were created. A 1 ml working solution of 
1 mg/ml of supplied bovine serum albumin was used to create 4 standards as per table 3.3.  
 
Volume of working solution (μL) Volume of milli q water (μL) Final BSA concentration (mg/ml) 
40 10 0.8 
30 20 0.6 
20 30 0.4 
10 40 0.2 
Table 3.3 Protein assay standards 
100 μL of standards and sample were then transferred by pipette to 2 ml dry test tubes. 500 μL of 
working reagent A was then added followed by 4 ml of reagent B. All test tubes were vortexed for 5 
seconds immediately after. After 15 minutes of incubation at room temperature both the standards 
and samples were analysed via a spectrophotometer (BioRad, Australia) at 750 nm. The linearised 
standard curve was then used to calculate the amount of protein in each sample.  
3.4.2 Western blotting protocol 
Samples were prepared by placing 50 ug of protein into microcentrifuge tubes and SDS loading 
buffer. Samples are then heated to 100°C for 5 minutes and loaded soon after. In preparation to run 
the western blot protocol 10% SDS was made up using 10 g of sodium dodecyl sulphate with 100 ml 
milli q water. Whilst electrophoresis buffer was made up using 30.2 g 0.12 M tris base, 144 g glycine, 
10 g SDS with 1 L milli q water. This electrophoresis buffer is a 10 x solution and was diluted to 1 x 
before use with milli q water. The 50 ug of total cellular protein and standards was then loaded on 
12% polyacrylamide gels (NuSep, New South Wales, Australia) and separated by standard SDS-PAGE. 
SDS-PAGE protocol involved running apparatus at 130 volts for 90 minutes in electrophoresis buffer.  
Gels were then transferred to polyvinylidine fluoride membranes (Bio Rad, Australia). Blots were 
blocked with Tris-buffered saline including 0.1% Tween 20 and 5% non-fat dried milk. Primary 
antibody (Santa-Cruz Bioscience, USA) against p47phox, NOX2 and GAPDH at a dilution of 1 in 2000 
was then added to the membrane and incubated overnight at 4°C. Secondary donkey-antigoat 
antibodies (Santa-Cruz, California, USA) conjugated to HRP at a 1 in 10,000 dilution was then added 
to the membrane for 1 hour at room temperature. Antigen-antibody complexes were analysed by 
chemiluminescence using the immune-star HRP detection kit (Bio Rad, Sydney, Australia). 
Subsequent development and detection of the membrane was achieved with the Chemidoc system 
(BioRad, Sydney, Australia). Protein expression data was then analysed using the Quantity One 
software as per manufactures instructions (BioRad, Sydney, Australia).  
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3.5 Histological analysis of cardiac tissue 
All harvested heart tissue was fixed in 10% buffered neutral formalin (Lomb Scientific, New South 
Wales, Australia). Hearts were then fixed in paraffin wax sections so that 5 micron transverse 
sections were mounted onto glass histology slides. All hearts were then subjected to masons 
trichrome staining to allow cardiac dimensions and collagen content of transverse sections using 
image J software. 
3.5.1 Preparation of cardiac tissue for staining procedure 
Hearts were harvested from the nude mice at the end of the defined experimental period. Hearts 
were then measured with digital callipers longitudinally so that the mid point could be identified and 
dissected transversely. Such that a atrial and ventricular half was separated. The ventricular half of 
the hearts was then immersed in 10% buffered neutral formalin until they could be fixed in paraffin 
wax. Tissues were then aligned in cassettes in preparation for paraffin wax fixation. 
The process of paraffin wax fixation involved the use of the automated tissue processor (Leica 
Microsystems, North Ryde) with buckets of solutions which the cassettes containing tissues would 
be immersed for a set period of time. The protocol was that was set into the tissue processor is 
detailed in table 3.4 below. 
Step Solution Changes Period of immersion 
1 70% Ethanol 2 1 hour each 
2 80% Ethanol 1 1 hour 
3 95% Ethanol 1 1 hour 
4 100% Ethanol 3 1.5 hours each 
5 Xylene 3 1.5 hours each 
6 Paraffin wax @ 50°C 2 2 hours each 
Table 3.4 Tissue processor paraffin embedding schedule 
The next step was to open the cassette containing the embedded heart tissue and placing it on a 
frozen block for preparation of sectioning. The paraffin embedded hearts are sliced into 5 μm 
sections using the Leica RM2235 microtome (Leica Biosystems, North Ryde). The paraffin heart 
ribbons are then immediately placed into a 40°C water bath to ensure tissues do not have wrinkles 
before carefully mounting onto glass slides. Sections were then allowed to air dry for 30 minutes 
followed by baking them in a 45°C oven overnight. Sections are then deparaffinised in 2 changes of 
xylene of 10 minutes duration. Following this sections are then rehydrated by immersing them in 
containers of decreasing concentrations of ethanol. This is achieved by immersing the deparaffinised 
sections in 2 changes of 100% ethanol for 3 minutes then 95% and 85% ethanol for 1 minute each 
followed by a rinse in distilled water.  
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 3.5.2 Masons trichrome staining procedure 
Masons trichrome is a three colour stain that allows the distinction between a pink/red muscle 
cytoplasm, black nucleus and blue collagen fibres. The consumables and methods to undertake the 
masons trichrome stain on hearts harvested were purchased from Lomb Scientific, Australia. The 
first step was to stain the deparaffinised/rehydrated sections in weigerts iron haematoxylin solution 
for 10 minutes. This was followed by a wash in running water for 10 minutes and rinse in distilled 
water. The second stain added was beibrich scarlet-acid fuchsin solution which was left for a period 
of 15 minutes. This was followed by another rinse in distilled water. The next step involved the 
immersion of tissue slides in phosphomolybdic-phosphotungstic acid solution for 15 minutes. Next 
the slides are counterstained in aniline blue solution for 10 mintues and subsequently rinsed in 
distilled water. The stained slides are differentiated in 1% acetic water for 5 minutes before being 
dehydrated in 95% ethyl alcohol, absolute ethyl alcohol and xylene. Each dehydration immersion 
consisted of 2 changes at 2 minutes each. A supplied mounting resin was then placed on the stained 
tissue slides. A glass cover slip was immediately and carefully placed on top avoiding air bubbles and 
contaminants.  
  3.5.3 Microscopy and image J analysis of cardiac histologic 
morphology and collagen content 
All of heart muscle samples stained in masons trichrome where analysed using the Leica DM2700 
light microscope (Leica Biosystems, North Ryde). The microscope was set to 40x magnification and 
images were captured using the provided Leica application suite version LAS 4.1). Default settings 
were used for brightness, contrast and colour for all images captured.  
The captured images were saved as jpeg files and exported into Image J. The image J software is 
open to the public version 1.43u (National Institutes of Health, USA). Before any software analysis 
was made distance and scale was set on the software based on the known distance of one pixel so 
that accurate measurements could be made.  
The measurements of ventricular diameter were made by simply selecting the area tool and setting 
it to measure perimeter only. Whilst cardiac wall dimensions were measured by using a line tool and 
setting a start and end point. Collagen content was assessed by adjusting the colour threshold to 
only allow blue light to pass. Thus an image of only blue pixels would appear and then allow the 
accurate measurement of blue pixels on screen. The amount of blue pixels were measured and 
compared to the total pixels that made up the cardiac tissue on the slide. Thus, cardiac collagen 
content was expressed as percentage making up the total histological slice.  
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3.6 Enzyme activity assays 
Heart tissues were washed in heparinised PBS and 15 mg of tissue was used for enzyme activity 
assays. Heart tissue was homogenised in 5ml of 20mM HEPES buffer (ph 7.2) containing 1mM EGTA, 
210mM mannitol, 70mM sucrose per gram of tissue. The protein concentration was determined via 
the Bradford method (BioRad, Sydney, Australia). These heart homogenates were then used in the 
superoxide dismutase (SOD) and xanthine oxidase (XO) activity assays detailed below.   
  3.6.1 Superoxide dismutase activity assay 
SOD activity was analysed using a commercially available kit (Cayman Chemicals, Ann Arbor, 
Michigan, USA). The assay is based on the ability for tetrazolium salt to be converted to a coloured 
formazan dye when exposed to superoxide radicals. The formazan dye will then absorb light 
between 440 and 460 nm. The superoxide radicals are produced by adding XO and hypoxanthine to 
the assay. One unit of SOD is defined as the amount of enzyme required to inhibit the dismutation of 
the superoxide radicals by 50%.  
The manufacturer’s instructions were followed to undertake the assay. Essentially this involved the 
addition of the radical detector (containing tetrazolium salt) to microplate wells. 10 μL of standards 
and diluted cardiac homogenate (1:5 in assay buffer) was added to the corresponding wells.  
Tube SOD Stock (pl) Sample   Buffer (pl) Final SOD Activity (U/ml) 
A 0 1,000 0 
B 20 980 0.005 
C 40 960 0.010 
D 80 920 0.020 
E 120 880 0.030 
F 160 840 0.040 
G  200 800 0.050 
Table 3.5 SOD standards 
The reaction was then started by the addition of 20 μL of XO enzyme to each well. The plate was 
then incubated on a platform shaker at room temperature for 20 minutes at which time a plate 
reader measured absorbance at 450nm (Perkin-Elmer, Precision). The absorbance values were 
averaged between replicates. The linearised rate was then calculated by dividing the absorbance of 
45 
 
each standard by the absorbance of the blank. This calculation was used to make a linearised rate 
standard curve. The equation of the standard curve was then used to calculate units of SOD per ml. 
3.6.2 Xanthine oxidase activity assay 
The XO activity assay was undertaken by the use of a commercially available Amplex Red 
Xanthine/Xanthine Oxidase Assay Kit (Invitrogen, Mount Waverley, Victoria). The XO assay kit is a 
detection method for XO activity. This is achieved by the superoxide produced by XO spontaneously 
degrading to hydrogen peroxide (H2O2), and the H2O2, in the presence of horseradish peroxidase 
(HRP), reacting stoichiometrically with Amplex Red reagent to generate the red-fluorescent 
oxidation product, resorufin.  
The assay procedure was undertaken by the manufacturer’s instructions. This involved preparing a 
working solution of 100 μM Amplex Red agent with 0.4 U/mL of horse radish peroxidase and 200 μM 
hypoxanthine. Next a XO standard curve was prepared by diluting 12 U/ml of XO stock and diluting 
this to a rage of concentrations (see table 3.6 below). 
96 well 
placement: well 
1 and 2 
Volume of XO solution Reaction 
Buffer 
Final XO standard 
Concentration 
(mU/ml) 
   12 
 500 μl of 12 mU/ml 500μl 6 
A 500 μl of 6 mU/ml 500μl 3 
B 500 μl of 3 mU/ml 500μl 1.5 
C 500 μl of 1.5 mU/ml 500μl 0.75 
D 500 μl of 0.75 mU/ml 500μl 0.375 
E 500 μl of 0.375 mU/ml 500μl 0.188 
F 500 μl of 0.188 mU/ml 500μl 0.094 
G  500μl 0 
Table 3.6 XO standard curve dilutions  
A positive control was prepared by diluting 20 mM of H2O2 with the reaction buffer supplied with the 
kit. The standard curve solutions, positive control and 1:10 diluted heart homogenates are then 
pipetted into the appropriate sections of a 96 well plate. The reaction is commenced by the addition 
of the working solution and the plate is incubated for 30 minutes at 37°C whilst been protected from 
the light. The microplate reader (Perkin-Elmer, Precision) is set to measure fluorescence at excitation 
range 530-560 nm and emission detection at 590 nm. Background fluorescence is corrected by 
subtracting the values of the no XO control from the samples and standards. XO activity is calculated 
by via the equation created from the standard curve.  
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3.7 DNA oxidative damage by-product (8-OH-2dG) assay 
8-hydroxy-2-deoxy-guanosine (8-OH-2-dG) is a by product of DNA oxidation in cells and a common 
measure of oxidative damage. Specifically, 8-OH-2-dG is produced via the oxidative modification of 
the DNA base guanosine (Valavanidis et al, 2009). Before the determination of 8-OH-2-dG DNA 
needs to be isolated and digested. 
  3.7.1 DNA isolation 
Tri-reagent (Molecular Research Corporation, Cincinnati) was used to isolate DNA from heart tissue 
using the manufacturer’s instructions.  This was achieved by homogenizing 10 mg of frozen cardiac 
tissue suspended in 7.4 pH PBS. The homogenate was then added to 750μL of tri-reagent, left at 
room temperature for 5min before 100μL of 1-bromo-3-chloropropane (BCP) was added to separate 
the solution into three phases. To define these phases fully, samples were mixed by vortex and then 
centrifuged at 12,000 x g for 15min at 4°C. The top clear aqueous phase containing RNA was 
removed, before 225μL of 100% ethanol was added to the remaining white inter-phase and pink 
organic phases. The ethanol was allowed to mix with these phases for 2-3min allowing the DNA to 
become ready to precipitate by centrifugation at 2,000 x g for 5min at room temperature. The 
supernatant was removed and the pellet was resuspended in 1 mL of 0.1M tri-sodium citrate 
solution containing 10% ethanol. This was incubated at room temperature for 30min to allow 
removal of contaminants. There was further centrifugation at 2,000 x g for 5min at 4°C after 
incubation. The supernatant was removed and the pellet was washed with 1 mL of 75% ethanol. 
After 15 minutes the samples were centrifuged at 2,000 x g for 5min at 4°C. After which time the 
supernatant was removed and the DNA pallet was left to air dry. The DNA pallet was then re-
suspended in 30μL of 8mM sodium hydroxide solution. The DNA supernatant was then moved into 
new eppendorf tubes and DNA quantity and quality were measured using a Nanovue 
spectrophotometer (GE Life Sciences). 
3.7.2 DNA digestion 
DNA concentration was first determined then 1μg of DNA was added to 49μL of sodium acetate 
buffer (20mM sodium acetate (CH3COONa), 5mM ZnCl2, 50mM NaCl: pH 5.3). This mixture was 
heated to 95°C in a water bath for 5 minutes to allow the DNA to denature. The DNA and buffer 
mixture was then cooled by placing it into an ice bath before the addition of 1μL of nuclease P1 
enzyme (Sigma-Aldrich, Sydney, New South Wales). The DNA samples were then incubated for 1 
hour at 50°C with nuclease P1 to break the DNA strands into single nucleotides. Following 
incubation, 24μL of alkaline buffer (50mM Tris-HCl, 5mM MgCl2: pH 8.5) was added to the DNA 
digest solution. Following this, 1μL of Shrimp alkaline phosphatase (Sigma-Aldrich, Sydney, New 
South Wales) was added and the mixture incubated at 37°C for a further 1 hour. Following this 
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incubation period, the enzymes were inactivated by heating the samples to 100°C for 10 minutes. 
Samples were then stored at 4°C until they were needed for 8-OH-2dG determination.  
  3.7.3 Measurement of DNA oxidation by product 8-OH-2dG 
The 8-OH-2-dG analysis occurs via a competitive assay. Whereby sample DNA oxidation byproduct 8-
OH-2dG competes with 8-OH-2dG bound to acetylcholinesterase (tracer). Both the sample 8-OH-2dG  
and the tracer compete for a 8-OH-2dG monoclonal antibody adhered to the base of each plate well. 
As the concentration of tracer supplied is constant in each reaction the amount of tracer bound to 
the adhered antibody will be inversely proportional to the amount of sample 8-OH-2dG. When the 
plate is washed any bound tracer will undergo an enzymatic reaction with the addition of Ellmans 
reagent to give off a yellow colour which absorbs at 412nm. Thus the intensity of yellow colour is 
proportional to the amount of tracer and inversely proportional to the amount of sample 8-OH-2dG 
(see figure 3.1 below). 
 
Figure 3.1 Schematic diagram of 8-OH-2-dG competitive assay 
Before beginning the assay procedure, both the EIA and wash buffers were prepared following the 
manufacturers’ instructions, diluting the supplied concentrated buffer solutions and storing them at 
4°C until use.  Reconstitution of the tracer and 8-OH-2-dG antibody vials was also performed before 
the assay, through addition of EIA buffer and stored at 4°C until needed. 
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Digested DNA from the previous procedure was brought to 100μL volume through by the addition of 
25μL of diluted EIA buffer. Samples were assayed in duplicate, and so 50μL of digested DNA sample 
was added per well in the 96 well plates supplied in the 8-OH-dG kit. Each plate contained blank, 
non-specific binding (NSB), maximum binding (Bo), total activity (TA) and a full set of 8 standards for 
use in calculating the concentration of unknown amounts of 8-OH-2-dG within each sample and to 
allow for the subtraction of background interferences. The standards were made by first diluting the 
stock standard (supplied as 3,000ng/mL) into a Bulk Standard (30ng/mL). This was then diluted to 
create the standard number 1 (S1; 3,000pg/mL). After S1 was made then part of S1 was diluted to 
make S2, part of S2 was then diluted to create S3. This pattern continued until part of S7 was diluted 
to create the S8 standard. Figure 3.2 shows the volumes of components used, and the final 
concentrations of the standards for the 8-OH-2-dG EIA assays.  
 
Figure 3.2 the 8-OH-2-dG assay standards preparation 
Once the standards were prepared, the 96-well assay plate map could be setup. Reagents and 
samples that were added on day 1 of the assay procedure are outlined in figure 3.3 below.  
 
 
 
 
 
 
49 
 
Figure 3.3 8-OH-2-dG assay standard plate setup 
After all reagents have been added the plate is covered and incubated for 18 hours at 4°C in the 
fridge. After the 18 hour incubation the plate was washed five times with wash buffer. After the fifth 
wash was drained, 200μL of Ellman’s reagent was added to every well. The 5μL of tracer was then 
added to the TA well before the plate was covered again and incubated on an orbital platform 
shaker at room temperature for 90 minutes. The Ellman’s reagent reacts to light and the tubes it was 
made up in, as well as the plate when it was loaded with Ellman’s reagent, were kept in darkness 
where possible by covering them in aluminum foil. Once the plate had incubated for 90 minutes, the 
foil was removed and the absorbance at 410 ±10nm was measured as soon as possible. The 
manufacturer recommends that the maximum absorbance (Bo) wells should have an absorbance 
between 0.3 and 1.0 AU if the plate has had sufficient time to develop the wells. All plates assayed 
were found to have a Bo within this range after the 90 minute incubation.  
The absorbance values were averaged across the replicates before they were corrected for 
background binding interference. To correct this, the NSB absorbance is taken away from all other 
absorbance readings. After calculating the bound tracer for each well with respect to the maximum 
bound (Bo) wells, a logit transformation of the data was performed to linearise the data. The 
linearised values for the standards are then plotted using a log scale x-axis and concentration on the 
y-axis. The equation of the log trendline of best fit is then used to obtain the slope and x-intercept 
values, which are then used to calculate the concentration of the samples.  
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3.8 Measurement of serum cytokines 
Serum pro-inflammatory cytokines IL-6, MCP-1 and TNF-α were measured using a specialised 96-well 
five-plex antibody bead kit (Invitrogen, Mount Waverley, Victoria). The 96-well plate data was 
gathered via the Bio-Plex analyser system (Bio-Rad, Gladesville, New South Wales). The experiment 
itself uses a sandwich immunoassay with colour coded microsphere beads coated with antibodies. 
Many target molecules can be analysed based on the antibodies present on the coated beads. The 
current study was able to analyse serum IL-6, MCP-1 and TNF-α in the same 96-well plate using the 
correct mix of beads. When the sample is added to the bead mix cytokines will bind to the 
appropriate antibodies present on the micro beads. A second set of antibodies is then added to bind 
to the other end of the cytokines which creates a sandwich effect. The second set of antibodies will 
fluoresce via the addition of streptadivin-R-phycoeythrin (Strep-RPE). Any reagents which remain 
unbound will be washed to lower non-specific background binding. The analyser itself uses dual 
detection laser systems one to detect the colour of the bead and the second to analyse the presence 
of fluorescence which is present if a cytokine is present. The analysis involves distinguishing, 
counting and determining how many beads have fluorescence. This information is then compared to 
the values obtained from a set of standards. Thus, the amount of cytokine in a sample is determined 
from a linearised standard curve.   
The procedure involves firstly heating a wash buffer to 37°C for a period of 30 minutes to dissolve 
crystals that are formed at lower temperature. Subsequently the 1x wash buffer is prepared by 
diluting the concentrated wash buffer with 500 ml of milli-Q water and kept at room temperature 
until used.  
Plasma samples used in the assay are first clarified to ensure that pores located in filter wells are not 
clogged. This was achieved by centrifugation at 1000x g for 10 minutes. The supernatant is then 
collected into an Eppendorf tube and kept at 4°C until further use. 
The stock standards are prepared by reconstituting in 1ml of the assay diluent supplied. Seven 
standards were prepared by serial dilution. A summary of volumes used to create the standards are 
shown in table 3.5 below. Mixing was via pipetting as vortex can cause damage to the cytokines in 
the standard solution.  
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Tube Vol. assay buffer Vol. of other solution Final Vol. 
Blank 300μL - 300μL 
S1 - 450μL of stock standard  300μL 
S2 300μL 150μL of S1 300μL 
S3 300μL 150μL of S2 300μL 
S4 300μL 150μL of S3 300μL 
S5 300μL 150μL of S4 300μL 
S6 300μL 150μL of S5 300μL 
S7 300μL 150μL of S6 450μL 
Table 3.7 Volumes used for the preparation of standards in the 5-plex assay  
Where: S1 – S7 = standard 1 through to standard 7, Vol. = volume. 
The beads used for cytokine detection were diluted in 1:11 was buffer. The diluted beads were kept 
in a tube covered with foil to minimise light exposure whilst vortexing the solution for 30 seconds. 
The specialised 96-well plate provided is washed with 200 μL of wash solution before the beads are 
added. A total of 25 μL of the bead mix is then delivered to each well. Followed by a wash of each 
well with 200 μL of wash solution. This pre-wash was left for 30 seconds and then drained through 
the bottom of the plate via manifold pump. A second wash is completed by adding 200 μL of wash 
buffer which is covered with foil and swirled for 30 seconds to keep the beads in suspended in 
solution. The wash buffer is once again removed via vacuum pump. Following the wash steps 100 μL 
of blank of solution and standards 1-7 are added to their respective wells. Then 50 μL of incubation 
buffer was added to each well. 50 μL of assay diluent is then added to all wells before covering the 
plate with foil and incubating on a plate shaker (500 rpm) at room temperature for a period of 2 
hours.  
The biotinylated secondary antibody is then prepared by diluting in 1:11 biotin solution. This was 
completed just before the end of the plate incubation period. When the 2 hour plate incubation was 
complete the plate is washed twice by adding 200 μL of wash buffer to each well and incubating for 
30 seconds whilst swirling. Once the second wash buffer is drained 100 μL of biotinylated secondary 
antibody was added to all wells. The plate is once again covered in foil and incubated on a plate 
shaker (500 rpm) for a one hour period. 
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Whilst the incubation with secondary antibody is being completed the Bio-plex analyser apparatus 
was prepared for use by undertaking a calibration and needle cleaning protocol as per manufactures 
instructions. Data was entered into the computer program to confirm the locations of blanks, 
standards and sample wells. Following this the strep-RPE solution was prepared with the addition of 
1:11 diluent and kept within foil covered tubes before use. When the one hour plate incubation was 
complete the wells were drained and washed twice with was buffer as previously mentioned. Once 
the second wash buffer was drained 100 μL of biotinylated secondary antibody solution was added 
to each well. The plate is then covered and incubated as previously mentioned for a period of 30 
minutes. Following the 30 minute incubation period the plate wells were washed and drained 3 
times as previously described. Following this 100 μL of wash buffer was added to each well, the plate 
covered and incubated on the plate shaker (500 rpm) for 3 minutes. Once this short incubation 
procedure was complete the plate was placed into the Bio-plex analyser and the program was set to 
run. The program was able to calculate concentrations of cytokines within the samples and the data 
was exported to excel for further statistical analysis.    
3.9 Phosphoprotein analysis 
Phosphoproteins are proteins which are postranslationally modified by a single phosphate group. A 
protein that has been modified in this fashion has been phosphorylated and confers a different 
function in many cases. For NFκβ and p38 MAPK the phosphorylation of these molecules activates 
them such that they are capable of downstream signalling.  
The analysis of NFκβ and p38 MAPK was undertaken using an ELISA kit (Invitrogen, Australia). The kit 
uses a solid phase sandwich enzyme linked-immuno-sorbent assay (ELISA). A monoclonal antibody 
specific for p38 MAPK and NFκβ has been coated onto the wells on microtitre strips provided. This 
allows the phosphoprotein antigen in the sample being analysed to bind to the antibody during an 
incubation period. A secondary antibody specific to either NFκβ or p38 MAPK is then added. After 
the addition of horse radish peroxidase (HRP) which binds to the secondary antibody a substrate 
solution is added to produce colour, the intensity of which is proportional to the amount of NFκβ or 
p38 MAPK in the sample. 
Before starting the ELISA method NFκβ and p38 MAPK standards must first be reconstituted and 
diluted to 100 units/mL using the diluent buffer solution provided. Serial dilutions of the standard 
are then prepared (refer table 3.8 below) 
 
 
53 
 
 
Table 3.8 Preperation of phosphoprotein standards 
The dilution of the anti-rabbit IgG HRP is diluted by taking 10 μL of the solution and adding 1 mL of 
the HRP diluent provided to create a working solution. The assay procedure begins by adding 100 μL 
of diluent buffer to the zero wells. Then 100 μL of standards and samples was added to the 
appropriate microtitre wells. The plate was then covered and incubated for 2 hours at room 
temperature. Following the first incubation period the wells were aspirated using a pipette and 
washed 4 times using 100 μL of wash solution. 100 μL of p 38 MAPK or NFκβ detection antibody 
solution was then added to each well except the blanks. The plate was again gently tapped and 
covered before being incubated at room temperature for 1 hour. After the second incubation period 
the wells were again aspirated via pipette and washed 4 times with wash buffer. Following this 100 
μL of IgG HRP working solution was added to each well except the blanks. The plates were once 
again covered and incubated for 30 minutes at room temperature. The plate was aspirated and 
washed 4 more times. The colour producing substrate solution was then added to each well in 100 
μL aliquots. The plate was again incubated for 30 minutes in a dark room. 100 μL of stop solution is 
then added to each well before reading the absorbance of the plate at 450 nm using the Bio-rad 
plate reader (Bio-rad, Australia). The results from the standards are used to create a standard curve. 
This standard curve was used to calculate the concentration of phosphoprotein in each of the 
samples.   
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3.10 Statistical analysis 
All statistical analyses were performed using SPSS Statistics Version 17.0 (IBM, Chicago, USA) or 
GraphPad Prism 5 (GraphPad Software, San Diego, USA), with results expressed as mean  ±  standard 
error of mean (SEM) and considered statistically significant if p= <0.05, unless otherwise stated. Data 
was analysed using two-way ANOVA, with a Tukey’s test post hoc analysis performed to determine 
differences between groups where appropriate. Correlation was analysed using Pearsons Test. 
Weight-loss data was analysed using Repeated Measures ANOVA with post-hoc analysis. 
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4.0 Oxidative balance and the ubiquitin proteasome system in the 
atrophic cachectic heart 
 4.1 Introduction 
 
Current research into the mechanisms of organ atrophy associated with CC is centred on the loss of 
skeletal muscle mass as it is one of the most profound physical changes of the disease. However, 
studies have also established that CC causes significant atrophy of the heart muscle in animal models 
(Acharyya et al, 2004., Costelli et al, 2001., Cosper & Leinwand, 2011). Decreases in heart weight by 
as much as 60% have been reported in a rat model of CC (Costelli et al, 2001). Clinical research does 
not currently exist examining the pathologic consequence of cardiac atrophy in cancer cachexia. 
However, Tian et al, 2010 used echocardiography to analyse the function of cachectic hearts in a 
mouse model of CC. The study found that 14 days after the inoculation with tumour cells the hearts 
of cancer cachectic mice had reduced heart rate and fractional shortening.    
4.1.2 Key catabolic events in cancer cachexia 
The mechanisms causing cardiac tissue wastage are largely unknown. However it is believed to 
involve a number of molecular interactions between the tumour and host. Elevated cytokines in 
response to tumour presence and tumour derived factors such as proteolysis inducing factor (PIF) 
and lipid mobilising factor (LMF) together produce tissue wasting (Hirai et al, 1998., Cariuk et al, 
1997., Todorov et al, 1996). Host factors such as cytokines including IL-1, IL-6, TNF-α, INF-γ and PIF 
derived from the tumour have been shown to create a state of oxidative stress and net protein 
catabolism in skeletal muscle (Gomes-Marcondes & Tisdale, 2001., Barreiro et al, 2005). Whether a 
state of oxidative stress exists in the cachectic heart and is linked to the activation of protein 
breakdown pathways is currently unknown. 
A key catabolic pathway known to contribute to both skeletal and cardiac muscle atrophy is the 
ubiquitin proteosome system (UPS). The UPS is the principle mechanism by which muscle proteins 
are degraded. The UPS has been found to be up-regulated in both experimental models and patients 
with CC (Khal et al, 2005., Bossola et al, 2003). Enzymes which allow ubiquitin to tag proteins for 
destruction are termed E3 ligases. Currently, only three of the discovered several hundred E3 ligases 
have been found to be important in the process of muscle atrophy. These are termed E3 alpha, 
muscle specific F-box (MAFbx) and muscle specific ring finger 1 (MURF-1) (Bodine et al, 2001). 
Examining a model of congestive heart failure, Adams et al, 2007 found a positive correlation 
between TNF-α and the E3 ligases MAFbx and MURF-1. Furthermore, the study found that TNF-α 
was able to bring about troponin I ubiquitinylation leading to impaired contractility of the heart.  
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4.1.3 Oxidative stress and cardiac atrophy 
Oxidative stress in a CC patient population may be an important link between the loss of tissue and 
initiation of key catabolic pathways (Vaughn et al, 2012). A study by Kaynar et al, 2005 found that 
patients with either non-small-cell or small cell lung cancer have elevated levels of xanthine oxidase 
(XO) activity compared with controls. In the heart XO is an important enzyme capable of catalyzing 
the oxidation of hypoxanthine and xanthine to uric acid whilst reducing O2 to O2- and H2O2. 
Traditionally increases in XO in the failing heart are associated with ventricular remodelling, fibrosis 
and hypertrophy (Bergamini, 2009). The contribution of  XO  in cancer induced cardiac atrophy has 
not been investigated despite the enzyme being implicated in  myocardial remodelling and 
dysfunction (Landmesser et al, 2002., Hayashi et al 2008). In terms of atrophy of the myocardium, 
like that of skeletal muscle, cardiomyocyte size is dependent on the relative rates of protein 
synthesis and degradation (Razeghi & Taegtmeyer, 2006). Increased levels of ROS have been found 
in cancer cachectic skeletal muscle and has been linked to the activation of the UPS (Gomes-
Marcondes & Tisdale, 2002). However, no such studies have examined the role of ROS in the cancer 
cachectic heart.  
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4.1 Results 
 
The animals in this study were randomised to one of three groups being a no tumour control, cancer 
or cachexia. Animals in the cachexia group displayed all of the hallmarks of cancer cachexia including 
the loss of body weight, skeletal (p=0.003) and cardiac (p=0.002) muscle with no significant 
differences in food and water intake between the groups (Table 4.1). An analysis was then carried 
out to ascertain whether key oxidative and proteolytic pathways were up-regulated in cardiac tissue. 
Weights  Control (n=8) Cancer (n=12) Cachexia (n=16) 
 
Body weight (g) 21.67 ± 0.42 22.31 ± 0.29 17.65 ± 0.45*#       
Heart weight (mg) 121.03 ± 0.01 112.63 ± 0.01 92.04 ± 0.01 *# 
Quadriceps  (mg) 122.92 ± 2.64 116.98 ± 4.17 90.07 ± 2.10 
Food (g) 3.84 ± 0.55 3.58 ± 0.34 3.64 ± 0.47 
Water (ml) 3.92 ± 0.13 3.61 ± 0.13 3.80 ± 0.21 
Table 4.1 Mean comparison of organ weights, food and water intake. Values are means ± SEM. * 
Significantly different from control group (p= <0.05). #Significantly different from cancer control 
group (p= <0.05). 
 
Oxidative damage in the heart muscle was assessed by measuring 8-hydroxy-2-deoxyguanosine (8-
OH-2dG), a biomarker of DNA oxidation. The hearts of cachectic mice displayed a significant 1.5 fold 
increase in 8-OH-2dG (71± 26.18 pg/ml) compared to control (45± 18.33 pg/ml, p= 0.02) and cancer 
(43± 24.03 pg/ml, p= 0.015) groups (figure 4.1). Further studies were then carried out to assess 
which pathways may be contributing to the oxidative damage in the cancer cachectic hearts. 
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Figure 4.1 DNA oxidation by-product 8-hydroxy-2-deoxyguanosine concentration in control, cancer 
and cachexia. Values are means ± SEM. * Significantly different from control group (P= <0.02). 
#Significantly different from cancer group (P= <0.015). 
  
To investigate the potential source of oxidative stress contributing to the oxidative DNA damage 
found in the cachectic hearts, we investigated the ROS producing enzymes, NADPH oxidase and XO. 
RT-PCR was performed on the key regulatory subunits (p40 phox and p67 phox) and the catalytic core 
units (NOX1, NOX2 and NOX4) of NADPH oxidase. There were no changes in the key regulatory or 
catalytic core units of NADPH oxidase in the heart muscle samples except for NOX2 (Table 4.2). The 
current experiment found a significant 1.7 fold decrease in the gene expression of NOX2 in cachectic 
hearts (p= 0.03) compared to the cancer group (Table 4.2). Accompanying a state of oxidative stress 
in cancer cachectic hearts were increases in the expression of the major muscle proteolytic pathway, 
the UPS. MURF-1 and MAFbx mRNA expression were significantly increased 4.3 fold (p= 0.04) and 
3.8 fold (p= 0.04) respectively, in the hearts of the cachexia mice compared to the cancer group 
(Table 4.2). Subsequently, the XDH enzymatic pathway known to produce ROS was investigated. The 
RT-PCR results showed a significant 2-fold increase in XDH mRNA (p= 0.04) levels in the heart of 
cachexia mice in comparison to control and cancer groups (Table 4.2). 
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 Experimental group 
Gene   Control Cancer control Cachexia 
MURF-1 
MAFbx 
NOX1 
0.025 ± 0.01 
0.014 ± 0.008 
482.00 ± 117 
0.008 ± 0.005 
0.016 ± 0.009 
440 ± 50 
0.04 ± 0.01# 
0.063 ± 0.02#* 
343 ± 52 
NOX2 176 ± 48 177 ± 32 99 ± 21 # 
NOX4 16 ± 7 8 ± 3 9 ± 2 
P67 7308 ± 2228 8737 ± 1522 8964 ± 926 
P40 1865 ± 1725 452 ± 226  263 ± 49 
CuZn SOD 490193 ± 206876 587792 ± 268737 458864 ± 215331 
Mn SOD 412103 ± 173485 431952 ± 173581 666478 ± 215331 
XDH 453 ± 69 469 ± 69 1421 ± 69 * # 
Table 4.2 gene expression data. Values are mean arbitrary units ± SEM. * Significantly different from 
control group (P= <0.05). #Significantly different from cancer control group (P= <0.05). 
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To assess the possibility of post translational modification to the NADPH oxidase protein 
components, a protein expression analysis was undertaken on p47phox and NOX2. There was no 
significant difference in either p47phox and NOX2 protein abundance in the cancer cachectic hearts 
compared to both the control and cancer groups (Figure 4.2 & 4.3). 
 
 
 
Figure 4.2 Protein expression data for the NADPH regulatory unit P47. Values are mean intensity 
units ± SEM.  
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Figure 4.3 Protein expression data for the NADPH catalytic core unit NOX2. Values are mean 
intensity units ± SEM.  
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Other possible contributors to the state of oxidative stress observed in the cachectic hearts, is the 
antioxidant enzyme, superoxide dismutase (SOD). Mitochondrial and cytoplasmic SOD displayed no 
change in mRNA levels (Table 4.2). However, further investigation of total SOD enzyme activity 
showed a significant 1.5 fold decrease in activity compared to control (p= 0.02) and cancer (p= 
0.001)  (Figure 4.4).  
 
 
 
Figure 4.4 Total SOD enzyme activity. Values are means ± SEM. * Significantly different from control 
group (P= <0.05). #Significantly different from cancer group (P= <0.05). 
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4.2 Discussion 
 
The cardiac atrophy secondary to CC observed in this study is associated with a pro-oxidative shift 
and consequential oxidative myocardial tissue damage. Furthermore, the  upregulation of the key 
ubiquitin ligases in cachectic hearts suggests  induction of the UPS may be in response to oxidative 
stress and subsequent protein damage.  
The study demonstrated the importance of cardiac atrophy as a hallmark of the disease with an 
average 20% decrease in heart muscle weight compared to controls. To date the mechanisms 
influencing cardiac tissue wasting in a state of CC are largely unknown. However, previous studies 
have shown that patients and animals with CC all show degrees of oxidative stress (Barreiro et al, 
2005., Murr et al, 1999).  
To elucidate whether a state of oxidative stress exists in the heart of mice afflicted with CC the 
current study measured levels of 8-hydroxy-2dG and found a significant increase in the cachexia 
group hearts. The increase in the 8-hydroxy-2dG suggests that the activation of pro-oxidant 
pathways in atrophied hearts of cachectic mice. Importantly both the release of cytokines such as 
TNF-alpha and tumour derived factors such as PIF have been shown to have pro-oxidant effects 
(Gomes-Marcondes & Tisdale, 2002., Barreiro et al , 2005). Gomes-Marcondes & Tisdale, 2001 used 
myotubes in cell culture exposed to FeSO4 and H2O2 which showed that key components of the 
ubiquitin proteasome system were upregulated by oxidative stress.  
NOX2 mRNA expression was decreased in cachexia hearts compared to the control group, while the 
western blot data was unchanged. The results suggest a decreased role for NADPH oxidase in 
contributing to cellular oxidative stress in cachectic hearts. The results are also in keeping with a 
previous study by Sullivan-Gunn, 2011 showing a decrease in NOX2 levels in skeletal muscles of 
cancer cachectic mice. The animals in this study were allowed to lose up to 25% of their initial body 
weight, thus constituting late stage cachexia. Considering that NADPH oxidase enzyme activity has 
been shown to degrade cultured myotubes in vitro (Gomes-Marcondes & Tisdale, 2002), a time 
course study would be beneficial in understanding whether the current results are specific to cardiac 
atrophy in late cachexia.  
Another key pathway of ROS formation in the myocardium is XDH which was measured using RT-
PCR. The results showed a 2 fold increase in XDH in the cachexia group hearts. The activation of XDH 
has been implicated in a number of disease states involving the myocardium such as heart failure 
and myocardial dysfunction (Bergamini, 2009., Hayashi et al, 2008). A study by Ekelund et al, 1999 
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highlighted the importance of XO in cardiac disease by showing that inhibition of the enzyme by 
allopurinol is capable of increasing left ventricular function and decrease myocardial oxygen 
consumption in a dog model of heart failure.  
In evaluating the potential contribution of antioxidant systems in the cachectic heart, SOD was 
analysed both at a gene and enzyme activity level. The SOD enzyme is a key endogenous antioxidant 
in the myocardium for the elimination of superoxide and has been implicated in the pathogenesis of 
CC (Russel et al, 2007). Interestingly, while the cytosolic and mitochondrial SOD mRNA levels were 
unchanged in cachectic hearts, total SOD enzyme activity was significantly decreased compared to 
controls. It appears that SOD is not compensating for increased levels of ROS and is therefore 
contributing to oxidative damage in the cachectic heart. Thus, the concurrent increase in levels of 
XDH and decrease in SOD activity may significantly contribute to a disruption in the balance between 
pro-oxidant and antioxidant mechanisms, leading to a state of oxidative stress as evidenced by 
increased DNA oxidation (8-Oh-2dG) in the cachectic heart. In terms of how oxidative stress 
contributes to cardiac atrophy in CC is currently unknown however evidence suggests induction of 
the UPS may be an important link between oxidative stress and atrophy in cachectic muscle (Gomes-
Marcondes & Tisdale, 2002). Otsuka et al, 2010 found that in patients hearts undergoing dilated 
cardiomyopathy, oxidative stress and the UPS activation are colocalised. Increases in levels of XO 
and altered SOD enzyme function in the myocardium is traditionally linked to cardiac fibrosis and 
cardiomypathies (Ito et al, 1995., Bergamini, 2009). However, this study shows a clear relationship 
between oxidative stress and cardiac atrophy suggesting an alternative pathologic role for oxidants 
in the myocardium. In elucidating the mechanisms by which ROS contributes to the loss of lean body 
mass Gomes-Marcondes & Tisdale, 2002 attempted to replicate the oxidative stress seen in cancer 
cachexia by using murine myotubes in cell culture. The myotube cells were exposed to H2O2 which 
induced oxidative stress. The results showed that the induction of oxidative stress caused an 
increase in the expression of important UPS elements including the 20s proteasome and the E214k 
conjugating enzyme.  
The UPS E3 ligases MURF-1 and MAFbx are expressed in cardiomyocytes and are an important 
component of cardiac protein turnover (Willis & Patterson, 2006). Increased mRNA expression of 
these ligases are linked to the degradation of cardiac troponin I, α-actin-2 and MyoD leading to 
impaired contractility (Adams et al, 2007 & Kedar et al, 2004). This study shows that both MURF-1 
and MAFbx are up-regulated at the mRNA level (Table 3) which is in keeping with results seen in 
studies analysing cachectic heart muscle tissue (Tian et al, 2011). Interestingly, Cosper and 
Leinwand, 2011 using CD2F1 hybrid mouse model of CC did not see any change in the UPS but found 
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an upregulation in autophagy related protein degradation. However, a recent study by Tian et al, 
2011 using a mouse model of CC similarly to this study found that mRNA of UPS E3 enzymes to be 
increased in cachectic hearts. Furthermore, Tian and colleagues found that there was increased 
protein ubiquitinylation in the hearts of cancer cachexia mice compared to controls suggesting that 
indeed the UPS has an important role to play in cardiac atrophy secondary to CC.  
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5.0 Temporal study of the molecular and structural alterations in the 
cachectic heart. 
5.1 Introduction 
Studying cardiac atrophy secondary to cachexia in a time dependent manner is a novel approach in 
this area of research. Current studies typically harvest tissues for analysis at one time at which point 
cachexia is advanced. One issue that may be problematic with this approach is that the initiating 
molecular mechanisms which are responsible for the advancement to a cachectic state may be 
overlooked. It is hoped by recognising the genesis of cardiac atrophy in CC and its evolution a 
potential therapeutic intervention can be elucidated.  
5.1.2 Ribosomal subunit 18s and protein synthesis 
An important assessment of possible cachectic mechanisms is the machinery which drives rates of 
protein synthesis namely the ribosome. 18s is an rRNA component of the eukaryotic ribosome 
where mRNA is translated.  18s is commonly used in experimental studies as a house keeping gene 
sequence as it is commonly correlated with the amount of tissue and hence genetic material present 
in a sample. However, Klein et al, 1991 has shown that in rat hearts heteroptopically transplanted 
infrarenaly experience unloaded haemodynamics. In this situation left ventricular protein synthetic 
rate dropped significantly compared to no transplant controls after only 7 days. This decrease in 
cardiac protein synthesis was accompanied by a significant decrease in ribosomal 18s RNA content. 
In terms of CC no current research exists as to whether 18s mRNA content changes with the disease. 
Important questions in terms of the use of 18s as a housekeeping gene for a disease where it is 
known that protein synthesis rates change should be further investigated (Sullivan-Gunn et al, 2011). 
5.1.3 Peripheral and local cytokine response  
In terms of what is known about the aetiology of CC it is well established that there is a host tumour 
interaction. LMF is a factor leading to adipose tissue breakdown in early cachexia whilst PIF is a 
powerful cachectic agent leading to the loss of muscle proteins (Cariuk et al, 1997). In terms of host 
factors, T-helper cell response to the tumour largely drives cytokine production particularly IL-6 and 
TNF-alpha. Patients with cancer cachexia have been found to have elevated circulating cytokines 
which experimentally have been shown to elicit an increase in muscle ROS and UPS activity 
(Martignoni et al, 2005., Noguchi et al, 1996). Increased levels of cytokines in CC patients have also 
been shown to be associated with increased REE (Roubenoff et al, 1994).  
In determining the role of how cytokines contribute to cancer cachexia Bonetto et al, 2012 used 
both an in-vivo C26 tumour mouse model and an in-vitro murine myotube method to establish the 
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downstream signalling of IL-6. Bonetto and colleges found that the C26 tumour model induces a high 
amount of circulating IL-6 in-vivo. Stat3 of the Jak/Stat system being a tyrosine kinase signalling 
pathway was found to be phosphorylated in the muscles of these animals. Similarly in-vitro studies 
showed that myotubes exposed to IL-6 had activated stat3 which also led to muscle atrophy. 
Furthermore, an inhibitor of the Jak/stat pathway was capable of reducing muscle atrophy both in 
animals and culture. Tsukinaka et al, 1996 found that mice that are transgenic for IL-6 suffer from 
atrophy which is ameliorated by IL-6 receptor antagonists. The study also found that enzyme levels 
and mRNA levels of ubiquitins were also elevated in transgenic mice suggesting that the UPS is 
responsible for protein degradation. As with most of the research thus far with regards to CC the 
studies have predominantly been analysing skeletal muscle samples. However, Razeghi et al, 2003 
used a rat model of cardiac atrophy to examine the contributions of protein synthesis and 
degradation pathways. The study found that transcripts of TNF-α are elevated early in an unloaded 
rat heart model of cardiac atrophy. The increased expression of TNF-α was paralleled by an increase 
in the expression of the important ubiquitin-conjugating enzyme UbcH2. Patten et al, 2001 mentions 
that there is a clear link between myocardial dysfunction and the release of circulating cytokines 
such as IL-1β and TNF-α in response to sepsis. It would appear that inflammatory cytokines have a 
role to play in driving muscle atrophy and in cardiac remodelling. Both TNF-α and IL-6 administered 
to rats have been shown to reduce the mRNA expression of β-myosin heavy chain and α-actin 
compared with saline controls (Patten et al, 2001). Interestingly, a study by Adams et al, 2007 used a 
rat model of congestive heart failure to assess the involvement of cytokines in the remodelling of the 
heart. The study found that levels of TNF-α were increased 3.1 fold and that this was positively 
correlated with increases in important UPP ligases namely MAFbx and MURF-1. Furthermore, these 
rats showed a decrease in contractility possibly via the proteolysis of troponin I.  
MCP-1 or monocyte chemotactic protein-1 is an important cytokine involved in governing cardiac 
remodelling and the inflammatory response to injury. MCP-1 binds to a G-protein coupled receptor 
on the surface of cardiomyocytes to elicit a response to allow recruitment and diapedesis of 
monocytes into cardiac tissue (Niu & Kolattukudy, 2009). Indeed, MCP-1 mRNA and protein levels in 
patients with an ischaemic myocardium correlates with the accumulation of leucocytes (Kumar et al, 
1999). The effect of the subsequent leukocyte recruitment in the myocardium includes cell 
differentiation, cell death and impaired cardiac function (Deo et al, 2004). Niu & Kolattukudy, 2009 
used a transgenic mouse model of MCP-1 expression exclusive to the myocardium. As these 
transgenic mice aged they developed cardiac hypertrophy, dilation, increases in LV mass and 
ventricular dysfunction. Conversely, short term expression of MCP-1 in transgenic mice following 
ischaemia repurfusion injury leads to a decrease in infarct size compared to wild type controls 
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(Martire et al, 2003). Both increases in TNF-α and IL-6 in the ischaemia injured myocardium and the 
activation of SAPK/JNK 1/2 (stress/inflammatory) signal transduction pathway were also found. 
Although, the downstream effects of increases in cytokines and activation of stress-activated protein 
kinases are currently unknown. Furthermore, it is unknown whether MCP-1 has any role to play in 
the cachectic heart or skeletal muscle. Similar to MCP-1, RANTES (regulated upon activation, normal 
T cells expressed and secreted) is another potent chemo-attractant molecule implicated in a number 
of inflammatory diseases including rheumatoid arthritis and atherosclerosis (Goldbergova et al, 
2012., Koh et al, 2009). RANTES can be produced by a number of cells including fibroblasts, 
monocytes and T cells and released into circulation. The effect of RANTES is a broad chemo-
attractive ability for T lymphocytes, monocytes, natural killer cells, basophils, eosinophils and the 
activation of immune cells (Krensky and Ahn, 2006). There is no current data investigating RANTES 
involvement in CC or cardiac atrophy/remodelling. However, it does appear that RANTES may play a 
role in the aggressiveness of malignancies. Cao et al, 2011 did find that increased expression of 
RANTES is related to metastasis of gastric cancer. Genetic polymorphisms in the gene coding RANTES 
have also been found in patients with prostate cancer suggesting a link between the cytokine and 
the inflammatory aetiology of the malignancy (Lopez et al, 2008).  
5.1.4 Oxidative stress and redox signalling 
Another important factor in the development of cancer cachexia is ROS. Increased levels of cytokines 
in the heart have been found to induce oxidative stress (Giordano, 2005). As seen in this thesis, the 
study detailed in chapter 4 demonstrated xanthine oxidase levels were significantly increased in the 
hearts of CC mice compared to controls. This correlated with DNA oxidative damage and decreased 
SOD activity. The current study aims to further evaluate the role ROS in various stages of CC. 
Currently there is no evidence other than the studies conducted in this thesis examining the role of 
oxidative stress in cardiac atrophy related to CC. With regard to skeletal muscle atrophy Gomes-
Marcondes & Tisdale, 2002 attempted to replicate the oxidative stress seen in cancer cachexia by 
using murine myotubes in cell culture. The myotube cells were exposed to H2O2 which induced 
oxidative stress. The results found that oxidative stress caused an increase expression of important 
UPP elements including the 20s proteasome and the E214k conjugating enzyme. In further elucidating 
the role of ROS in cachexia important factors such as PIF have been introduced to myogenic cell 
culture. PIF administration to myotube cells caused significant proteolysis. Importantly antioxidant 
therapy with butylated hydroxytoluene and D-α-tocopherol led to the attenuation of total protein 
breakdown in these cells. This may explain the success of antioxidant therapy in certain patient 
populations. Furthermore, in this same experimental model specific inhibitors of NADPH oxidase 
such as diphenylene iodonium were shown to attenuate ROS production in cells exposed to either 
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PIF or angiotensin II. Thus, the ROS and subsequent oxidative stress seen in cachexia may be in large 
part derived from NADPH oxidases (Russell & Tisdale, 2007).  In assessing pathways which link ROS 
production from the induction by cachectic factors and proteolysis Wyke & Tisdale, 2005 
administered PIF to murine myoblasts in culture. PIF was able to induce total protein breakdown 
including the loss of myosin. PIF also increased the expression of the UPP which was attenuated via 
the use of a Iκβα mutant. Usually NFκβ needs the phosphorylation of its inhibitory molecule Iκβα to 
translocate to the nucleus to promote transcription of an array of genes. The Iκβα mutant however 
had mutations of the phosphorylation sites required for degradation. Hence PIF’s inability to induce 
expression of the UPP in the mutant Iκβα myotubes suggests a key role for NFκβ in linking PIF to the 
activation of proteolysis. Thus, PIF appears to be capable of inducing proteolysis in cachectic muscles 
by both inducing oxidative degradation of Iκβα possibly through the activation of NADPH and or 
xanthine oxidase. The exact mechanism that links ROS to cancer cachexia and its contribution to the 
pathogenesis of the disease is still incompletely understood. Furthermore, little is known with 
regards to the role of ROS as a contributing mechanism of cardiac muscle atrophy as a consequence 
of cancer cachexia. 
There are a number of intracellular signalling pathways implicated in the regulation of cardiac 
muscle wasting with cancer cachexia. Both anabolic and catabolic pathways like that seen in skeletal 
muscle such as the UPP and the mTOR pathway are likely to be involved. In skeletal muscle it has 
been shown that cachectic factors are able to increase proteolytic activity whilst suppressing protein 
synthesis. Furthermore, the induction of protein degradation via PIF, TNF-α and ROS all appear to 
activate NFκβ (Eley & Tisdale, 2007). Thus, the nuclear transcription factor NFκβ appears to be a 
common pathway mediating proteolysis. NFκβ is a transcription factor that regulates a myriad of 
processes in cardiomyocytes including inflammation, apoptosis, proteolysis and protein synthesis 
(Skipworth et al, 2006). Although pathways involving the production of ROS and the activation of 
NFκβ appear to bring about increases in the expression of key UPS units in skeletal muscle, it is 
unclear if this occurs in the heart. Another pathway being p38MAPkinase is also important in muscle 
atrophy as it is sensitive to redox signalling. Derbre et al , 2012 found that in unloaded rat hind limbs 
there is increased XO activity and ROS in the soleus muscle along with an increase in p38MAPkinase. 
Furthermore, previous research by Reid et al, 2005 found that p38 signalling promotes skeletal 
muscle atrophy via MAFbx ubiquitin ligase. Thus, providing a link between pro-oxidant enzymes such 
as XO and the predominant protein breakdown pathway in muscle.  
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5.1.5 Alterations in structural collagen content in cardiac 
remodelling  
The heart is capable of structural remodelling in response to a number of environmental demands. 
Physiologically the heart can undergo non pathological hypertrophy in response to exercise and 
atrophy due to bed rest. Structural cardiac alterations have been predominantly studied from the 
perspective of increased myocardial demand instigated by stress related to hypertension or post 
myocardial infarction. The resulting pathologic hypertrophic growth can lead to cardiac failure and 
malignant arrhythmias. With pathologic cardiac remodelling there is commonly alterations in 
calcium handling, contractility, loss of myocytes and fibrosis. Essentially pathologic hypertrophy 
occurs in response to neurohormal activation of the myocardium and a chronic response of the 
muscle to increased haemodynamic load or lack of functioning tissue with infarction. Typically the 
result of prolonged stress on the heart results in irreversible decompensation whereby the heart 
dilates and becomes fibrotic leading to systolic failure. Remodelling of the extracellular matrix is 
central to myocardial fibrosis (Weber, 1997). In terms of the remodelling of the heart with cardiac 
atrophy little is known. Cosper & Leinwand, 2010 did find that increases in collagen content did 
accompany cardiac atrophy of mice with CC. This study used a CD2F1 mouse strain and colon-26 
adenocarcinoma to induce cachexia in both male and female mice. Hearts were fixed for histological 
analysis on day 27 post inoculation where male animals lost on average 20% whilst females lost less 
than 10% of their body weight. On day 27 male and female mice showed increases in cardiac 
collagen content by 60% and 50% respectively. Interestingly this model of cancer cachexia showed 
that cardiac atrophy occurs to a greater extent in male compared to female mice. Unfortunately this 
study only examined the hearts of these mice at one late time point when cachexia was profound. 
Analysis of extracellular remodelling in cachectic hearts over time has yet to be studied.  
Furthermore, other cardiac atrophy studies where left ventricular assist devices in patients lead to 
unloading of the heart and subsequent atrophy comparatively lead to a reduction in collagen. (Li et 
al, 2001). A multicentre study by Maybaum and collages in 2007 found that after having a left 
ventricular assist device for 30 days patient hearts had significant reductions in cardiac myocyte size, 
collagen content and TNF-alpha. Contrasting these results Buck et al, 1996 found that nude mice 
inoculated with Chinese hamster ovarian cells secreting TNF-alpha exhibited cachexia and impaired 
wound healing. Along with the impaired wound healing skin samples analysed showed decreased 
expression of growth factor beta-1 which is a potent fibrogenic factor.  
The current study is an analysis of the temporal profile of the molecular and structural changes seen 
in cardiac muscle secondary to cancer cachexia. Importantly, there is paucity in CC research 
examining changes in an organ system in a time dependent manner. The implication of the current 
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research is to better understand the precipitating mechanisms of cardiac atrophy and to understand 
whether these mechanisms change over time. The latest research into cardiac alterations in CC using 
animal models typically involves measuring animal weight on a daily basis during the experimental 
phase whilst organs are harvested for molecular analysis at a time point when cachexia is advanced 
(Tian et al, 2010., Tian et al 2011. Cosper & Leinwand, 2010). The issue with such an experimental 
design is that valuable information regarding the early or initiating cachectic mechanisms may be 
overlooked. Indeed molecular mechanisms may well change in advanced cachexia giving a distorted 
view in terms of the important mechanisms driving the initiation of the disease. This current study 
will harvest cardiac tissue for histological and molecular analysis at 4 separate time points in order to 
provide a thorough analysis of how CC evolves. These time points were derived from a pilot study 
where the data was used to formulate which days of tissue harvest would cover early, mid and late 
cachexia. A day 0 time point was used to provide a no cachexia control whilst day 12, 21 and 29 were 
used to track cardiac atrophy from early, mid to late cachexia (refer to methods chapter 3).  
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5.2 Results 
8 week old nude (BALB/c nu nu) mice acclimatised for one week and then randomised to 
one of four time points. Day 0 (control), day 12 (early cachexia), day 21 (mid cachexia) and 
day 29 (late cachexia). At each of the day 12, 21 and 29 time points two groups existed 
being cancer cachexia (inoculated with MAC16 cells) and cancer control (inoculated with 
MAC13 cells). Please refer to methods section chapter 3 for a full description of the 
techniques used.  
5.2.1 Gross body and tumour measurements 
Figure 5.1 below shows that the cancer group did not lose weight and indeed gained weight 
over time compared to day 0. Weight gain in the cancer control group was significant from 
day 10 compared to day 0 from (p=0.007). The cancer cachexia animals had lost a significant 
amount of body weight by day 9 compared to cancer control and day 0 (p=0.01). Weight 
continued to decline in the cancer cachexia group reaching a total of 10% total body weight 
loss by day 26 (p=<0.0001). With reference to figure 5.1 the cachexia group did appear to 
then gain weight after day 26. However, this is explained by the fact that 5 cachectic animals 
where euthanised at this time point for ethical reasons and those larger less cachectic 
animals remained, thus increasing the average body weight.   
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Figure 5.1. Daily body weight comparison between the cancer and cancer cachexia groups 
over time. Values are expressed as a percentage of the initial mean weight for each 
group±SEM. Statistically significant differences are represented by * beginning at day 9. 
From day 9 onwards there is a significant degree of weight loss for the cancer cachexia 
versus cancer group on each day until day 29. * p<0.05 day 9-29. n = 20 at each time point 
for cancer cachexia and cancer groups. 
Daily tumour size did not vary significantly between cancer and cancer cachexia groups until 
day 21. From day 21 onwards the cancer cachexia group had a significantly larger tumour 
size compared to cancer (p<0.05, Figure 5.2). Despite this the cancer cachexia was the only 
group to experience a significant reduction in body weight over time (figure 5.1). Figure 5.3 
shows the total number of animals with palpable tumours over time. It was evident that the 
MAC 16 tumours which produce cachexia took on average 3 more days to become large 
enough to palpate compared to the cancer group. Despite this, the number of animals 
having palpable tumours by day 12 was the same for both groups.  
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Figure 5.2. Tumour size comparison between cancer and cancer cachexia groups. Tumour 
size became significantly larger for the cachexia group from day 21 to day 29 in comparison 
to cancer (* p<0.05 day 21-29). Values are mean ± SEM. n = 20 at each time point for cancer 
cachexia and cancer groups. 
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Figure 5.3. Comparison of the number of animals exhibiting palpable tumours between 
cancer cachexia and cancer groups. Values are expressed as total animal numbers for each 
group. n=18 animals per group. 
The scatter plot shown in Figure 5.4 shows a strong positive correlation between mean 
animal weight and tumour size for the cancer cachexia group (R2 = 0.94). The trend shows 
that as tumour volume increased animal weight inversely decreased.  
 
Figure 5.4a. X,y scatter plot with line of best fit and R2 value for mean cancer cachexia 
animal weight (g) versus tumour size (mm3). R2= 0.94 showing a strong correlation between 
cancer cachectic mouse weight and MAC16 tumour size.  
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Figure 5.4b. X,y scatter plot with line of best fit and R2 value for mean rate of cancer 
cachexia animal weight loss (mg/day) versus tumour size (mm3). R2= 0.0024 showing a no 
correlation between cancer cachectic mouse rate of weight loss and MAC16 tumour size.  
 
Table 5.1 shows that there were significant reductions in overall body, quadriceps muscle, 
kidney and heart weight over time for the cachexia group (p =<0.05) compared to cancer. 
Heart length measured from base to apex also significantly reduced consistently over time 
for the cancer cachexia group (p = <0.05). The cancer group animals did not have cachexia 
and no reductions in total body or organ wet weight were seen (figure 5.1).  
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  Days post inoculation 
C
an
ce
r 
ca
ch
ex
ia
 g
ro
up
 d
at
a 
 0 (Saline) 12 21 29 
Body weight (g) 20.1±0.3 18.3±0.5 16.6±0.2 16.2±2 
Total heart weight 
(mg) 
103.3±3 87.2±2# 83.6±1# 80.6±1#* 
Heart weight as an 
index of body 
weight 
5.1 4.7 5.0 4.9 
Heart base to apex 
(mm) 
7.5±0.08 7.0±0.1#* 6.7±0.07#* 6.7±0.06#* 
Brain (mg) 367.1±12 356.2±11 366.7±7 393.7±8 
Liver (mg) 981.4±33 1015.1±32 828.2±39 1452.0±469 
Kidney (mg) 154.2±6.9 130.9±3.2 116.6±2.9 115.6±3.5 
Peri-renal fat (mg) 41.7±6 33.4±3 19.26±4* 11.4±1* 
Quadriceps (left) 
(mg) 
90.7±4 92.9±4 87.6±4 70.3±4* 
C
an
ce
r 
co
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l g
ro
up
 d
at
a 
 0 (Saline) 12 21 29 
Body weight (g) 20.1±0.3 19.91±1 20.32±1 21.39±0.8 
Total heart weight 
(mg) 
103.3±3 85.65±7 86.73±9 90.18±8.08 
Heart base to apex 
(mm) 
7.54±0.08 7.23±0.2 7.23±0.4 7.54±0.3 
Brain (mg) 367.1±1 368.61±2 353.35±2 363.33±3 
Liver (mg) 981.4±3 920.93±1 921.29±1 946.74±9 
Kidney (mg) 154.2±6 140.71±8 141.43±10 144.67±9 
Peri-renal fat (mg) 41.7±6 37.88±7 42.76±14 46.54±9 
Quadriceps (left) 
(mg) 
90.7±4 91.68±10 90.51±10 93.75±8 
Table 5.1 Mean comparison of body and wet organ weights at harvesting time points for the 
cancer cachexia and cancer groups. # represents results that are a significant reduction in 
weight from day 0 and * represents significant weight loss versus cancer control at the same 
time point. Values are means to 1 decimal place ± SEM.  
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Peri renal fat wet weight represented in figure 5.5 was measured at each time point when 
tissues were harvested. The cancer cachexia group lost a significant amount of peri renal fat 
from day 21 to day 29 (p<0.05).  
 
Figure 5.5. Comparison of peri renal fat wet weight between cancer control and cancer 
cachexia groups over time. Values are expressed as wet weight in mg ± SEM. Statistically 
significant differences are represented by * comparing cancer control to cancer cachexia. n 
= 20 for cancer cachexia and cancer groups at each time point.  
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The left quadriceps muscle weight represented in figure 5.6 shows a significant loss of 
quadriceps wet weight by day 29 in the cancer cachexia group compared with cancer (p = 
<0.001).  
 
Figure 5.6. Comparison of left quadriceps wet weight between cancer control and cancer 
cachexia groups over time. Values are expressed as wet weight in mg ± SEM. Statistically 
significant differences are represented by * comparing cancer control to cancer cachexia. n 
= 20 for cancer cachexia and cancer groups at each time point.  
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This study demonstrated that cardiac atrophy is a consequence of cancer induced cachexia. 
Figure 5.7 shows that compared to day 0 the cancer cachexia group lost up to 22% of heart 
wet weight by day 29. Cardiac atrophy in the cancer cachexia group was an early event and 
decline in heart weight was consistent compared to time 0 until the final time point on day 
29 (p = <0.0001).  
 
Figure 5.7. Comparison of heart wet weight between cancer control and cancer cachexia 
groups over time. Values are expressed as wet weight in mg ± SEM. Statistically significant 
differences of cancer cachexia are represented by * compared to cancer control and # 
compared to time 0. n = 20 for cancer cachexia and cancer groups at each time point. 
Cardiac size in the current study measured from heart base to apex using digital callipers. 
Together with a significant decline in heart wet weight figure 5.8 shows that heart length 
base to apex declined significantly at days 12-29  (p=<0.0001). 
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Figure 5.8. Comparison of heart base to apex length between cancer control and cancer 
cachexia groups over time. Values are expressed as wet weight in mm ± SEM. Statistically 
significant differences of cancer cachexia are represented by * compared to cancer control 
and # compared to time 0. n = 20 for cancer cachexia and cancer groups at each time point. 
 
Mouse food and water intake was monitored daily. Both food and water intake between 
groups did not significantly differ (Table 5.2). 
 TIME POINT (Days post inoculation)) 
Food intake (g) 0 12 21 29 
Cancer Cachexia  104±1.1 102±6.5 106±15.2 108±7.4 
Cancer 99±5.5 103±3.9 105±4.7 106±4.3 
Water intake (ml)     
Cancer Cachexia 123±8.5 113±8.1 116±9.3 119±11.9 
Cancer 115±4.0 115±5.0 118±3.0 118±7.0 
Table 5.2 Comparison of food and water intake. The values in grams are accumulative food 
and water intake at the end of each week.  No statistical differences were found between 
groups. Values are means in g or ml ± SEM. 
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5.2.3 Histological analysis 
As shown in figure 5.9 total heart area analysed histologically significantly decreased on day 
21 in the cancer cachexia group compared to day 0 (p=0.01). By day 29 total heart area for 
the cancer cachexia group had decreased significantly compared to day 0 and day 29 of the 
cancer control group (p=0.001). No change in total heart area was found on day 12 between 
cancer cachexia and controls. This is despite the measurements shown in table 5.1 
demonstrating a significant decrease in cardiac wet weight and base to apex length in 
cancer cachectic hearts as early as day 12.  
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Figure 5.9. Bar graph and representative images displaying total heart area of cancer 
cachexia compared to cancer control over time. Bar graph data is displayed as mean area in 
μm2 ± SEM. Statistically significant difference between cachexia to day 0 is represented by #. 
Significant differences between cancer cachexia and cancer control represented by *. 
Transverse cardiac sections are captured images from light microscopy from Masson’s 
trichrome stained sections. n = 20 for cancer cachexia and cancer groups at each time point. 
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Figure 5.10 shows representative light microscopy of Massons trichrome stained sections of 
the cancer cachectic hearts from each time point. At day 12 no significant changes in 
myocardial wall thickness was detected. However, by day 21 there was a significant 
decrease in the posterior myocardium by 13 % and a decrease in the left ventricular lateral 
wall by 26 % compared to day 0. By day 29 a decrease in myocardial wall was seen at all 
points measured including posterior, lateral, anterior left ventricular wall, ventricular 
septum, and medial right ventricular wall. The greatest change in myocardial wall size was at 
the left ventricular lateral wall which decreased in thickness by 68% (p<0.05). 
 
Figure 5.10. Images of representative cancer cachectic hearts from each experimental time 
point. Images are taken from light microscopy of massons trichrome stained transverse 
sections. Significant decreases in myocardial wall size are indicated by yellow arrows with 
the average percentage decrease in myocardial wall size (p = <0.05). n = 20 for cancer 
cachexia and cancer groups at each time point. 
To date there is only a small amount of data examining the structural alterations cancer 
cachexia has on the heart muscle. The current study undertook massons trichrome staining 
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of cancer cachectic and cancer control hearts to better understand the changes in 
connective tissue with cachexia. The Massons trichrome stain is able to highlight cardiac 
collagen content staining it blue. Figure 5.11 shows representative images of cardiac 
collagen content between groups at each experimental time point. Figure 5.12 shows the 
mean values of collagen content in cachectic and control hearts over time. The collagen 
content for each heart was highly variable. Despite collagen content trending to decrease in 
the cachectic hearts compared to controls at each time point only day 29 had significant 
results. On average there was over a 50% reduction of collagen content in the day 29 cancer 
cachectic hearts versus time point 0 and day 29 cancer control (p=<0.05).  
 
Figure 5.11.  Representative images of the cancer control and cancer cachexia groups at 
each time point. Images are taken from light microscopy of Massons trichrome stained 
transverse sections. Image analysis produced a black and white image of collagen within the 
sections.  
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Figure 5.12. Bar graph comparing cardiac collagen content between cancer control and 
cancer cachexia groups over time. Values are expressed as % collagen content of total 
transverse cardiac area ± SEM. Statistically significant differences of cancer cachexia are 
represented by * compared to cancer control and # compared to time 0. n = 20 for cancer 
cachexia and cancer groups at each time point. 
5.2.4 Molecular analysis 
The second part of this study involved the molecular analysis of events linked to cardiac 
atrophy in cancer cachexia. The analysis encompasses circulating mediators of CC, 
myocardial expression of key enzymes and protein signalling molecules thought to 
contribute to cardiac atrophy. Figure 5.13 represents levels of circulating cytokine IL-6. IL-6 
has been shown to be elevated in both animal models and in patients with cancer cachexia.  
Interestingly IL-6 levels were found to be significantly elevated compared to cancer control 
on day 12 but not day 29 (p = 0.03).  
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Figure 5.13. Comparison of day 12 and day 29 serum IL-6 levels between cancer control and 
cancer cachexia groups. Values are expressed as means in pg/ml ± SEM. Statistically 
significant differences of cancer cachexia are represented by * compared to cancer control 
at the same time point. n = 20 for cancer cachexia and cancer groups at each time point. 
Serum levels of MCP-1 were also measured, unlike IL-6 MCP-1 did not differ significantly 
from the cancer group on day 12. However, on day 29 although MCP-1 levels for the 
cachexia group were not different in comparison to the same group on day 12 there was a 
significant difference on day 29 compared to cancer. Cancer appeared to have elevated 
levels of MCP-1 compared to cachexia on day 29 (p = <0.001) shown in figure 5.14.  
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Figure 5.14. Bar graph comparing day 12 and 29 serum MCP-1 levels between cancer control 
and cancer cachexia groups. Values are expressed as mean pg/ml ± SEM. Statistically 
significant differences of cancer cachexia are represented by * compared to cancer control. 
n = 20 for cancer cachexia and cancer groups at each time point.  
Similar to IL-6, TNF-α is known to be elevated in both animal models and patients with 
cancer cachexia. However, unlike the elevated serum levels of IL-6 observed on day 12 for 
the cachexia group TNF-α levels were found to be significantly lower in the cachexia group 
compared to cancer at day 12 (p=0.04).  
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Figure 5.15. Comparison of day 12 and 29 serum TNF-α levels between cancer control and 
cancer cachexia groups. Values are expressed as means in pg/ml ± SEM. Statistically 
significant differences of cancer cachexia are represented by * compared to cancer control. 
n = 20 for cancer cachexia and cancer groups at each time point. 
To expand on the serum levels of cytokines analysed above this study also examined the 
molecular events of cachectic hearts at a local level. Cardiac tissue was harvested at four 
time points to provide a temporal analysis of the in vivo perturbations which may be 
essential to the initiation and progression of cardiac atrophy secondary to cancer cachexia.   
As mRNA of various transcripts for important structural and enzymatic proteins have been 
shown to change with cancer cachexia in skeletal and heart muscle this study has 
undertaken PCR on various important mRNA targets.  
The cancer cachexia group had a significant increase in 18s mRNA at time point 12 
compared to cancer control (p=<0.001) and time 0 (p=0.005). At time point 21 the results 
were more variable, however the cachexia group had increased  18s mRNA compared to the 
cancer group (p=0.005). By day 29 however, the opposite was true in that cancer group had 
increased levels of 18s mRNA compared to the cachexia group (p=<0.001).  
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Figure 5.16. Comparison of 18s cardiac mRNA expression between cancer control and 
cancer cachexia groups over time. Values are expressed as mean arbitrary units (AU) ± SEM. 
Statistically significant differences for the cancer cachexia group are represented by * 
compared to the cancer control group and # compared to day 0. n = 20 for all groups at each 
time point. 
Our initial molecular study detailed in chapter 4 of this thesis found a significant increase in 
XDH at both a gene and enzyme activity level. To further analyse these findings this current 
study included analysis of XDH in a time course manner. As seen in figure 5.17 levels of XDH 
gene expression were elevated in late cachexia (day 29) as was seen in chapter 4. mRNA 
levels of XDH were significantly increased at all other time points versus cancer and time 
point 0 except day 12 cachexia which was significant against cancer only (p=<0.05). 
Interestingly when comparing the cancer versus time point 0 the cancer group had 
significantly decreased levels of XDH (p=<0.001).  
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Figure 5.17. Comparison of XDH cardiac mRNA expression between cancer controland 
cancer cachexia groups over time. Values are expressed as mean arbitrary units (AU) ± SEM. 
Statistically significant differences for the cancer cachexia group are represented by * 
compared to the cancer control group and # compared to day 0. n = 20 for all groups at each 
time point. 
The UPS has been shown to be an important pathway contributing to cachectic skeletal 
muscle. In this current study mRNA expression of important UPS E3 ligases were analysed by 
PCR in cachectic hearts. Both murf-1 and mafbx showed similar patterns of gene changes. 
Figure 5.18 and 5.19 show a significant; over 2-fold increases in mRNA of cachexia hearts 
compared to time point 0 and cancer on day 21 (p=<0.05). However, at time point 12 and 29 
both UPS ligases only showed significant increases compared to cancer (p=<0.05). The 
cancer group at each time point did have lower levels of UPS ligases compared to time point 
0 (p=0.001). 
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Figure 5.18. Comparison of murf-1 cardiac mRNA expression between cancer control and 
cancer cachexia groups over time. Values are expressed as mean arbitrary units (AU) ± SEM. 
Statistically significant differences for the cancer cachexia group are represented by * 
compared to the cancer control group and # compared to day 0. n = 20 for all groups at each 
time point. 
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Figure 5.19. Comparison of mafbx cardiac mRNA expression between cancer control and 
cancer cachexia groups over time. Values are expressed as mean arbitrary units (AU) ± SEM. 
Statistically significant differences for the cancer cachexia group are represented by * 
compared to the cancer control group and # compared to day 0. n = 20 for all groups at each 
time point. 
Figure 5.20 shows that IL-6 mRNA levels did not significantly increase in cancer cachectic 
hearts until day 21 where cancer cachexia hearts had a over 2-fold increase in IL-6 
compared to time 0 (p=0.001)) and cancer control (p=0.003). At time point 29 IL-6 levels in 
the cancer cachexia group did not change from time 0 however due to significantly lower IL-
6 levels in cancer control versus time point 0 there was a significant difference between 
cancer and cachexia groups (p=0.02). 
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Figure 5.20. Comparison of IL-6 cardiac mRNA expression between cancer control and 
cancer cachexia groups over time. Values are expressed as mean arbitrary units (AU) ± SEM. 
Statistically significant differences for the cancer cachexia group are represented by * 
compared to the cancer control group and # compared to day 0. n = 20 for all groups at each 
time point. 
In reference to figure 5.21 the RANTES cytokine had a similar pattern of mRNA expression to 
IL-6 across the experimental time points. At time point 21 RANTES mRNA levels showed a 
more than 2-fold increase in the cachexia group compared to both time 0 (p=0.009) and 
cancer (p=0.001). At day 29 cancer had a significantly lower level of RANTES mRNA 
expression compared to time 0 (p=0.0003) 
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Figure 5.21. Comparison of RANTES cardiac mRNA expression between cancer control and 
cancer cachexia groups over time. Values are expressed as mean arbitrary units (AU) ± SEM. 
Statistically significant differences for the cancer cachexia group are represented by * 
compared to the cancer control group and # compared to day 0. n = 20 for all groups at each 
time point. 
The gene expression of MCP-1 was different compared to IL-6 and RANTES in that MCP-1 
mRNA levels for the cancer cachexia group were increased significantly early in cachexia on 
day 12 (p=<0.05) as well as day 21 (p=<0.05) compared to controls (figure 5.22). At day 29 
the gene data for the cancer cachexia showed high variability thus increased expression only 
reached significance compared to cancer control.  
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Figure 5.22. Comparison of MCP-1 cardiac mRNA expression between cancer controland 
cancer cachexia groups over time. Values are expressed as mean arbitrary units (AU) ± SEM. 
Statistically significant differences for the cancer cachexia group are represented by * 
compared to the cancer control group and # compared to day 0. n = 20 for all groups at each 
time point. 
 
NFkβ and MAPK are important endogenous factors which govern an array of cellular 
processes including inflammation, cell cycle, apoptosis and gene expression. NFkβ has 
already been shown to be activated in cancer cachexia however no research exists as to 
how the transcription factor relates to cachexia in a temporal manner. MAPK on the other 
hand has yet to be investigated as a contributor to cachexia and is thus also another focus of 
this study. Phosphoprotein levels or the activated phosphorylated form of NFkβ and MAPK 
were analysed. Interestingly in cardiac tissue of cachectic mice NFkβ levels were increased 
compared to time point 0 (p=0.005). No changes were seen between cancer cachexia and 
cancer control (Figure 5.23). Contrasting with MAPK although activity levels of MAPK was 
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highly variable in control samples the cancer cachexia group had significantly lower levels at 
time point 12 compared to time 0 and cancer control (p=<0.05, Figure 5.24).   
 
Figure 5.23. Comparison of NFKβ cardiac phosphoprotein levels between cancer control and 
cancer cachexia groups over time. Values are expressed as mean pg/mg± SEM. Statistically 
significant differences of cancer cachexia are represented by * compared to cancer control 
and # compared to time 0. n = 20 for all groups. 
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Figure 5.24. Comparison of MAPK cardiac phosphoprotein levels between cancer control 
and cancer cachexia groups over time. Values are expressed as mean pg/mg± SEM. 
Statistically significant differences of cancer cachexia are represented by * compared to 
cancer control and # compared to time 0. n = 20 for all groups. 
This study has demonstrated in chapter 4 that oxidative stress in the form of DNA oxidative 
damage is present in cachectic hearts. To further evaluate this, the following has examined 
DNA oxidative damage in a temporal manner. Figure 5.25 shows that levels of the DNA 
oxidative damage marker 8-OH-2dG are elevated in the cancer cachexia group compared to 
time 0 at all time points (p=<0.05) and compared to cancer control at day 21 (p=0.01). 
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Figure 5.25. Comparison of 8-OH-2dG levels between cancer control and cancer cachexia 
groups over time. Values are expressed as mean pg/ml± SEM. Statistically significant 
differences of cancer cachexia are represented by * compared to cancer control and # 
compared to time 0. n = 20 for all groups. 
SOD enzyme activity was found to be decreased significantly in the previous study detailed 
in chapter 4 of this thesis thus this study aimed to understand changes in cachectic heart 
SOD levels over time. SOD activity shown in figure 5.26 was found to be significantly 
decreased at day 12 (p=0.03) and significantly increased at day 29 compared to day 0 
(p<0.008). No changes in SOD activity was found at day 21 or comparing cancer cachexia to 
time point 0.   
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Figure 5.26. Comparison of SOD enzyme activity levels between cancer control and cancer 
cachexia groups over time. Values are expressed as mean units of activity/ml ± SEM. 
Statistically significant differences of cancer cachexia are represented by * compared to 
cancer control and # compared to time 0. n = 20 for all groups. 
 
* 
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Figure 5.27. Comparison of XDH enzyme activity levels between cancer control and cancer 
cachexia groups over time. Values are expressed as mean units of mu/ml ± SEM. Statistically 
significant differences of cancer cachexia are represented by * compared to cancer control 
and # compared to time 0. n = 20 for all groups. 
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5.3 Discussion 
The current study saw a significant decrease in weight 9 days post inoculation with MAC16 cells and 
a peak weight loss of 10% by day 26 in the CC group. Similar studies using the using a similar model 
of cancer cachexia showed  that MAC16 cells induce weight loss after a short period of time post 
inoculation (Monitto et al, 2001, Sullivan-Gunn et al, 2011). This study was able to achieve a 
significant weight loss in the cancer cachexia group bearing MAC16 cells 9 days post inoculation into 
their flank. In contrast to this a study by Monitto et al, 2001 the same nude mouse model of cancer 
cachexia achieved significant weight loss by day 18. The methodology between this current study 
and that of Monitto et al, 2001 is similar with respect to MAC16/13 cell culture. However, this study 
did additionally keep cells warmed to 37deg before injection into the balb/c nude mice. 
Furthermore, in contrast to Monitto et al, 2001 whereby they injected MAC cells into the thigh of 
the animal this study inoculated the cells into the flank of the nude mice. Thus, keeping the MAC 
cells at the same temperature used in incubation and the injection into the animals flank appears 
advantageous in providing shorter time from inoculation to the appearance of cachexia. These 
techniques might be a consideration in future experiments of a similar animal model. Another 
advantage of this current study was the calculation and administration of an equivalent amount of 
MAC cells in to the flank of the nude mice. Unlike the spread of maximal weight loss of MAC16 
inoculated mice in the Monitto study over a 11 day period this study saw tighter spread of animal 
weight loss over time.  This study saw a maximal weight loss in the cancer cachexia group (MAC16) 
spread across six days compared to the previous study by Monitto et al, 2001 which had a spread of 
11 days.  
Cancer patient’s tumour size and degree of metastases is a determinant of the extent of cancer 
cachexia and clinical prognosis (Yokota et al, 2002). This study hypothesised that tumour size would 
be correlated to the extent of weight loss seen in the cancer cachexia group over the 29 day period. 
Mean animal weight was plotted against tumour size for the cancer cachexia group. A strong 
correlation was seen as tumour size increased mouse weight decreased (R2 = 0.94). Unfortunately, 
no previous research exists examining tumour size in relation to the amount serum or local chemical 
mediators in cancer cachexia. In determining whether serum cytokine levels are related to tumour 
size the current study examined peripheral levels of IL-6, MCP-1 and TNF-alpha. Interestingly, none 
of the cancer cachexia group serum cytokines were elevated at time point 29 where tumours were 
largest. Thus, suggesting that at least in a mouse model of cancer cachexia cytokine response is not 
influenced positively by tumour size. Furthermore, there was no correlation found between tumour 
size and the rate of CC mice weight loss per day. 
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In general the appearance of tumours in the flank of nude mice used in this study appeared at 
varying time points. The time taken to reach 10 animals with palpable tumours was 6 days in cancer 
control (MAC13 cells) versus 8 days in the cancer cachexia (MAC16cells) group. Likewise time taken 
to reach all animals having palpable tumours was day 10 for cancer control and day 12 for the cancer 
cachexia group. Thus, it appears that there may be a difference in the growth of MAC13 and 16 cells 
in in vivo. However, this study only used a subjective measure (palpation) of tumour growth at the 
beginning of the study. As tumour size became larger digital callipers were capable of providing 
much more accurate tumour growth data.  
There is no evidence from previous studies and the current study that brain atrophy is evident in 
cancer cachexia. Likewise liver weight did not change significantly over time when comparing cancer 
cachexia and cancer control groups. Peri-renal fat mass was expected to drop in weight over time in 
the cancer cachexia group. Indeed the cancer cachexia group had significantly atrophied levels of 
peri-renal fat compared to cancer control at day 21 and 29.  These results are consistent with 
previous studies of animal models and patients with cancer cachexia. The loss of adipose tissue has 
been described as an early and profound consequence of cancer cachexia (Skipworth et al, 2007., 
Bing et al, 2006). Previous research has found that in starvation where there is a loss of adipose 
tissue which leads to decreased leptin levels thus leading to a corrective increase in appetite. 
However, the cancer cachectic mice in this study did not have any increase in caloric intake even 
though food was provided ad libitum. A Study by Wigmore, 1997 found that there is increased 
expression and release of leptin in cancer cachexia which was proposed to be one mechanism by 
which the corrective drive for increased appetite despite weight loss is inoperable in CC. This study 
did not analyse leptin levels however the addition of assessing markers of appetite would be a useful 
future direction in terms of CC research. Adipose tissue loss has been shown to be an early sign of 
cancer cachexia and found to occur earlier than lean tissue atrophy in the disease (Ryden et al, 
2008).  Interestingly, peri-renal fat levels were not significantly decreased at day 12 in the cancer 
cachexia group. This is despite a significant decrease in overall body weight in these animals. 
However, peri-renal fat loss did predate lean skeletal muscle atrophy in the cancer cachexia animals. 
There is a large body of evidence suggesting that CC causes loss of skeletal muscle in cancer patients 
and animal model of the disease (Costelli et al, 2001., Gordon et al, 2005). Likewise, this study found 
that by day 29 the cancer cachexia group mice had a significant decrease in left quadriceps weight by 
26.1% compared to cancer control at the same time point. In terms of muscle atrophy this study has 
focused its attention on the less researched cardiac atrophy. In terms of basic analysis of cardiac 
atrophy the study weighed the hearts of all mice at four time points described earlier as well as 
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measure heart base to apex length with digital callipers. At day 29 the cardiac atrophy of the cancer 
cachexia mice peaked at 22% compared to day 0. Whilst loss of total body weight of the cancer 
cachexia group as measured on day 29 compared to day 0 peaked at 15.7%. The largest loss in 
cardiac muscle wet weight was between day 0 and day 12 where 73% of the total atrophy seen in 
the heart occurred. Compared to total body weight loss between day 0 and cancer cachexia day 12 
which was only 2% of the total seen. This suggests that cardiac atrophy in this model may precede 
loss of other body tissues and may account to a large degree of total body weight loss in early cancer 
cachexia. These results also suggest that unlike that of body weight the degree of cardiac atrophy 
does not correlate with tumour size. Another analysis in the current study was assessing the 
dimension of the atrophying heart in the form of base to apex length. The hearts of the cancer 
cachexia group mice did have significantly shorter base to apex measures compared to day 0 and 
cancer control at days 12, 21 and 29. The significant decrease in base to apex length in the cancer 
cachexia group suggests that as with heart weight cardiac structural changes in this model is an early 
and significant part of cancer cachexia. Cardiac atrophy seen in previous studies such as Costelli et al, 
2001 has shown heart weight loss in CC animals to be up to 60% compared to the initial reading. 
However, the study undertaken by Costelli et al, 2001 used male Wistar rats and transplanted 
Yoshida AH 130 ascites hepatocellar cells which produced a significant reduction in heart wet weight 
within 6 days of cancer transplant. The current study used the inoculation of cells which takes time 
to proliferate in the flank of the animal before producing CC. It should be stated that the discrepancy 
between studies also exist in terms of the degree of atrophy seen in organ systems. Busquets et al, 
2004 used a similar model to Costelli et al, 2001, however after 7 days only saw a 11% decrease in 
cardiac weight compared to control. Other studies by Tian et al, 2010 & Cosper Leinwand, 2011 
using CD2F1 mice with the inoculation of colon cancer 26 adenocarcinoma cells saw a reduction in 
heart weight comparable to the current study of 20%. 
Importantly all of the above analysed results showing significant loss of total body, skeletal and 
cardiac muscle atrophy with cancer cachexia are despite no change in animal caloric intake. There 
are no significant differences in food or water intake between groups at any time point. This also 
suggests that as cancer cachexia group animals were losing body weight, the amount of calories 
consumed for their body weight actually increased. Despite this the cancer cachexia group continued 
to lose weight over time. 
As part of the structural analysis of cardiac atrophy seen in this study the cancer cachexia group 
hearts were prepared in cross sectional slices to analyse total heart area including chamber size over 
time. Although cancer cachexia heart wet weight at day 12 was significantly reduced compared to 
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day 0 no significant change in total heart cross sectional area was found.  Reductions in base to apex 
length may explain why cachectic hearts had significantly reduced mass at the day 12 time point. 
However, cancer cachexia hearts at day 21 and 29 did have significantly reduced cross sectional area 
compared to day 0 and cancer controls. When we then examine the individual walls of the cachectic 
heart it is obvious that not all areas of the myocardium are subject to atrophy equally over time. 
There is research examining myocardial wall size using m-mode (motion-mode) echocardiography of 
CD2F1 mice. Tian et al, 2011 found that 14 days after inoculation with C26 adenocarcinoma there 
was a significant 18% decrease in mouse body weight. M-mode echo detected a 28% reduction in 
interventricular septum (IVS) and 30% decrease in posterior myocardial wall size. This study aimed to 
further assess structural changes in cachectic hearts by analysing the wall thickness of hearts over 
the four time points. At day 21 the posterior and lateral left ventricular wall thickness was 
significantly reduced by 13 and 26% respectively. By day 29 constituting late or advanced cachexia all 
right and left ventricular wall thickness measures including septum was significantly reduced. The 
cancer cachectic hearts by day 29 had between a 41 to 68% reduction in myocardial wall thickness. 
The results suggest that cardiac remodelling in cancer cachexia does not occur in a uniform manner. 
Indeed, at day 12 the cancer cachexia hearts had significant reductions in base to apex length. After 
which by day 21 and to a greater extent by day 29 significant reductions in myocardial wall thickness 
assessed in cross sectional area appear to be part of the remodelling process. Such a profound 
change in myocardial wall thickness would suggest that there may indeed be clinically significant 
cardiac dysfunction. The cardiac dysfunction seen by Hellerstein & Santiago-Stevenson, 1950 
evidenced by declining blood pressure may indeed be related to reductions in myocardial wall 
thickness as seen in the current study. Tian et al, 2010 again using a mouse model of cancer cachexia 
found that 14 days after inoculation with tumour cells echocardiographic assessment of cachectic 
hearts revealed a reduced heart rate as well as impaired fractional shortening compared to no 
tumour controls. One possible explanation for impaired cardiac function in cancer cachexia apart 
from protein degradation is cardiac fibrosis.  
This study unlike previous research aimed to assess cardiac collagen content over a number of time 
points to gain a complete picture of how cardiac fibrosis may contribute to the atrophying cachectic 
heart. There is an extensive network of collagen in the myocardium. The network connects myocytes 
to other myocytes and orientates cells into anatomical units. The network of collagen and myocytes 
ensure that cardiac tissue contracts in a unified and consistent fashion (Caulfield & Bork, 1979). 
Recent studies have focused on the interaction of the cardiac extracellular matrix (ECM) to cardiac 
contraction and relaxation. Normal aging, hypertension and diabetes have been associated with 
functional alterations in the ECM. Myocardial infarction results in changes in myocardial cell death 
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and a subsequent increased synthesis of collagen within the heart leading to stiffness and cardiac 
contractile dysfunction (Koshy et al, 2003).  Indeed a lot of evidence exists showing that myocardial 
stress caused by hypertension, aging or infarct causing cardiac dysfunction partly due to cardiac 
fibrosis. Tian et al, 2010 showed similarly that cardiac atrophy secondary to cancer cachexia in mice 
also causes cardiac dysfunction evidenced by impaired fractional shortening assessed with echo. 
Furthermore, studies by Tian et al 2011 and Cosper & Leinwand, 2011 showed that there is cardiac 
fibrosis in CC animals which could explain the cardiac dysfunction previously demonstrated. 
However, unlike the data from the Tian et al 2011 or Cosper & Leinwand, 2011 studies this current 
study did not find a significant change in cardiac collagen content over time except at time point 29. 
At day 29 post inoculation with MAC16 cells the CC group had a significant reduction cardiac 
collagen compared to time matched cancer control and time 0. It is unknown why there is a disparity 
between this study and those previous in terms of collagen in cardiac atrophy secondary to CC. 
However, the data from the current study would suggest that cardiac atrophy in CC occurs at the 
level of the cardiac muscle cell and the ECM collagen structure.  
The molecular analysis of this study aimed to determine the alterations that may be key initiating 
factors inducing cardiac atrophy in cancer cachexia. To accomplish this, an  analysis was undertaken 
of factors which have been previously shown to be involved in the pathogenesis of skeletal muscle 
atrophy in CC. The results detailed in chapter 4 of this thesis were also considered when which the 
molecular markers to analyse. The novel aspect of the analysis is that the molecular systems 
analysed in the current study have been done so in a time course manner and are focused on cardiac 
muscle atrophy. Plasma samples were collected using a cardiac puncture before the heart muscle 
was harvested from each animal. Plasma from these samples were analysed for serum levels of key 
cytokines namely IL-6, MCP-1 and TNF-α. Due to limitations in the amount of sample available unlike 
other analysis, the cytokines were measured at two time points being days 12 and 29 comparing 
cancer control to cancer cachexia groups. The hypothesis regarding serum levels of the measured 
cytokines was that each cytokine would be elevated at the day 12 and 29 time points in the cancer 
cachexia group compared to controls. Interestingly only serum IL-6 levels were elevated in the 
cancer cachexia group at time point 12 but not 29.  Previous animal models have shown that 
tumours such as the C26 adenocarcinoma cause elevations in IL-6 levels in-vivo whilst IL-6 can cause 
myotube atrophy independently in-vitro (Bonetto et al, 2012). This nude mouse model shows that a 
MAC16 tumour like that of the C26 adenocarcinoma also caused increases in serum IL-6. However, 
as this study has been executed in a time course manner it has shown that serum IL-6 levels are 
significantly elevated pre cachexia when body weight loss is only 2% of its initial reading. The lack of 
change in cancer cachexia serum IL-6 at day 29 may represent a compensatory mechanism in late 
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cachexia remembering that by day 21 the majority or 72% of total body weight loss in the cancer 
cachexia group has occurred. Indeed it is possible that serum IL-6 may be a driving force for atrophy 
in pre cachexia to cachexia. With particular reference to cardiac atrophy seen in this study the 
majority of heart muscle mass loss seen was within the first 12 days after inoculation with MAC16 
cells. The cancer cachexia group lost 72% of the total cardiac weight loss by day 12 which also relates 
to high serum IL-6 levels seen on day 12. It would appear that the results of the current study 
suggest that serum IL-6 levels are not related to the stage of cachexia as the disease progresses over 
time but may be a factor associated with initiating profound early atrophy of the heart. IL-6 has also 
been shown to be elevated in patients of cancer cachexia. A study by Scheede-Bergdahl et al, 2012 
showed that IL-6, IL-1β and TNF-α are all elevated in advanced CC patients and may represent 
potential markers for staging. The study aimed to assess the potential for IL-6 as a marker for the 
progression of cancer cachexia patient weight loss. However, IL-1β was the only cytokine associated 
with patient weight loss.  
With regard to serum MCP-1 it was found that there was a significant difference in the cytokine level 
between cancer control and cancer cachexia on day 29 but not day 12. However, between day 12 
and 29 the cancer cachexia group was stable. Thus, the result likely represents an increase in MCP-1 
in the cancer control group; the reason of which is unknown. The result was unexpected considering 
that MCP-1 is important in initiating recruitment and diapedesis of immune cells into tissues 
including the myocardium and it is hypothesised that there if a significant inflammatory response in 
the cachectic heart. It was expected that serum MCP-1 levels would be higher in the cancer cachexia 
group leading to WBC infiltration of tissues. Interestingly, serum TNF-α level results were also 
unexpected. TNF-α levels on day 12 compared to cancer control at the same time point were 
significantly decreased. The results of peripheral cytokine levels with particular reference to MCP-1 
and TNF-alpha may be explained by previous work examining plasma of cancer cachectic patients. 
Falconer et al, 1994 found that levels TNF-α were unchanged in cancer patients plasma while local 
levels of TNF-α were significantly increased. Thus, this study further evaluated gene expression 
levels of IL-6, TNF-alpha, MCP-1 and RANTES from cardiac tissue.  
The increased expression of cytokines in the heart has been associated with myocardial infarct and 
ventricular remodelling (Ono et al, 1998). There is currently no data looking at local levels of 
cytokines in the atrophying heart secondary to cancer cachexia. Again as per other analysis this 
study has used a time course model to examine cytokine expression levels in cachectic hearts. . 
Unlike peripheral cytokine levels IL-6 mRNA levels were unchanged at day 12 between groups. 
However, on day 21 there was a significant 2.5 fold increase in IL-6 levels in cancer cachexia hearts 
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compared to cancer control and time 0. Interestingly, IL-6 mRNA levels in the cachectic hearts did 
not mimic peripheral levels as described above. Considering that by day 12 the bulk of cardiac 
atrophy (73%) over the 29 day time period had occurred. Early elevation in serum IL-6 levels may be 
more important in CC cardiac atrophy than local levels. At least local levels of IL-6 may sustain 
cardiac atrophy beyond early cachexia considering heart tissue continued to atrophy by 17% of total 
after day 12.  
Gene expression of the RANTES has not been previously studied in cancer cachexia. Heart muscle 
levels of RANTES was found to be upregulated in the cancer cachexia group on days 21 and 29. 
Similarly to Il-6 mRNA levels of RANTES peaked on day 21. MCP-1 gene expression had increased 
levels in the cancer cachexia group hearts compared to cancer control at all time points whilst 
peaking on day 21. Both RANTES and MCP-1 are potent chemotactic factors for the recruitment of 
inflammatory cells into cardiac tissue (Niu & Kolattukudy, 2009). The current study results suggest 
that both RANTES and MCP-1 are involved in the pathogenesis of cardiac atrophy secondary to 
cancer cachexia.  Remembering that the gene expression of MCP-1 is correlated to levels of 
leukocytes in the myocardium RANTES and MCP-1 may be an important signalling mechanism 
bringing about inflammation of the myocardium. Another interesting point is that beyond increased 
serum IL-6 the only cytokine with upregulated expression in the cachectic myocardium at day 12 pre 
cachectic stage when the bulk of cardiac atrophy has occurred is MCP-1. Like elevated serum levels 
of IL-6, MCP-1 may also be an important instigator of cardiac atrophy in early cancer cachexia. There 
is currently no research into MCP-1 and CC related atrophy. It would be advantageous for future 
studies to include an analysis of MCP-1 in CC muscle atrophy both at a gene and protein level. 
Levels of increased oxidative stress has been well established in models of CC (Gomes-Marcondes & 
Tisdale, 2001., Barreiro et al, 2005). Furthermore, oxidative stress has been found in patients with 
cancer and cancer cachexia. The consequence of oxidative stress in a CC patient population is 
importantly correlated with the stage of disease and a negative prognosis (Murr et al, 1999., Kaynar 
et al, 2005. On a molecular level ROS results in damage to cell membranes, organelles, DNA and 
proteins leaving them susceptible to denaturation and proteolysis predominantly by the activation 
of the UPS (Haddad, 2002). This study aimed to understand how levels of oxidative stress change 
over time in atrophying cachectic heart and understand how pro and antioxidant factors may 
contribute. Significantly elevated level of the DNA oxidation by-product 8-OH-2dG was apparent in 
the analysed cachectic hearts at all time points. There was a peak increase in 8-OH-2dG on day 21 
compared to day 0. This peak in DNA oxidation correlates with peak local gene expression levels of 
pro-inflammatory molecules being IL-6, RANTES and MCP-1. Indeed, IL-6 has been shown previously 
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to induce ROS in patients with arthritis (Sung et al, 2000). Likewise there is evidence for the converse 
whereby ROS can induce IL-6 in muscle cells (Kosmidou et al, 2002). A study by Kosmidou found that 
the stimulation for the production of IL-6 in C2C12 murine myocytes by XO is dose dependent. Thus, 
there appears to be a close relationship between ROS from XO and IL-6. Both of which were elevated 
in the cancer cachexia group in the pre cachexia state.   
RANTES and MCP-1 are known to be redox sensitive and activated by ROS. In assessing potential 
contributors to oxidative stress in the cachectic myocardium levels of XDH mRNA and XO activity 
were measured. The results of the XDH gene analysis showed that XDH mRNA levels were 
significantly increased in CC hearts compared to controls. Furthermore, an activity analysis of cardiac 
XO was undertaken. Despite variation in the results of the samples there was a significant increase in 
XO activity on day 12 pre cachexia compared to cancer control. This significant increase in XDH 
activity levels correlates with increases in serum IL-6 levels. Thus, serum IL-6 may indeed be a 
stimulus for the activation of XDH activity at the myocardium level.  
Further analysis of the SOD antioxidant system was also undertaken to examine its potential 
contribution to increased DNA oxidation levels in the cachectic hearts. Interestingly at the same time 
point (day 12) where there was an increase in XO activity in cachectic hearts there was a significant 
decrease in SOD activity. However, by day 29 SOD activity in the cachectic hearts was significantly 
increased compared to controls. This increase in SOD activity at day 29 did not appear to be enough 
to alleviate ROS induced DNA oxidation as shown by increases in 8-OH-2dG on the same day in 
cachectic hearts. Furthermore, the lack of increased XO activity in mid (day 21) and late (day 29) 
cachexia suggests that another factor is contributing to oxidative stress in the cachectic heart at 
these later time points. The results taken in summation suggest that reduced SOD activity and 
increased XO activity levels in pre cachexia are important factors producing oxidative stress in 
cachectic hearts as evidenced by increased 8-OH-2dG. Other driving factors of oxidative stress in 
cachectic hearts may be elevated serum IL-6 on day 12 and increased local levels of cardiac IL-6, 
RANTES and MCP-1. However, with regard to RANTES and MCP-1 it is unknown whether these 
chemokines are responding to ROS as they are redox sensitive or at the same time promoting white 
cell infiltration of cardiac tissue, inflammation and initiating ROS in the first instance.  
Increased ROS can lead to the activation of redox sensitive pathways including NFKB and MAPK. 
Cachectic factors such as PIF, IL-6 and ROS all appear to activate NFκβ (Elley & Tisdale, 2007). NFKB is 
able to become more transcriptionally active in response to excess ROS which leads to the 
degradation of its inhibitor IKB (Haddad, 2002). The redox sensitive NFKB and MAPK has been shown 
to be involved in promoting inflammation, apoptosis and cell death (Skipworth et al, 2006., Derbe et 
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al, 2012). Importantly in terms of CC induced atrophy both the redox sensitive NFKB and MAPK have 
both been shown to upregulate the UPS (Elley & Tisdale, 2007., Derbe et al, 2012., Reid et al, 2005). 
However, both NFKB and MAPK have not previously been investigated with regard to cardiac 
atrophy secondary to CC. This study used an assay able to detect phosphorylated (activated) protein 
levels of both NFKB and MAPk. The results show that MAPK levels were highly variable in the control 
groups at days 0 and 12. However, there was a significant decrease at pre cachexia day 12 in MAPK 
phosphoprotein levels in cancer cachectic hearts compared to controls. There are a number of 
different factors which can stimulate MAPK in-vivo. This study has established that the cachectic 
heart is under oxidative stress from pre to late cachexia. If we consider MAPK activation as a 
response to redox signalling the pathway leads to apoptosis, cell cycle arrest, promotion of cell 
differentiation and activation of the UPS. Thus, these results suggest that MAPK is not contributing 
to cardiac atrophy secondary to CC. Indeed the fact that there is decreased levels of MAPK in the 
cachectic hearts on day 12 compared to controls may suggest that MAPK pathway is to some extent 
limiting or compensating for the cardiac atrophy seen in CC mice. In comparison phosphoprotein 
levels of NFKB in cachectic hearts was shown to be elevated in comparison to controls on day 12. 
NFKB as a transcription factor has an array of genes which it influences. With reference to CC it has 
been established that the cachectic factors such as PIF, TNF-alpha and ROS can all activate NFKB 
which leads to the up regulation of the UPS in skeletal muscle (Elley & Tisdale, 2007). This is the first 
study showing that NFKB phosphoprotein levels are elevated in cachectic hearts. The implication is 
that similarly to skeletal muscle ROS may activate the transcription factor instigating protein loss 
through the UPS as seen in skeletal muscle. To further substantiate this theory gene expression of 
the UPS was analysed at the experimental time points.   
In terms of CC it is well known that the activation of the UPS is important in the atrophy of skeletal 
muscle. However, recent research into whether the UPS plays a clear role in cardiac atrophy 
secondary to CC is lacking. Firstly Copser & Leinwand, 2010 did not find any upregulation of the UPS 
in the hearts of a C26 adenocarcinoma mouse model of CC.  Following this Tian et al, 2011 using an 
identical model of CC to Cosper & Leinwand found that 17 days post inoculation with tumour cells 
the analysis of cachectic hearts showed increased expression of Murf-1 mRNA and protein levels. 
The study also used a western blott analysis to show that there was a significantly higher level of 
ubiquitinated proteins in the myocardium of mice in the tumour group. The results of Tian et al, 
2011 clearly show that indeed the UPS plays an essential part of cardiac atrophy in CC. This study 
aimed to further understand how levels of the important ubiquitin ligases Murf-1 and Mafbx change 
over time in the cachectic heart. Gene expression of Murf-1 was increased significantly on day 12 
and day 21 compared to controls. At day 21 the increased expression of Murf-1 was 7.4 fold higher 
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compared to cancer control. Likewise Mafbx peak expression in mRNA of cachectic hearts occurred 
on day 21 with a 7.9 fold increase compared to cancer control. The peak increase in mRNA of the 
ubiquitin ligases do not match the early peak of cardiac muscle atrophy on day 12. However, due to 
limited tissue further investigation could not be completed in this study examining protein levels of 
Murf-1 and Mafbx. The levels of peak ubiquitin ligases expression at day 21 does correlate with the 
peak mRNA up regulation of cachectic heart cytokines IL-6, MCP-1 and RANTES. Cytokines such as IL-
6 and TNF-alpha have been shown to independently activate the UPS in-vitro (REF). Likewise, both 
ROS and the redox sensitive transcription factor NFKB have been shown to increase levels of the 
UPS. NFKB phosphoprotein levels were elevated in early cancer cachexia cardiac atrophy. The 
consequences of the up regulation of the UPS in the cachectic myocardium include atrophy and 
cardiac dysfunction (Tian et al, 2011).  
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6.0 Therapeutic intervention of cancer induced cardiac atrophy with 
eicosapentaenoic acid and oxypurinol  
 
6.2 Introduction 
Cancer cachexia (CC) is a complex condition presenting a multitude of potential therapeutic targets 
particularly relating to skeletal muscle breakdown. However, there is little current data with respect 
to the molecular events that are responsible for cardiac atrophy secondary to CC. However, this 
thesis in the preceding chapters has found some important molecular alterations in the cachectic 
heart that may provide potential therapeutic targets. Although difficult to employ therapies that 
cover all of the molecular alterations that occur in CC it is possible to target key areas that may be 
initiating events. Oxidative stress, inflammation and proteolytic activation are findings that are 
central to CC. Oxidative stress has been found to be part of cachectic disease in both patients and 
animal models examining plasma and skeletal muscle samples (Gomes-Marcondes & Tisdale, 2002, 
Barreiro et al, 2005, Murr et al, 1999, Mantovani et al, 2004). Both tumour derived PIF and host TNF-
alpha have been shown stimulate ROS production in skeletal muscle (Russel et al, 2007). 
Furthermore, ROS has been shown to activate the ubiquitin proteasome system (UPS) and thus 
initiate proteolysis (Russel et al, 2007). With regard to studies detailed in chapters 4 and 5 of this 
thesis we have found that indeed ROS and markers of the UPS are upregulated together in the heart 
of CC animals. Likewise results from post myocardial infarction and heart failure studies also show 
that ROS is a key event initiating cardiac remodelling and atrophy (Hori & Nishida, 2009). In the 
studies undertaken in chapters 4 and 5 of this thesis we have also found that the pro-inflammatory 
cytokine IL-6 is elevated in the cachectic heart and that serum levels of IL-6 are increased in early CC. 
The results obtained in the current thesis may be used to adopt therapies targeting the changes seen 
in the cachectic heart.  
6.2.1 Previous intervention studies 
Initial CC treatment studies aimed to ameliorate weight loss via nutritional supplementation with the 
addition of anabolic steroids and appetite stimulants. However, treating patients with increases in 
caloric intake and appetite stimulants has been shown to be largely inadequate (Coss et al, 2011). 
Many randomised control trials using appetite stimulants initially appeared to increase patient body 
mass. However, after careful investigation most of this weight gain was attributed to water retention 
and in some cases fat gain rather than lean body mass (Dodson et al, 2011). Furthermore, the 
assessment of therapeutic efficacy in CC has been always focused on skeletal rather than cardiac 
muscle.  
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Treatment trials have also examined the potential for anti-inflammatory agents in CC. Agents such as 
thalidomide, anti-IL-6 antibodies and immune modulators are currently being investigated. Early 
results suggest that thalidomide is able to ameliorate some of the total body weight loss and lean 
tissue wastage in CC (Gordon et al, 2005). However, the severe side effect profile of thalidomide may 
limit the drugs use in the treatment of CC. Whilst the use of anti-IL-6 antibodies and immune 
modulators show promise their investigation as therapeutic cachectic agents is at an early stage 
(Coss et al, 2011). 
6.2.2 The current basis for intervention in cancer cachexia 
This study is focusing on two agents that have a good safety profile and are in current use for the 
treatment of gout and cardiovascular disease. Oxypurinol (oxy) is the active metabolite of allopurinol 
which is a common drug used in gout, heart failure and the treatment of tumour lysis syndrome. 
Oxypurinol has already been shown to improve cardiac function in rats with CC (Springer et al, 2012). 
Furthermore, studies detailed in chapters 4 and 5 of this thesis found that XDH is increased at the 
mRNA and enzyme activity level in atrophic hearts of CC mice. Eicosapentanoic acid (EPA) is another 
potential therapeutic agent that has been shown to ameliorate weight loss in some CC patient 
populations (Barber et al, 1999, Wigmore et al, 2000).  
6.2.3 Eicosapentanoic acid as a therapeutic agent for cancer 
cachexia 
EPA is currently being investigated for the treatment of CC in phase III human trials. However, EPA 
has not as yet been investigated as a potential anti cardiac atrophy agent in CC. Omega 3 
polyunsaturated fats (PUFAs) are ubiquitously found in marine life particularly in fatty type fish such 
as salmon and shellfish (Psota et al, 2006). Over the last decade dietary recommendations have 
included the intake of fish with high omega-3s due to their protective role they have in preventing 
heart disease. Omega-3s are the precursors for eicosanoids that are predominantly anti-
inflammatory products of the arachadonic acid pathway (Singer et al, 2008). Omega-3s are also 
essential structural phospholipids and modulate cell signalling (Wall et al, 2010). The 
cardioprotective effects of the omega-3 long chain fatty acids such as EPA were first observed in 
Greenland Eskimos who showed lower rates of heart disease compared to other populations 
(Goodnight et al, 1981). Further studies examining the cardioprotective mechanisms of omega-3 fats 
have shown that these lipids are capable of reducing thrombosis formation via inhibiting the 
arachidonic acid thromboxane A2, inhibiting atherogenesis and reducing cholesterol accumulation 
(Simopuolos, 2008). Together these physiological effects have been shown to lower rates of 
ischaemic heart disease and cardiac related mortality (Narayan et al, 2006).  
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The interest in EPA as a potential therapeutic in CC clinical trials is predominantly due to its anti-
oxidant and anti-inflammatory effects. The previous studies of this thesis detailed in chapter 4 and 5 
found that oxidative stress is a feature of the cachectic heart. Furthermore, oxidative stress co-exists 
with a significant increase in the pro-inflammatory cytokine IL-6 and mRNA of the UPS in the pre-
cachectic heart. Supplementation with EPA and DHA n-3 polyunsaturated fats have been shown to 
significantly decrease both superoxide and hydrogen peroxide production in stimulated human 
neutrophils (Varming et al, 1995). A study by Fisher et al, 1990 showed that supplementation of EPA 
and DHA can also reduce the production of hydrogen peroxide in human monocytes. Apart from 
limiting the production of ROS a study by Li et al, 2006 showed the potential for EPA to alter 
important endogenous antioxidant enzymes. The authors investigated the mechanisms by which 
EPA is able to induce apoptosis of adrenal cancer cells and also found that EPA significantly increased 
antioxidant enzyme activities. The activities of SOD, catalase and glutathione peroxidase were all 
significantly increased in the experimental cells with EPA supplementation. Considering that our 
early experimentation in this thesis (chapters 4 and 5) showed that SOD levels in cachectic hearts 
were unable to respond to increases in cardiac oxidative stress, EPA may provide a therapeutic 
means to treat that perturbation. 
Typical inflammatory cells contain a high degree of n-6 PUFA in the form of arachidonic acid. 
Arachidonic acid is the major substrate of eicosanoid synthesis (Simopoulos et al, 1999). These 
eicosanoids are essential for modulating the inflammatory response to infection, injury and cancer. 
Examples of eicosanoids produced by the archidonic pathway are prostaglandin E2 (PGE2) and 
leukotriene B4 (LTB4). LTB4 is a proinflammatory molecule that increases vascular permeability and 
the production of TNF-alpha, IL-1 and IL-6, all of which are important in CC. Similarly, PGE2 is also 
pro-inflammatory and in turn increases the synthesis of IL-6. The potential benefits of increased long 
chain n-3 PUFAS such as EPA in CC are related to increasing their proportion in cell phospholipids at 
the expense of arachidonic acid. As arachidonic acid decreases PGE2 and LTB4 is also reduced 
(Calder, 2006). Furthermore, EPA alone can act as a substrate for the synthesis of COX 
(cyclooxygenase) and 5-LOX (5-lipoxygenase) giving them a different structure that are less 
inflammatory (Calder, 2006). Apart from dampening the potency of the archidonic pathway, EPA has 
been shown to inhibit chemotaxis of monocytes and ICAM expression on inflammatory and vascular 
cells (Calder, 2006). Importantly for the treatment of CC, n-3 PUFAs have been shown to inhibit the 
production of IL-1, TNF-alpha, IL-6 and IL-8 in monocytes and endothelial cells (Calder, 2006).  
Polyunsaturated fats are also known for their direct anti-cancer effects. A study be He, et al, 2013 
evaluated the rates of pancreatic cancer which is often associated with profound CC in 66,615 
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participants as part of a large cohort study. Of these adults aged 50-76 years, 161 of these patients 
developed pancreatic cancer over a 6-year follow up. Interestingly, there was an inverse relationship 
between the consumption of fish, high in polyunsaturated fats and pancreatic cancer. To investigate 
the mechanisms by which omega 3’s have proposed anti-cancer effects, cell culture studies have 
exposed human colon cancer cells to EPA. Tang et al, 2009 found that lycopene and EPA 
administered together were able to inhibit macrophage enhanced cancer cell migration. Similarly, 
Wu et al 2012 found that EPA and DHA was able to inhibit gastric cancer cell migration by inhibiting 
both macrophage induced migration and attenuation of the expression of matrix metalloproteinase 
10. Importantly, studies have found that EPA and DHA are also capable to directly inhibiting cancer 
cell growth. A study by Nikolaopoulou et al, 2013 found that both EPA and DHA inhibited pre-
malignant human keratinocytes in cell culture. Another recent study again found that EPA and DHA 
were able to induce apoptosis of pancreatic cancer cells in culture. Mechanistically, EPA and DHA 
were found to induce ROS and caspase-8-dependent cell death in the human pancreatic cancer cells. 
EPA was also shown concomitantly to induce autophagy of these cells in culture (Fukui et al, 2013).  
Tissue wastage in CC is associated with muscle inflammation, oxidative stress and metabolic 
derangement. Omega 3 PUFAs have a number of properties that are known to target these 
important aspects of CC aetiology. Thus, fish oil has the potential for treating CC at a number of 
levels. However, there is no current data regarding its potential to treat cardiac atrophy secondary 
to CC. Studies examining the ability of fish oil to ameliorate CC weight loss in animals does provide 
some evidence for its efficacy. Whitehouse et al, 2001 treated mice bearing MAC16 tumours and CC 
with EPA. Compared to control EPA was shown to attenuate total body weight loss. Similarly a study 
by Vaughan et al, 2012 found that treatment of CC nude mice with EPA was able to significantly 
delay total body weight loss over time compared to controls. The mechanism of weight loss 
attenuation in animal models appears to be in part due to a reduction in proteasome activity and 
expression of UPS subunits 20S and thep42. With regard to the effectiveness of EPA 
supplementation in a CC patient population the benefit is more difficult to discern. Fearon et al, 
2003 using a randomized double blind study that included 200 cancer patients administered fish oil 
as part of their nutritional supplementation and compared the assessed results to nutritional 
support without fish oil. However, this study was inconclusive, as enrichment of nutritional 
supplementation with fish oil did not show a clear advantage over standard nutrition. Only a post 
hoc dose response relationship suggested an affect if omega-3s were given in sufficient quantities 
(Giacosa & Rondanelli, 2008). However, subsequent studies have shown benefits of EPA treatment 
in CC patients (Ryan et al, 2009., Weed at al, 2011, Murphy et al 2011). Studies showing benefits 
appear to differ from studies not showing a positive outcome in that they offer patients a choice of 
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supplementation i.e. capsules or liquid, include CT image analysis and provided EPA as a treatment 
as early as possible (Murphy et al, 2011). Prolonged treatment with fish oil in patients with advanced 
cancer and in particular patients with upper gastrointestinal tract and pancreatic cancers shows 
benefits such as weight gain, increases in appetite, reduced post-surgical morbidity and increased 
quality of life (Colomer et al, 2007).  However, the effect of fish oil supplementation on cardiac 
atrophy secondary to CC in animal models or patients is yet to be evaluated.  
6.2.4 Oxypurinol as a therapeutic agent for cancer cachexia 
Data from chapter 4 and 5 of this thesis shows that the oxidative stress seen in cachectic hearts is at 
least in part due to the enzyme upregulation of XO (Hinch et al, 2013). Oxidative stress may be an 
important factor in the pathogenesis of cardiac atrophy secondary to CC as it has been shown to 
induce muscle atrophy (Marcondes & Tisdale, 2002). XO is the rate-limiting enzyme of purine 
metabolism that produces superoxide and hydrogen peroxide as a by-product. XO is been shown to 
be a significant contributor to ROS in the failing heart. Saavedra et al, 2002 showed that inhibition of 
XO by allopurinol decreased levels of oxidative stress and improved cardiac function. Traditionally it 
has been shown that increases in XO in the failing heart are associated with ventricular remodelling, 
fibrosis and hypertrophy (Bergamini, 2009). Hirsch et al, 2012 found that the XO inhibitor allopurinol 
is also able to increase ATP and creatinine kinase concentration by 11% in patients with non-
ischaemic cardiomyopathy. The implications of XO as an important enzyme in cardiac disease is 
exemplified by a recent article suggesting that levels of uric acid could be used as a marker of heart 
failure. Harzand et al, 2012 reviewed studies examining the contribution of XO in cardiac disease and 
the benefits of XO inhibition. The study determined that uric acid levels are linked to haemodynamic 
stability, functional status and survival in heart failure patients.  
Although only limited, evidence does exist for the upregulation of XO in the development of cancer 
cachexia. Springer et al, 2012 found that low dose allopurinol and its active metabolite oxypurinol 
are capable of limiting fat and skeletal muscle wasting in male Wistar rats inoculated with Yoshida 
AH 130 tumour cells. Recent studies have also been able to provide a link between XO and skeletal 
muscle atrophy. Derbre et al, 2012 showed that mechanical unloading of Wistar rats hind limbs 
increases the main redox sensitive signalling cascades in skeletal muscle, namely p38 MAPKinase and 
the expression of UPS E3 ligases MAFbx and atrogin-1. Apart from increases in the UPS there were 
increases in XO activity and endogenous antioxidant enzymes. When XO was inhibited with 
allopurinol, partial amelioration of soleus muscle atrophy by 20% was seen. This was after hind limb 
unloading which was associated with downstream inhibition of the p38 MAPKinase pathway. 
Springer et al, 2009 showed that cachectic Wistar rats bearing Yoshida AH-130 tumours have 
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impaired cardiac function. Echocardiography was used to show that ejection fraction and muscle 
fractional shortening was improved with XO inhibition. Specifically, the inhibition of XO in rats 
treated with allopurinol and oxypurinol reduced ROS and proteasome activity in the rat hearts. The 
Springer et al, 2009 study was the first to suggest an important role for XO in experimental cardiac 
atrophy secondary to cancer cachexia. The study however was limited in that it only measured 
cardiac function with the non-invasive echocardiography at one time point mid way through the 
protocol. Furthermore, no molecular examination was undertaken to evaluate the possible 
alterations of endogenous antioxidants or other metabolic pathways. Despite the evidence that XO 
is an important contributor to poor cardiac function and cardiac atrophy its evaluation, as a 
contributor to the loss of heart mass in cancer cachexia is incomplete. 
The current study was designed to test the hypothesis that EPA and oxy will be able to ameliorate 
cardiac atrophy secondary to CC. The study protocol is using the same animal model of CC as the 
previous studies in this thesis (chapter 4 and 5). Nude mice inoculated with MAC16 cells were 
randomised into four groups. A no treatment, EPA, oxy and combination of EPA/oxy group. The 
study administered the treatments from the time of MAC16 cell inoculation to mimic the effect of 
early intervention and tracked animals daily over a 29 day period. At day 29 the animals were 
sacrificed and the heart harvested for further molecular analysis. The study aimed to provide data 
on the efficacy of EPA and oxy as treatments of CC and understand which molecular changes bring 
about potential amelioration of cardiac atrophy secondary to CC. 
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6.3 Results  
Animal food and water intake was assessed and recorded daily. Animal total body weight 
was recorded daily and is shown as a percentage change from their initial reading in figure 
6.1 below. The no treatment animals displayed all of the hallmarks of cancer cachexia and a 
significant reduction in weight by day 17 (p= 0.002). The oxypurinol treatment group had an 
earlier time to significant weight reduction, which was on day 14 (p=0.003). Whilst the 
combination treatment group of EPA and oxypurinol delayed the time to significant weight 
reduction to 21 days (p=0.02).  The group having EPA treatment alone however, had the 
longest time to weight reduction being 26 days (p=0.04). From the point at which a group 
reached a significant weight reduction compared to their respective baseline reading weight 
loss continued and was significant until day 29. 
 
Figure 6.1 Mean daily body weight change as a percentage of baseline for each treatment 
group. Data is expressed as percentage mean ± SEM. Arrows depict point at which body 
weight became significantly decreased compared to baseline (p = <0.05). n = 10 animals per 
group. 
On average the no treatment group lost 80.31 mg/day of weight over the 29 day 
experimental period (Figure 6.2). While the oxy group had 60.37 mg/day of weight loss this 
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was not significant compared to no treatment. The EPA/Oxy group however did have a 
significant 2.16 times lower daily weight loss compared to no treatment (p=0.005). The EPA 
group had the lowest average daily weight loss of any group and was significantly 2.42 times 
lower compared to no treatment (p=<0.0001).   
 
Figure 6.2 Average weight loss per day between groups. Data is expressed as mean ± SEM. 
Statistically significant differences are represented by * where p = <0.05 compared to no 
treatment control.     
 
The presence of a palpable tumour on the flank of the mice was assessed daily. Daily 
measures of palpable tumour size were recorded in mm3 (figure 6.3). The appearance of the 
first palpable tumour in animals varied between groups. However, due to the difficulty in 
identifying early signs of tumour growth results may not be consistent, as evidenced by the 
fluctuating tumour size data in the EPA group. The data is thus analysed statistically by the 
time to reach 50% of the n value with palpable tumours. There was a significant delay to the 
appearance of palpable tumours compared to no treatment in each of the treatment 
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groups, specifically EPA, Oxy and EPA/Oxy (p=<0.05). Animals in the no treatment group had 
palpable tumours at day 9 compared to 16 days in the EPA group (p=<0.05).  The oxypurinol 
group reached palpable tumours by day 12 that was significantly delayed by 3 days 
compared to no treatment (p=<0.05). The EPA/Oxy group had palpable tumours by day 11 
that was significantly delayed by 2 days compared to the no treatment group (p=<0.05).  In 
addition, the appearance of tumours was also significantly delayed in the EPA group 
compared to the Oxy and EPA/Oxy treatment groups by 4 and 5 days respectively (p=<0.05). 
 
Figure 6.3 Number of animals with palpable tumours assessed daily. Data is presented as 
absolute numbers. Statistically significant differences are represented by * where p = <0.05 
compared to no treatment and # comparing EPA to the other treatment groups Oxy and 
EPA/Oxy where p = <0.05. 
Tumours size was recorded daily once a palpable tumour was detected. Average tumour 
size for the control and treatment groups are represented in mm3 in Figure 6.4 below. The 
average increase in tumour size over time was not significantly different between the 
experimental groups. Although some groups appear to have reduced tumour size after day 
27, this reduction can be explained by the elimination of animals for ethical reasons such as 
tumour size over 1000 mm3 or deteriorating health. The animals that remained invariably 
had smaller MAC16 tumours and thus better health.  
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Figure 6.4 Comparison of tumour size in mm3 between groups. Data is expressed as means ± 
SEM. 
Figure 6.5 below represents wet heart weight and base to apex measurement at the time of 
tissue collection. With regard to heart wet weight the EPA group had significantly greater 
mass compared to no treatment (p=0.0002). The mice with palpable MAC16 tumours at 16 
days and EPA treatment for 29 days conserved 9 mg of heart weight compared to no 
treatment. There were no significant differences in heart wet weight in the Oxy and 
EPA/Oxy groups compared to no treatment. Despite the EPA group showing the only 
significant maintenance in heart wet weight there was a significant preservation of heart 
base to apex length in all three treatment groups compared to no treatment (Figure 6.5).  
Specifically, the base to apex length of the heart was significantly higher in each of the 
treatment groups, EPA (7.5mm; p=0.007), Oxy (7.6mm; p=<0.0001) and EPA/Oxy (7.3 mm; 
p=0.01), compared to the control  (6.74 mm).  
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Figure 6.5 Heart wet weight and base to apex measure. Data is presented as mean ± SEM. 
Statistically significant differences are represented by * where p = <0.05 compared to no 
treatment 
The levels of 8-OH-2dG were measured in cardiac tissue homogenates harvested from each 
group at the end of the 29-day supplementation period (Figure 6.6). There was a significant 
reduction in levels of the DNA oxidation by-product 8-OH-2dG in each of the three 
treatment groups compared to controls. Control 8-OH-2dG levels were 59.2 pg/ml 
compared  to a significant reduction of 13.6% for EPA (p=<0.01, 8.9% for Oxy (p=0.01) and 
18.1% in the EPA/Oxy group (p=<0.01). There was also a significant 10% reduction of 8-OH-
2dG in the EPA/Oxy group compared to Oxypurinol alone.  
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Figure 6.6 8-OH-2dG levels in heart homogenates from group. Data is expressed in pg/ml ± 
SEM. Statistically significant differences are represented by * compared to no treatment and 
# represents significance between EPA/Oxy compared to Oxy where p=<0.05. 
To further evaluate the changes in levels of the DNA oxidation as seen in increases 8-OH-
2dG and potential influence of the trial treatments on endogenous antioxidants, SOD 
activity was assessed (Figure 6.7). Total SOD activity increased by 45% increase in the oxy 
and EPA/oxy groupscompared to no treatment (p=<0.05). While Oxy alone had the largest 
increase in total SOD activity compared to no treatment of 63% (p=0.01) (Figure 6.7). The 
EPA group did not change compared to control (Figure 6.7).  
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Figure 6.7 SOD enzyme activity levels from heart homogenates in each treatment group. 
Data is expressed as activity in U/ml ± SEM.  Statistically significant differences are 
represented by * where p = <0.05 compared to no treatment.  
XDH is the rate limiting enzyme in purine metabolism and a significant contributor to 
oxidative stress in cardiac tissue. This thesis has found that XDH is increased in CC cardiac 
tissue (chapter 4 & 5). Thus, this study evaluated XDH activity levels within all of our 
treatment groups. 
This study found a significant increase in XDH activity in all treatment groups compared to 
control (figure 6.8). In comparison to control XDH activity increased 2.6 fold in the EPA 
group (p=0.001), 2.7 fold in the Oxy group (p=<0.0001) and 2.1 fold in the EPA/Oxy group 
(p=0.0005) (figure 6.8). 
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Figure 6.8 XDH enzyme activity levels from heart homogenates in each treatment group. 
Data is expressed as activity in mu/ml ± SEM.  Statistically significant differences are 
represented by * where p = <0.05 compared to no treatment. 
Gene analysis was also completed on harvested cardiac tissue from all four groups to 
ascertain any changes at the mRNA level. Interestingly, despite increases in XDH activity 
mRNA levels of the enzyme were significantly decreased in the treatment groups compared 
to control (Figure 6.9). XDH mRNA expression levels were 43 fold lower in EPA group 
(p=<0.0001), 23 fold lower in the Oxy group (p=0.002) and 20 fold lower in the EPA/Oxy 
group (p=<0.0001).  
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Figure 6.9 Bar graph comparing mRNA expression of XDH between groups. Data is expressed 
as arbitrary units (AU) ± SEM. Statistically significant differences are represented by * where 
p = <0.05 compared to no treatment. 
To understand if the increase in SOD enzyme activity in the Oxy and EPA/Oxy groups (Figure 
6.7) is related to changes in gene expression, mRNA levels of CuZn SOD (cytosolic SOD) and 
exSOD (extracellular SOD) were also analysed. There was a significant 2.9 fold decrease in 
CuZn SOD mRNA in the Oxy group compared to control (p=0.01) (Figure 6.10).  
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Figure 6.10 Comparisonof CuZnSOD gene expression between groups. Data is expressed as 
arbitrary units (AU) ± SEM. Statistically significant differences are represented by * where p 
= <0.05 compared to no treatment. 
There was a significant 1.9 fold reduction in the mRNA expression of exSOD in the EPA 
group and a 4.2 fold reduction in the Oxy group compared to controls (p=<0.05). However, 
there were no significant differences between EPA/Oxy and controls (figure 6.11). 
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Figure 6.11 Comparison of exSOD gene expression between groups. Data is expressed as 
arbitrary units (AU) ± SEM. Statistically significant differences are represented by * where p 
= <0.05 compared to no treatment. 
In chapter 5 of this thesis analysis of serum IL-6 levels revealed increases in the cytokine in 
precachectic animals (Figure 5.13). Whilst genetic analysis revealed that IL-6 mRNA was 
increased in established CC hearts (Figure 5.20). The current treatment study found that 
mRNA expression of IL-6 was significantly decreased in the EPA and EPA/oxy groups 
compared to no treatment (Figure 6.12). There was an 84 fold decrease in the mRNA 
expression of IL-6 in the EPA group (p=0.005) and a 63 fold decrease in the EPA/Oxy group 
(p=0.005) compared to control.   
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Figure 6.12 Comparisonof IL-6 mRNA expression between groups. Data is expressed as 
arbitrary units (AU) ± SEM. Statistically significant differences are represented by * where p 
= <0.05 compared to no treatment. 
The catalytic core unit of NADPH oxidase, NOX2 gene expression was also analysed in 
cachectic cardiac tissue. There was an 11.1 fold decrease in the mRNA levels of NOX2 in the 
EPA group (p=<0.0001), a 4.2 fold decrease in the Oxy group (p=<0.0001) and a 1.8 fold 
decrease in EPA/Oxy (p=<0.0001) compared to the controls (Figure 6.13).  
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Figure 6.13 Comparison of NOX2 mRNA expression between groups. Data is expressed as 
arbitrary units (AU) ± SEM. Statistically significant differences are represented by * where p 
= <0.05 compared to no treatment. 
Results from the chapter 5 of this thesis demonstrated elevated levels of UPS ligase MAFbx 
mRNA expression in cachectic cardiac muscle compared to cancer controls. Whilst this 
treatment study found a significant 244 fold decrease in the expression of MAFbx in the EPA 
group (p=0.0007), a 5.5 fold decrease in the Oxy group (p=0.0005) and a 12 fold decrease in 
the EPA/Oxy group (p=0.0003, Figure 6.14).  
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Figure 6.14 Comparison of Mafbx mRNA expression between groups. Data is expressed as 
arbitrary units (AU) ± SEM. Statistically significant differences are represented by * where p 
= <0.05 compared to no treatment. 
Similarly, there were significant decreases in the ubiquitin ligase MURF-1 in the treatment 
groups compared to no treatment. There was a significant 131 fold decrease in MURF-1 
mRNA expression in the EPA group (p=0.0001), a 10 fold decrease in the Oxy group 
(p=0.0002) and a 66 fold decrease in the EPA/Oxy group (p=0.0001, Figure 6.15).   
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Figure 6.15 Comparison of MURF-1 mRNA expression between groups. Data is expressed as 
arbitrary units (AU) ± SEM. Statistically significant differences are represented by * where p 
= <0.05 compared to no treatment. 
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6.4 Discussion 
This study assessed the ability of EPA and the XO inhibitor oxypurinol to alleviate CC related 
weight loss, cardiac atrophy and examine their associated molecular interactions. Previous 
experimentation detailed in this thesis examined the molecular characteristics of the 
atrophied heart secondary to CC. It was evident from these earlier studies that a state of 
oxidative stress exists in the cachectic heart. The pro-oxidant enzyme XDH was elevated at 
both the gene and enzyme activity level (Hinch et al, 2013). Accompanying this, the 
endogenous antioxidant SOD did not compensate for the increase in oxidative stress in pre 
CC hearts. Furthermore, serum levels of IL-6 were increased in pre-cachectic mice and 
similar to skeletal muscle samples, mRNA of the UPS was elevated. These results provided 
valuable data for the selection of the potential therapeutics EPA and oxypurinol. The ability 
of EPA to potentiate the activity of SOD is particularly important as impaired SOD activity in 
the atrophied myocardium secondary to CC is a novel finding (Li et al, 2006). Furthermore, 
EPA has substantial evidence as an anti-oxidant and anti-inflammatory compound (Varming 
et al, 1995, Fisher et al, 1995, Calder, 2006). Oxypurinol on the other hand is a selective 
inhibitor of XO and has been shown to lower levels of ROS and improve cardiac function in 
mice with structural myopathy (Maloyan et al, 2009).  
When considering the efficacy of a potential therapeutics in treating CC total body weight is 
an important clinical sign (Wigmore et al, 1997). According to Fearon et al, 2011 the clinical 
classification of cachexia is weight loss greater than 5% which is related to a disease such as 
cancer. This current study used time to reach a significant degree of total body weight loss 
from baseline as a means to compare treatment groups. Considering calorie intake was not 
significantly different between groups, using time to significant weight loss allowed us to 
detect CC weight loss as early as possible. With no treatment this current study found that 
nude mice with MAC16 tumours would lose a significant amount weight by day 17. The no 
treatment group lost on average 80.31 mg/day of weight. The treatments used in the study 
were all hypothesised to delay the time for the animals to reach a significant degree of 
weight loss and reduce the amount of weight lost per day.  
Currently oxypurinol is used clinically for the indication of gout, tumour lysis syndrome and 
more recently to improve cardiac dysfunction in the failing heart (Hare et al, 2008). Cardiac 
dysfunction in CC hearts is also a feature as found in a mouse model of CC (Xu et al, 2011). 
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Furthermore, a study by Springer et al, 2013 should that oxypurinol given to CC rats is 
capable of reducing cardiac muscle loss and improve myocardial dysfunction post 
treatment. Specifically, Springer et al, 2013 found that CC rats treated with the same dose 
as used in the current study of 4mg/day of oxy was able to significantly half the animals rate 
of weight loss per day. Whilst there is precedent for the use of oxy to treat cardiac 
dysfunction and weight loss in CC this study found that it did not delay the time taken to 
reach a significant degree of total body weight loss. This was unexpected as our hypothesis 
was that oxypurinol would be beneficial in ameliorating weight loss in CC. Indeed, 
oxypurinol accelerated the time to significant weight loss in this model of CC by 3 days 
compared to no treatment. The implication is that although mRNA and enzyme activity of 
XO was found to be increased in our previous studies (chapters 4 & 5) its inhibition may lead 
to an acceleration of weight loss in cancer cachectic mice. The acceleration of animal weight 
loss was most apparent from days 10 to 20. From day 20 the rate of weight loss plateaued 
and followed a similar trajectory to the no treatment group. The results of this current study 
vary from that of Springer et al, 2012 using a rat model of CC. The discrepancy between this 
study and that of Springer and colleges may be partly explained by an increase in food 
intake in the animals treated with oxy compared to controls of the Springer et al study. 
Furthermore, differences in the type of CC model used in this study being murine MAC16 
compared to a rat hepatocellular carcinoma model may also account for the differences 
seen. The non-beneficial effect of oxy on total body weight was further exemplified by 
comparing the anti-cachectic effects of oxy to the other treatment groups. EPA alone was 
able to significantly delay the time to significant weight loss to day 26 with a reduction in 
the average weight lost per day compared to the oxy group. However, when EPA and oxy is 
given in combination the time to significant weight loss was 5 days earlier compared to EPA 
alone. This suggests that when oxy when given in combination is blunting the anti-cachectic 
effect of EPA. Contrary to our hypothesis the enzyme XO may indeed by protective for 
weight loss secondary to CC in this mouse model. Similarly experimentation of the same 
mice used in this thesis by Vaughn et al, 2012 found that whilst certain skeletal muscles 
were preserved by treatment with oxy overall weight loss was not.  
Unlike the lack of anti-cachectic effect oxy had on the MAC16 bearing mice; EPA alone was 
able to significantly delay the time to significant weight loss compared to no treatment. 
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Previous studies have shown that CC patients supplemented with EPA have improved 
quality of life (Burns et al, 2004, Moses et al, 2004). Furthermore, fish oil enriched 
nutritional supplementation over a 3 week period has been shown to reduce the acute 
phase response in pancreatic cancer patients (Barber et al, 1999). With regard to omega 3 
supplementation on total body weight of cachectic patients studies have shown both 
benefits and no effect with supplementation (Taylor et al, 2010, Fearon et al, 2006, Read et 
al, 2007, Jatoi et al, 2004). As stated before studies showing benefits of omega 3 
supplementation differ from that of non beneficial studies by supplementing patients early 
(Murphy et al, 2011, Murphy et al, 2011). There also appears to be a greater efficacy for 
omega 3 supplementation ameliorating weight loss in patients with gastrointestinal tract 
and pancreatic cancers (Murphy et al, 2011) This current study supplemented animals from 
the time of tumour cell inoculation to examine the effect of the potential therapies on 
tumour growth whilst replicating the early supplementation of studies showing beneficial 
effects of EPA administration. In our nude mouse model of CC EPA supplementation alone 
was the most effective of all the therapeutic groups in lowering the average daily total body 
weight loss compared to no treatment. EPA supplementation in our model delayed time to 
significant weight loss by 9 days and showed a 60% reduction in mean weight loss per day 
compared to control. Thus the current study shows a significant effect on ameliorating total 
body weight loss secondary to CC with EPA supplementation. This effect is greater than that 
found in human trials. Part of this difference is likely to be related to obvious differences in 
rodent versus human physiology. The efficacy of EPA treatment in this study may also be 
attributed to supplementation of animals before the onset of cancer itself. This may suggest 
a role for EPA supplementation in groups at high risk of cancer occurrence. Furthermore, 
patients who have undergone treatment for cancer such as a resection, radio or 
chemotherapy may benefit with omega 3 supplementation to ameliorate some of the 
cachectic effects of reoccurrence.  
All groups were able to significantly delay the time until a palpable tumour was detectable 
in the flank of our experimental animals. The oxy and combined EPA and oxy groups delayed 
time to palpable tumour by 3 and 4 days respectively compared to control. Interestingly EPA 
alone fared better than the combination group and significantly delayed time to detection 
of a palpable tumour by 7 days. Despite no significant difference in palpable tumour size, 
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the growth delay of MAC16 cells may partly explain why EPA treatment was successful in 
delaying the time to significant animal weight loss. Whitehouse et al, 2001 found in a similar 
mouse model of cancer cachexia that EPA was able to inhibit MAC16 tumour growth. 
Further investigation showed that tumour growth inhibition was associated with lower 
expression levels of UPS proteasome subunits. Furthermore, the tumour suppressive effect 
of EPA may be a factor in the treatment of CC patients. As shown in a systematic CC 
treatment review, fish oil supplementation of cancer patients is most effective if 
administered early to patients (Murphy et al, 2011). This may be the case as early treatment 
with EPA is still able to influence tumour size and prevent or delay tumour growth. Indeed, 
EPA has a number of known anti-tumour effects which have been shown to slow cancer cell 
growth and metastasis (Tang et al, 2009, Wu et al, 2012, Fukui et al, 2013) Furthermore, the 
large epidemiological cohort study by He et al, 2012 showed that adults who consume 
higher amounts of fish laden with polyunsaturated fats are protected against pancreatic 
cancer. Furthermore, the increased efficacy in tumour growth delay of EPA over oxy and the 
combined EPA oxy groups may be explained by a study which showed that another XO 
inhibitor allopurinol enhanced experimental liver tumours in rats compared to controls 
(Carlsson et al, 1989). Although this study did not show enhancement of tumour growth 
with oxy, the EPA/oxy combined group did have a blunted ability to delay tumour growth 
compared to EPA alone.  
A previous study showed that oxypurinol treatment has a role in maintaining some skeletal 
muscle mass such as tibialis anterior and gastrocnemius whilst EPA has a greater affect in 
maintaining skeletal muscle mass (Vaughn et al, 2012). The primary interest of this thesis is 
to establish the potential therapeutic effect of these drugs on the atrophying cachectic 
heart. In terms of the gross effects of treatment only EPA was able to significantly reduce 
the degree of cardiac atrophy secondary to CC. The EPA treatment was able to preserve 9 
mg of heart weight compared to no treatment 29 days after inoculation with MAC16 cells. 
There was no significant changes in heart wet weight between the oxy and EPA/oxy group 
versus control suggesting that oxypurinol was not only unable to treat cardiac atrophy in CC 
mice but it also again blunted the anti-cachexia effect of EPA. However, the results do show 
that all treatment groups were able to preserve a degree of cardiac base to apex length. This 
suggests that EPA and oxy are able to alter the morphological changes in the myocardium 
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secondary to CC. This is the first time that a study has shown changes in gross organ 
morphology with regard to CC. The reason for significant change in cardiac morphology with 
the oxy and combined EPA oxy group is currently unknown. This may be explained in the 
way cardiac tissue undergoes atrophy which may depend on the axis being assessed 
morphologically. In terms of treatment efficacy it appears that EPA and not oxy is capable of 
reducing the impact of CC on the heart. Although, oxypurinol has been found by Springer et 
al, 2009 to improve cardiac function in CC rats, this study finds no evidence that it is able to 
preserve cardiac mass. EPA however, does appear promising at least in this model of CC in 
preventing cardiac atrophy associated with CC. Duda et al, 2007 investigated omega-3 
supplementation from the perspective of cardiac hypertrophy in a rat model left ventricular 
pressure overload. Indeed, omega-3 supplementation was able to partially ameliorate 
ventricular remodelling by preventing increases in ventricular mass. Thus it appears from 
the results of this current study and that of Duda and colleges that omega-3 
supplementation has a stabilising effect on cardiac mass regardless of the instigating factor. 
This current study is novel in that EPA is able to ameliorate cardiac tissue atrophy with 
supplementation. Further studies are needed in understanding the functional benefit of 
such therapy particularly in a patient population.   
From the above results the gross measurements suggest that EPA and to a lesser extent EPA 
combined with oxy is able to ameliorate cancer induced weight loss by inhibiting tumour 
growth and preserving lean organ mass such as cardiac tissue. This study is the first to 
analyse the molecular characteristics of cardiac tissue preservation with EPA and in 
combination with oxy. Firstly, it has been established that oxidative stress is a feature in 
cancer cachectic patients the degree of which is correlated to survival time (Murr et al, 
1999). Our previous studies detailed in this thesis have also established that oxidative stress 
measured via the biomarker 8-OH-2dG is a feature of disease from pre to late cachexia 
(chapter 5). As both EPA and oxy have been shown previously to reduce levels of ROS in 
both patients with CC and cardiovascular disease the current study is once again used 8-OH-
2dG as a marker of oxidative stress (Saavedra et al, 2002, Barbosa et al, 2003, Mantovani et 
al, 2004). This study found that EPA, oxy and in combination were able to significantly 
reduce 8-OH-2dG levels in cachectic hearts compared to no treatment. Springer et al, 2012 
also found that oxy alone given at a rate of 4 mg/Kg/day to rats bearing Yoshida AH130 
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tumours also had reduced ROS. Similarly, Wang et al, 2004 found that ApoE mice fed a diet 
rich in fish oil had decreased levels of ROS and had a better antioxidant status. In this study 
the greatest reduction in 8-OH-2dG was in the EPA/Oxy group which had an additive effect 
in lowering the oxidative stress marker 8-OH-2dG by 18.1%. Despite the combination 
treatment group having the greatest oxidative stress reducing effect in cardiac tissue EPA 
performed best on delaying significant total body weight loss, inhibiting tumour growth and 
was the only treatment able to preserve cardiac mass. This suggests that EPA has other 
beneficial molecular effects over that of oxy that extends beyond its anti-oxidant ability.  
The results in chapter 5 of this thesis showed that SOD enzyme activity is significantly 
reduced in cachectic hearts. In this treatment study we examined the possibility that EPA or 
oxy would be able to ameliorate the reduction of SOD and maintain the antioxidant status in 
the cachectic heart. Previous research has found that fish oil supplementation and purified 
EPA fed to rodents is able to improve antioxidant status (Wang et al, 2004). A study by Kong 
and Liu, 2006 used rat pheochromocytoma cells and induced lipid peroxidation which was 
ameliorated by increases SOD enzyme activity due to EPA supplementation. However, in this 
current study EPA did not significantly change levels of SOD in the cachectic heart. However, 
in the oxy alone and in the combination EPA/oxy group levels of SOD activity increased 
significantly by 63 and 45% respectively compared to no treatment. A study my Landmasser 
et al, 2002 also found a link between xanthine oxidase and SOD. In patients with heart 
failure increased levels of XO were associated with reduced SOD and endothelial 
dysfunction. The opposite in this study suggests that inhibition of XO by oxy is able to 
increase levels of SOD. However, as seen in the results although increased levels of SOD in 
the oxy group led to reduced oxidative stress it did not translate to preservation of lean 
cardiac mass or total body weight. A study by Kliment et al, 2009 found that SOD is an 
important element in preserving cardiac function in times of stress. As stated previously 
animal models of CC show cardiac dysfunction which is partly ameliorated by oxy (Springer 
et al, 2009). Thus, this preservation of cardiac function shown in previous studies may occur 
via increases in SOD activity levels with oxy treatment. Furthermore, it was evident that all 
treatment groups were able to reduce levels of 8-OH-2dG. An increase in total SOD enzyme 
activity with direct XO inhibition in the groups with oxy treatment can perhaps explain why 
the combination of EPA and oxy had the largest effect on significantly reducing 8-OH-2dG 
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levels in cachectic hearts. Conversely, as EPA did not significantly increase levels of SOD the 
omega 3 treatment must alleviate oxidative stress through an alternate mechanism in 
cachectic hearts. As per a study by Wang et al 2004, fish oil supplementation may also work 
to alleviate oxidative stress via increases in the endogenous antioxidant catalase. 
Unfortunately, due to limitations of time and tissue volume this study was unable to 
measure catalase levels. Furthermore, the antioxidant effect of EPA may also relate to a 
reduction in super oxide anion production as seen in a study by Supari et al, 1995 in male 
cynomolgus monkeys fed a atherogenic diet. Future studies should also include levels of 
other endogenous enzymes and total antioxidant status in investigating EPA and oxy for the 
treatment of CC.  
It has been established from our previous studies in this thesis that gene transcripts and 
activity levels of XDH are increased in the atrophying cachectic heart. Our previous study 
detailed in chapter 5 showed that XDH activity is significantly increased in the pre-cachexia 
stage and that this may explain why there is oxidative stress at the same time. Beyond our 
current study Derbre et al, found that skeletal muscle atrophy due to hindlimb unloading is 
partially prevented by XO inhibition. Whilst other studies have suggested that XO is a 
significant contributor to total weight loss and cardiac atrophy in animal models of CC 
(Springer et al, 2013, Springer et al 2012). Levels of XDH enzyme activity was measured to 
ascertain any influence of EPA and oxy on the enzyme in CC. The results were unexpected 
whereby all three treatment groups showed increased levels of XDH compared to no 
treatment. It is difficult to interpret these results, as activity levels were the opposite of 
expected given that the XO inhibitor oxy did not show an ability to reduce XO activity. The 
oxy drug was administered at a dose previously used and shown to be effective in rodents. 
The unexpected results may be explained by the fact that adequate levels of the oxy 
treatment are perhaps not bioavailable in the heart homogenates tested. The increase in 
enzyme activity may be a consequence of both the withdrawal of treatment bioavailability 
and increased enzyme efficiency after 29 days of inhibition. The opposite was the case with 
regard to XDH mRNA levels in cardiac tissue, were all three treatments EPA, oxy and 
EPA/oxy were able to significantly decrease levels of XDH mRNA compared to no treatment.  
Like that of XDH, gene data did not mirror SOD enzyme activity where it was found that the 
oxy group significantly reduced CuZn SOD (cytosolic) mRNA level compared to no treatment. 
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Likewise extracellular SOD levels were significantly decreased in the oxy and EPA group. This 
suggests that an increase in total SOD enzyme activity does not need to mirror mRNA levels 
and that post translational modification of the enzyme is the likely cause of its 
augmentation with oxy treatment in CC.  
Argiles et al, 2006 stated that IL-6 amongst cytokines such as TNF-alpha and IFN-gamma are 
important mediators of CC. Indeed patients with CC have elevated levels of cytokines such 
as IL-6 which is positively correlated with disease progression (Fearon et al, 1990). In this 
study the gene levels of IL-6 was measured in cachectic hearts across all groups and 
provided key information in the differences between EPA and oxy which may have led to 
the fish oil extract being a better anti-cachexia agent. The oxy treatment alone did not bring 
about any significant change in cardiac IL-6 gene expression however EPA alone and in 
combination with oxy was able to bring about a significant decrease. IL-6 has been shown 
previously to potentiate CC when administered alone and in combination with other 
cytokines (Moldawer et al, 1992). In chapter 5 of this thesis we found that IL-6 mRNA is 
increased in the heart tissue of CC mice compared to controls and that serum levels of IL-6 is 
elevated in the pre cachexia stage. Thus, IL-6 may be a key initiating factor driving the 
disease. Importantly a study by Kim et al, 2012 investigated cytokine levels in lung and 
colorectal cancer patients before the induction of therapy. Kim and colleges found that in 
cancer patients who had high baseline levels of IL-6 were more likely to experience the 
greatest degree of weight loss. Moreover, high baseline IL-6 also signified that levels were of 
the cytokine were maintained and increased over time. Kim and colleges suggested that IL-6 
is likely to be responsible for inducing and maintaining cancer cachexia related weight loss. 
In this study the significant decrease in cardiac tissue mRNA of IL-6 in EPA and EPA/oxy 
groups but not oxy alone may explain why the EPA treatment has better anti-cachectic 
effects in terms of total body weight and cardiac mass preservation. It is yet known whether 
EPA supplementation can decrease peripheral levels of IL-6 and it would worthwhile 
investigated further. Due to a lack of tissue this study was unable to assess protein levels of 
IL-6 in the cardiac tissue. A western blot analysis of local and peripheral cytokines with 
treatment would be a valuable future experimental direction.  
The catalytic core unit of NAPH oxidase, NOX2 was significantly decreased at a gene levels in 
EPA, oxy and EPA/oxy groups compared to no treatment. Our first study detailed in chapter 
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4 found that NOX2 mRNA is significantly decreased in cardiac tissue of MAC16 mice 
compared to MAC13 control. However, further protein analysis found that NOX2 protein 
levels did not significantly vary between groups (Hinch et al, 2013). This current study has 
found that treatment with both EPA and oxy are able to reduce mRNA levels of NOX2. The 
largest change in NOX2 expression was in the EPA group with a 4.2 fold decrease in gene 
expression compared to no treatment. Whether a reduction of NOX2 levels below that 
found in in cachectic hearts contributes to preservation of lean tissue is still unknown. 
Sullivan-Gunn et al, 2011 found that superoxide levels are elevated in cancer cachexia 
skeletal muscle of mice. However, gene expression analysis revealed that mRNA of NOX 2, 
p40phox and p67phox were downregulated. Sullivan-Gunn and colleges also showed a 
decrease in the endogenous antioxidant enzymes in skeletal muscle of CC mice. In the 
current study it is unknown whether the downregulation of NOX2 mRNA overall contributed 
to the amelioration of cardiac atrophy with EPA treatment as oxy also decreased NOX2 gene 
levels but had no effect on rescuing cardiac mass. Further investigation of NOX2 and its 
subunits in terms of protein quantification and activity levels with EPA treatment would be a 
useful future direction.  
The final analysis of this study was the examining the gene expression of the important UPS 
E3 ligases Mafbx and MURF-1. The importance of these E3 ligases has been well established 
in the literature as critical for the activation of proteolysis (Muscaritoli et al, 2007, Bodine et 
al, 2001). Both Mafbx and MURF-1 are expressed in cardiomyocytes and are associated with 
the degradation of cardiac proteins (Adams et al, 2007). As previously mentioned both 
MAFbx and MURF-1 mRNA have been shown to be elevated in atrophic skeletal muscle and 
cardiac tissue of CC animals (Vaughan et al, 2012, Hinch et al, 2013). Studies have previously 
shown that UPS E3 ligases are increased and that ubiquitinylation in the myocardium is 
increased in CC animal models (Tian et al, 2011, Hinch et al, 2013). Conversely, a study by 
Cosper & Leinwand, 2010 found increases in markers of autophagy but not the UPS. 
However, given the mounting evidence from previous studies mentioned and our work 
detailed in chapters 4 and 5 of this thesis it is unlikely that autophagy alone is capable of 
bringing about such rapid loss of cardiac mass in CC models. Considering that autophagy 
accounts for less than 10% of protein breakdown in cardiac muscle. Whilst the UPS accounts 
for 80-90% of all protein catabolism (Herrmann et al, 2005). Willis et al, 2013 note that the 
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UPS and autophagy pathways do interact at varying levels and it is likely that both pathways 
may be activated in the CC heart.  
We have shown in our studies described in chapter 5 of this thesis that both of the UPS E3 
ligases are increased at a gene level in CC hearts compared to cancer controls. In this 
current study all treatments being EPA, oxy and EPA/oxy significant decreased gene 
expression levels in cardiac Mafbx and MURF-1. The results were unexpected as only the 
EPA group was able to significantly preserve cardiac tissue compared to no treatment. 
However, the ability for EPA to bring about the preservation of cardiac mass over the oxy 
group may be related to the degree of gene changes between groups similar to that seen in 
mRNA of IL-6. Where EPA brought about a very large reduction in Mafbx levels by 244 fold, 
the oxy and EPA/oxy group reductions were more modest being 5.5 and 12 fold decreases 
respectively. Likewise decreases in MURF-1 gene expression was more profound in the EPA 
group compared to EPA/oxy and oxy alone. Due to limitations in the amount of cardiac 
tissue available for analysis this study was unable to carry out experimentation to further 
observe any changes in UPS protein or activity levels. However, this would be an important 
future direction in particular to future elucidate the anti-cachectic efficacy of EPA over that 
of oxy treatment.  
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7.0 Conclusions 
In developing the principles of experimentation in this thesis we first evaluated the literature 
regarding cancer cachectic skeletal muscle atrophy to find common themes of molecular events that 
may also occur in cardiac muscle. These common themes were used to produce hypotheses and 
aims with regard to experimentation surrounding cardiac atrophy secondary to CC. With regard to 
cachectic cardiac muscle no experimental molecular data existed at the time of commencing this 
thesis. Thus, our first study broadly aimed to assess whether molecular events which appear to be 
central to skeletal muscle breakdown are also evident in cardiac atrophy in an experimental model 
of CC. Specifically the first study of this thesis aimed at assessing whether a state of oxidative stress 
is accompanied by increased gene transcripts of the UPS in the cachectic heart. The nude mouse 
model of CC used in this thesis produced significant reduction in gross body mass and a reduction in 
heart wet weight by 20%. The experimental data in chapter 4 of this thesis demonstrated that 
cardiac atrophy of cachectic mice is related to a state of oxidative DNA damage in the myocardium. 
Levels of XDH mRNA were elevated in CC hearts suggesting that XO may have an important role to 
play in producing oxidative stress and potentially driving the disease process. Most evidently it 
appeared that the combination of increased XDH expression and decreased SOD enzyme activity are 
key contributors to oxidative stress and cardiac tissue damage in cancer induced cardiac atrophy. 
Oxidative stress in the myocardium as with skeletal muscle may also induce increased expression of 
the E3 ligases MURF-1 and MAFbx as seen in increased mRNA levels of both in our first study (Hinch 
et al, 2013). These results suggest that indeed similar mechanisms of tissue breakdown are involved 
in cardiac and skeletal muscle tissue. From our early experimentation we surmised further research 
is needed in a time dependent manner to ascertain whether these changes are seen in pre-cachexia 
and how these molecular events evolve over time.  
The second study of this thesis aimed to build upon the results of the first and create a more 
complete picture of cardiac atrophy in CC over time. From the initial literature review it was evident 
that there was little data investigating the evolution of molecular events regarding muscle atrophy in 
CC. Specifically, previous research would harvest organs for molecular analysis at one time point late 
in the disease process. Research was lacking in terms of the initiating mechanisms of cancer cachexia 
which may be the most important therapeutic targets. Thus, the study design focused on gathering 
both gross measures of tumour and anthropometric weight related data to compare and evaluate 
against the biochemical alterations occurring in the cachectic heart as part of a temporal study. Both 
molecular and structural characteristics of the atrophying heart were evaluated over the pre-
cachectic, cachectic and late cachexia stages in our nude mouse model. The murine adenocarcinoma 
model of CC produced profound tissue loss over a period of 29 days post inoculation. These animals 
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progressively lost peri-renal fat, skeletal and cardiac muscle tissue over time despite no significant 
change in calorie intake. From the results discussed earlier increased tumour size was negatively 
correlated to total body weight loss but not cardiac tissue atrophy. Specifically cardiac tissue atrophy 
was not correlated to tumour size as the myocardium atrophied early before significant tumour 
burden. Indeed, measurement of serum cytokines were also not correlated to tumour size.  Cardiac 
muscle atrophy was evident by 12 days post inoculation with MAC16 cells at which point the bulk 
73% of total cardiac atrophy over the 29 days was apparent. Thus cardiac atrophy in this model 
occurs most profoundly in the early stages of CC. Structurally early cardiac atrophy was due to a 
decrease in the length of the heart as measured longitudinally from base to apex. From mid cachexia 
on day 21 the cardiac cross sections showed that the lateral and posterior left ventricular wall were 
the only significantly atrophied transverse sections of the cachectic heart. By late cachexia all 
ventricular walls were atrophied in the CC mice hearts. It is currently unknown why the lateral and 
posterior left ventricular wall was preferentially atrophied before other area of the heart in CC. 
Cardiac fibrosis was not a feature of cancer cachexia in this animal model despite previous studies 
collagen deposition as a feature of disease, indeed by late cachexia decreased collagen content was 
noted. This suggests that collagen is not spared in CC and contributes to the overall loss of cardiac 
tissue in late disease. Cardiac fibrosis may also explain why previous research has shown diastolic 
dysfunction and decreased fractional shortening of cachectic hearts in animals. In terms of the 
molecular mechanisms which contribute to cardiac muscle loss it was shown that serum levels of IL-
6 was elevated early in this model. Elevated IL-6 at this early time point also correlated with the bulk 
of cardiac atrophy and thus may represent an important initiating factor. Both mRNA levels of MCP-
1 and RANTES peaked at day 21 which correlated with the largest increases in oxidative stress levels. 
Interestingly both MCP-1 and RANTES are chemo-attractant molecules and thus peak oxidative 
stress levels in cachectic hearts may relate to local production of free radicals by leukocytes. Whilst 
cardiac muscle breakdown may be instigated by the redox sensitive NFKB but not MAPK. As a 
consequence of the redox activation of NFKB may have contributed to increases in transcripts of 
ubiquitin ligase genes and thus driving cardiac atrophy.   
The final study of this thesis aimed at trialling potential therapeutics capable of targeting 
the molecular events our previous studies have found with regard to cardiac atrophy in CC. 
As our previous studies detailed complex and varied molecular events in cachectic cardiac 
tissue the final study used two novel treatments which targeted different facets of the 
disease process. Furthermore, it was hypothesised that these two therapeutics when used 
in concert would work in a summative fashion to ameliorate CC related cardiac atrophy. 
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Trialling potential anti-cachectic agents is particularly important when considering there are 
no approved treatments for cancer-induced cachexia (Murphy et al, 2011, Fearon et al, 
2011). The final study of this thesis explored the gross and molecular changes found in the 
cachectic heart with two potential anti-cachectic treatments. EPA and oxy are two very 
different drugs that were hypothesised to provide a potential multimodal therapy for CC. 
Our results show that oxy was not able to preserve total body weight loss and cardiac tissue 
mass in CC mice. This was despite the ability for oxy to significantly inhibit tumour growth 
and augment antioxidant defence leading to reduced oxidative stress levels. Furthermore, 
oxy was capable of inducing a significant decrease in gene expression of important 
proteolytic components. Treating animals with the EPA however did produce significant 
anti-cachectic effects. EPA was able to delay total body weight loss, preserve cardiac mass 
and inhibit tumour growth. Indeed the inhibition of tumour growth is likely part of the 
reason EPA as a treatment was able to ameliorate CC total body and cardiac weight loss. In 
terms of how EPA contributes to the preservation of total body weight loss and cardiac 
atrophy secondary to cancer cachexia appears to be multifactorial. Firstly EPA alone was the 
only treatment able to significantly reduce cardiac atrophy in CC mice.  
The studies detailed in chapters 4 and 5 of this thesis found that oxidative stress in cachectic 
hearts occurs concurrently with heart muscle atrophy and the up-regulation of UPS mRNA 
transcripts. Oxidative stress and inflammation in the myocardium is influenced by a number 
of endogenous systems including cytokines, NADPH oxidase and XO (Giodano, 2005, Hori, 
2009). As EPA treatment in this study showed that it was able to reduce gene expression of 
NOX2, XO and IL-6 the down-regulation of these important pro-oxidants may have led to 
reduced oxidative stress that was seen in the CC hearts. Also oxidative stress has been 
shown to independently activate the UPS brining about muscle atrophy. Thus, a significant 
reduction in oxidative stress by EPA treatment alone compared to the other treatment 
groups may have led to the reduced transcription of the UPS mafbx and murf-1 mRNA seen 
in this study. Although protein levels of E3 ligases and ubiquitinylation of cardiac proteins 
were not measured in this study, decreased levels of both MAfbx and MURF-1 mRNA has 
been correlated with reduced UPS activity in past research. In this current study a reduction 
in protein catabolism may be mediated by a reduction in the expression of IL-6, key pro-
oxidant pathways and subsequent dampening for UPS signalling.   
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8.0 Future directions 
There is only limited experimental data on the molecular and functional characteristics surrounding 
cardiac atrophy secondary to cachexia. This influenced early study design with respect to this thesis 
and allowed investigation into a variety of molecular systems in the cachectic heart.   
This thesis has provided an array of results which give insight into the mechanisms responsible for 
cardiac atrophy secondary to CC. In terms of study limitations one aspect that needs to be addressed 
are the gene transcript results. The gene data in this study was further analysed by protein or 
activity levels for certain areas of interest such as SOD, XDH and NOX 2. However, other genes which 
were significantly altered in disease and with treatment were not further evaluated due to time and 
tissue volume constraints. In particular the protein quantification of the UPS E3 ligases would be a 
beneficial future experimental direction. Measuring E3 ligases and ubiquitinylation of proteins would 
give more beneficial information on the evolution of cachexia related cardiac atrophy and solid 
evidence for the use of potential therapeutics. Furthermore, recent experimental data from Cosper 
and Leinwand (2011) also suggest that autophagy may be a feature of cardiac atrophy in CC. 
Together with the results of the current study future experimentation would benefit from assessing 
both the UPS and autophagy proteolytic systems in cachectic cardiac wastage. The data from this 
thesis and past experimental data now shows a growing body of evidence that cardiac atrophy in CC 
is an important event (Hinch et al, 2013, Cosper & Leinwand, 2011, Springer et al, 2009). However, 
evidence is now lacking in terms of the effect CC has on the human heart. It would be of great 
benefit and scientific interest to include cardiac parameters of heart size and functional status in 
patients with cancer. This includes patients which are in the pre-cachectic stage as this study shows 
that cardiac atrophy occurs early in the cachectic process.   
Our third study (chapter 6) also noted that EPA reduced tumour growth rate in vivo. This data would 
also benefit from further study by analysing tumour molecular biology to ascertain the events of 
tumour suppression by EPA. This is particularly important when considering that most data showing 
EPA tumour suppression is in in-vitro experimentation. With regard to the evaluation of the 
therapeutics used in this thesis human trials for the use of EPA have already begun. However, more 
data is needed to make a recommendation for its use in CC. Importantly, all of the data gathered 
from the treatment trials have focused on body weight, fat and lean skeletal muscle composition in 
response to EPA supplementation. Considering that this thesis has found ample evidence that 
cardiac tissue wastage is an important early event in CC it would be beneficial to include cardiac 
related measures in EPA treatment trials. This can be achieved by the non invaisive 
echocardiography method of heart size and function. The benefit of treating cardiac dysfunction in 
CC has the potential to increase cancer treatment efficacy and increase quality of life.  
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